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Visceral obesity, a serious health issue is implicated in insulin resistance and altered 
cardiac structure and function. Elevated inflammation, increased oxidative stress, insulin 
resistance, excessive extracellular matrix (ECM) deposition and tissue remodeling are among the 
possible mechanisms linking obesity with cardiomyopathy. Since, the cytoprotective role of the 
heme oxygenase (HO) system is well acknowledged, the present study investigated the effects of 
upregulation of the HO system by HO-inducer hemin on cardiomyopathy in obese Zucker Fatty 
(ZF) rats. This study also investigated the mechanisms by which HO improves insulin signaling, 
glucose metabolism and cardiac function in this model. HO modulates adiponectin and atrial 
natriuretic peptide (ANP). However, the interaction of these proteins with the HO system in ZF 
rats is unclear. ANP and adiponectin were also measured in this study.   
My thesis work showed that treatment with hemin abated inflammation and oxidative 
stress by attenuating pro-inflammatory-M1 phenotype macrophage infiltration and suppressing 
cytokines/chemokines including TNF-α, IL-1β, IL-6, monocyte-chemoattractant protein-1, 
macrophage inhibitory protein-1α and endothelin-1. Furthermore, hemin treatment suppressed 
ECM/heart failure proteins such as osteopontin and osteoprotegerin, collagen IV, fibronectin and 
transforming growth factor-𝛽, reduced cardiac hypertrophy and cardiac lesions and enhanced 
ANP, adiponectin, insulin sensitivity and HO-1 concentrations. Interestingly, hemin treatment 
improved several compromised echocardiographic and hemodynamic parameters including left-
ventricular diastolic and systolic free wall thickness, mean-arterial pressure, arterial systolic 
pressure, arterial diastolic pressure and cardiac output. In contrast, the HO inhibitor, stannous 
mesoporphyrin nullified the effects of hemin. 
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In conclusion, my thesis data strongly suggest protective effects of hemin-induced 
upregulated HO system against impaired insulin signaling and cardiomyopathy in obese Zucker 
rats. The suppression of inflammatory/oxidative mediators, ECM and profibrotic proteins, heart 
failure proteins, left-ventricular hypertrophy, cardiac lesions and the concomitant increase in 
ANP and adiponectin levels are some of the mechanisms by which HO enhanced insulin 
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Visceral obesity is an established risk factor for cardiovascular diseases (1-14). During 
obesity, elevated inflammation, increased oxidative stress, altered lipid metabolism, insulin 
resistance, impaired glucose metabolism, excessive extracellular matrix (ECM) deposition  and 
tissue remodeling are among the possible mechanisms which are implicated in altered cardiac 
structure and function (13, 15-31) and links obesity with cardiomyopathy and other related-
complications. Although, considerable efforts have been made in elucidating mechanisms 
implicated in obesity-related cardiovascular disease, new therapeutic strategies with novel 
mechanisms of action, are urgently needed. Since, the cytoprotective role of heme oxygenase 
(HO) system is well acknowledged (3-5, 32-54), an upregulated HO system can be explored as a 
novel paradigm against micro-vascular and macro-vascular complications associated with 
obesity-induced cardiomyopathy. In the present thesis the role of an upregulated HO system by 
HO-inducer hemin (a drug used against porphyria) (55, 56) on cardiomyopathy in obese Zucker 
fatty (ZF) rats was investigated and the mechanism by which HO improves insulin signaling, 
glucose metabolism and cardiac function was evaluated. The present study for the first time 
highlights the novel role of the HO system on macrophage polarization in the cardiac tissue of 
ZF rats. Importantly, my thesis work provides novel insights in the beneficial effects of 
concomitantly upregulating the HO system, atrial natriuretic peptide (ANP) and adiponectin by 
hemin against inflammation, insulin resistance, oxidative stress, pericardial adiposity and cardiac 




This thesis consist of four chapters. The first chapter is the general introduction that 
includes a brief description about obesity and the link between obesity, inflammation, insulin 
resistance, oxidative stress and cardiovascular disease. ANP, adiponectin and HO system has 
been discussed briefly. More detailed description are given in appendices. Appendix A, appendix 
B, appendix C are three of my first-authored published manuscripts. These manuscripts provide 
up-to-date and detailed knowledge of the scientific literature on obesity-related cardiomyopathy 
and nephropathy. In addition, the functional significance of the HO system and its downstream 
signaling molecules such as bilirubin, carbon monoxide (CO) and ferritin as potential therapeutic 
tools for effective management of cardio-metabolic diseases and related complications including 
cardiomyopathy have been acknowledged.  
The results of this thesis has been published as two manuscripts (chapters 2 and 3). In 
these chapters, my role is described on the first page of the manuscripts. Chapter-2 explains the 
role of an upregulated HO system by the HO-inducer hemin on cardiomyopathy in ZF rats, an 
obese rat model characterized by insulin resistance and cardiomyopathy. This chapter also 
describes the mechanisms by which hemin therapy improves glucose metabolism and enhances 
cardiac function. Chapter-3 underscores how an upregulated HO system by hemin suppresses 
pericardial adiposity, abates inflammation, enhances insulin signaling and attenuates diabetic 
cardiomyopathy. Chapter-4 is the general discussion of the entire research results and it 
highlights the importance of my research in the context of cardiomyopathy co-morbid with 
obesity and insulin resistance as well as the potential therapeutic benefit of a hemin-induced 
upregulated HO system that may be explored as a novel alternative approach against 




To fully address all the themes of my thesis, in the ensuing paragraphs below, an outline 
of obesity and the link between obesity, inflammation, insulin resistance, oxidative stress and 
cardiomyopathy are described in detail. 
 
1.1 Obesity  
1.1.1 Prevalence of obesity  
Obesity is a serious health problem growing rapidly worldwide. The prevalence of 
obesity is increasing at an alarming rate and has almost doubled in the last few decades (1, 11, 
15, 27, 57-65). It is estimated that over the world more than one billion people are obese (61, 62, 
65, 66). The World Health Organization reported that obesity is growing at a fast pace, with 
nearly 35% of the population being obese globally (61, 67). Approximately, the worldwide 
prevalence of obesity between 1980 and 2008 has risen from 4.8% to 9.8% in men and from 
7.9% to 13.8% in women (60, 61) respectively. Although obesity has escalated globally, 
epidemiological data from North America indicates that the prevalence of obesity has reached 
epidemic proportions in the USA compared to other parts of the world. For example, in a related 
survey in the USA, it was shown that approximately, 26 % of adults are obese (60, 61, 63), 
whereas in South East Asia, the situation is less dramatic as only 3% of adults are considered 
obese (60). Obesity has increased in every segment of the population including children. The 
global burden of childhood obesity between 1990 and 2010 has risen from 4.2% to 6.7% 
respectively (60, 61). Approximately, 43 million children are obese and it is expected that this 
total may rise to over 60 million by 2020 (61). 
The global rise in prevalence of obesity in both adults and children is a matter of great 
concern since the major health consequences of obesity include an increased risk for 
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cardiometabolic complications and associated comorbidities such as type-2  diabetes, insulin 
resistance, hypertension, dyslipidemia and renal diseases (1, 11, 14, 15, 27, 57-60, 62, 64, 65, 68, 
69) (Figure 1-1). Moreover, the increased prevalence of obesity is an independent risk factor for 
cardiovascular disease and heart failure (1, 15, 60, 63-65, 69, 70). Epidemiological study showed 
that approximately 32%–49% of individuals with heart failure are obese (63) displaying that 
obesity is associated with significant cardiovascular morbidity and mortality in both men and 
women (1, 11, 57, 59). Thus, obesity has emerged as a major global public health challenge.  
 
Figure 1-1:  Consequences of obesity. Adapted and modified from Med Clin N Am 97 (2013) 
59–74. 
Abbreviations: Type-2 diabetes (T2DM), Insulin resistance (IR), Chronic kidney disease (CKD) 
and Cardiovascular disease (CVD). 
 
1.1.2 Adipose tissue - a dynamic endocrine organ 
Adipose tissue plays important regulatory roles in energy homeostasis (7, 71-73). The primary 
function of adipose tissue is to store excess nutrients in the form of triglycerides and to release 
free fatty acids (FFA) during nutritional deprivation (7, 71-73). Due to its ability to generate heat 
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via non shivering thermogenesis as well as insulator properties, adipose tissue also functions as a 
thermoregulator (74). However, with the discovery that adipocytes can produce and secrete the 
pro-inflammatory cytokine tumor necrosis factor-α (TNF-α) (75, 76) as well as the hormone 
leptin, that plays a role in appetite and energy homeostasis, adipose tissue is now recognized as 
an active endocrine organ that regulates metabolism (1, 5, 77). Adipose tissue serves as an 
important endocrine gland that secrets different bioactive molecules including adipokines 
(cytokines and chemokines) as well as lipokines (lipid mediators) (1, 5, 77), which function  in 
an autocrine, paracrine or systemic manner and regulate important physiological functions 
related to lipid and glucose homeostasis (75, 78-81). Moreover, adipokines are involved in the 
regulation of crosstalk between adipose tissue and major metabolic organs including heart, liver, 
muscle, pancreas as well as the nervous system (6, 75, 78, 79). Under normal physiological 
conditions the storage of triglycerides in non-adipose tissues (pancreas, liver and heart) is 
minimal and is strictly regulated (1, 6). However, excess fat accumulation in these vital organs 
occur during obese conditions (1, 6, 7). Therefore, any alterations in the normal function of 
adipose tissue may in turn impair metabolic functions of these vital organs that leads to the 
development of  metabolic diseases such as insulin resistance and cardiovascular disease (7, 75, 
78, 79) (See Appendix D 1 for more details).  
 
1.1.3 Pathophysiology of adipose tissue 
Leptin, resistin, visfatin, adiponectin, TNF-α, interleukin-1 (IL-1), IL-6, IL-8, IL-10, 
plasminogen activator inhibitor-1 (PAI-1), retinol binding protein-4 and monocyte-
chemoattractant protein-1(MCP-1) are among the adipokines released from adipose tissue that 
play important roles in energy metabolism (72, 75, 79, 81) (Figure 1-2). Under the normal 
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healthy state, adipose tissue acts as a storage organ for deposition of excess triglycerides (7, 71-
73). To accommodate excess fat, the fully differentiated adipocytes first enlarge to their 
maximum size. After that, further storage is done by increasing the number of adipocytes 
through the process of proliferation of progenitor cells. However, during obesity the normal 
physiological functions of adipose tissue are disrupted (7, 71-73) and pro-inflammatory 
cytokines such as TNF-α, IL-6, visfatin, resistin, angiotensin II and PAI-1 are produced mainly 
by adipose tissue (1, 5, 75, 77). In contrast, anti-inflammatory adipokines such as adiponectin, 
IL-10, IL-4, IL-13 and apelin are mainly produced by adipose tissue from non-obese individuals 
that facilitates physiological functions (72, 75, 79, 81). As a consequence, impaired adipokine 
production during obese conditions activates altered paracrine and endocrine immune responses 
that lead to the development of obesity related cardiovascular and metabolic disorders (72, 75, 
79, 81). This indicates that depending upon the pathophysiological conditions of the body 
different kinds of adipokines regulate lipid and glucose metabolism in both a positive and 
negative manner. 
 
Figure 1-2:  Adipokines produced by adipose tissue. Adapted and modified from Pediatr 
Gastroenterol Hepatol Nutr 2013; 16: 143∼152 
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Abbreviations: Tumor necrosis factor (TNF-α); Interleukin (IL); Interferon-γ (IFN-γ); Vascular 
endothelial growth factor (VEGF), Transforming growth factor-β (TGF-β); Plasminogen 
activator inhibitor-1 (PAI-1).  
 
1.1.4 Adipokines in obesity related metabolic disorders (See Appendix D2 for more details) 
1.1.4.1 TNF-α 
TNF-α is a pro-inflammatory cytokine that plays a central role in inflammatory and 
immune responses (3-5, 58, 82-84). It is a pleiotropic cytokine that mediates a wide range of 
biological activities. Depending upon cytokine levels, TNF-α exhibits dual roles in both 
physiology and pathology (85, 86). At normal physiological levels, TNF-α regulates apoptosis, 
host-defense interactions, cell proliferation, adipogenesis, lipid and glucose metabolism as well 
as participates in innate immune responses (58, 85, 87). However, elevated levels of TNF-α have 
been shown to mediate inflammatory responses and tissue injury (58, 85, 87) related to obesity 
and associated comorbidities (3-5, 58, 82-84, 88). The first molecular link between inflammation 
and obesity arise from the finding that in the rodent model of obesity, the pro-inflammatory 
cytokine TNF-α was overexpressed (76, 86, 89). Similarly, it was reported that both obese and 
type-2 diabetic animal models as well as obese individuals displayed overexpression of TNF-α 
(81, 83, 84, 90) in adipose and muscle tissue. In vitro and in vivo studies also revealed that 
administration of recombinant TNF-α impairs the insulin signaling pathway, while an improved 
insulin sensitivity is observed in knockout obese mice having dysfunctional TNF-α or TNF 
receptors, (91, 92). Studies showed that inhibition of TNF-α expression improved insulin 
sensitivity in obese rat and mice models (81, 93). Moreover, the long term inhibition of TNF-α 
improved glucose metabolism in patients with metabolic syndrome (94) and reduced insulin 
resistance in individuals with rheumatoid arthritis and psoriasis (95, 96). However, the beneficial 
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effect of TNF-α inhibition was not observed in a recent clinical study (97) and in the obese rat 
model (98), suggesting that blocking of TNF-α signaling may improve impaired insulin signaling 
under certain conditions of excessive inflammatory states (81). 
Depending upon the stimuli, TNF-α is produced by different cell types including immune 
cells and adipocytes. The potent stimulator of TNF-α production from these cells includes 
bacteria, viruses, hypoxia, ischemia, complement factors and various pro-inflammatory 
cytokines (76, 86, 89). Interestingly, the production of TNF-α is governed by both positive and 
negative feedback loop mechanisms. The positive feedback loop mechanism includes TNF-α 
stimulated secretion of pro-inflammatory cytokines such as IL-1β, IFN-γ and IL-2 which, in turn 
governs TNF-α production. On the other hand, in the negative feedback loop mechanism, the 
production of TNF-α is inhibited by the TNF-α induced anti-inflammatory cytokine IL-10 (87). 
In hypertrophic adipose tissue, TNF-α is mainly secreted by activated macrophages and 
monocytes in response to inflammatory signals (87, 91). Increased levels of TNF-α in turn 
initiate the production of other pro-inflammatory cytokines and chemokines such as IL-6, MCP-
1, resistin and PAI-1 (58, 88). As a consequence, more circulating monocytes are recruited at 
inflamed sites in response to chemokines such as MCP-1 (13). Thus, the interaction among 
macrophages, endothelial cells and adipocytes further amplifies inflammatory signals and 
promotes the secretion of pro-inflammatory cytokines and chemokines. This, leads to a state of 
local or systemic inflammation and subsequent insulin resistance (3-5, 58, 82-84). It is suggested 
that one of the possible mechanisms for TNF-α mediated impaired insulin signaling is that 
elevated levels of TNF-α inhibits tyrosine phosphorylation of the insulin receptor substrate 1 
(IRS1) and thereby prevents binding of IRS1 to insulin receptors which in turn results in insulin 
resistance in muscle and adipose tissue (58, 81, 82, 99). In addition, it is reported that depending 
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upon stimuli, TNF-α activates different signaling pathways including, nuclear-factor κ B 
(NFκB), caspases and mitogen-activated protein kinases (MAP kinases) (82, 88) and the 
interactions among these pathways is responsible for a wide range of TNF-α mediated 
pathophysiological functions (13, 88). Thus, higher expression of TNF-α in adipose tissue is a 
characteristic feature of obesity and is a risk factor for insulin resistance and cardiovascular 
complications (3-5, 58, 82-84). Therefore, inhibition of TNF-α action might be a beneficial 




IL-6 is a multifunctional cytokine that plays an important role in the regulation of 
humoral and cellular immune responses, haematopoiesis, inflammation and tissue injury (16, 75, 
100, 101). It is a pleiotropic cytokine with pro-inflammatory and anti-inflammatory action (75, 
101).  IL-6 belongs to a family of granulocyte colony stimulating factor proteins that includes IL-
11, leukemia inhibitory factor, oncostatin M and ciliary neurotrophic factor as other cytokine 
members (101). It has been observed that these cytokines, including IL-6, signal through a 
ubiquitously expressed transmembrane glycoprotein 130 (gp130), a common β-receptor (102-
105). However, each member of the IL-6 super family possesses a specific α-receptor. Under 
different conditions, the pleiotropic effects of IL-6 is initiated by formation of a heterocomplex 
through  its binding to a receptor complex comprising a specific receptor subunit IL-6 receptor α 
(IL-6Rα) and gp130 (105-107). Binding of IL-6 to this heterocomplex, activates IL-6Rα, that 
initiates the activation of a signaling cascade namely, the janus kinase/signal transducers and 
activators of transcription (JAK-STAT) pathway (108, 109). IL-6 is produced by various cell 
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types such as monocytes, fibroblasts, endothelial cells and also by the liver, skeletal muscle and 
adipose tissue (16, 75). However, secretion of IL-6 is cell specific and is mainly governed by 
immune, hormonal and metabolic stimuli (110). It is observed that under normal physiological 
conditions transient expression of IL-6 exerts anti-inflammatory function and regulates glucose 
metabolism (16, 75, 100). However, under the obesity-induced chronic inflammatory state, the 
elevated levels of systemic IL-6 induce dysfunctional insulin signaling (81, 111). IL-6 exhibits a 
dual functional state depending upon cell-type and metabolic state (16). For example, in skeletal 
muscles during exercise, IL-6 exerts its anti-inflammatory effect and facilitates glucose uptake 
that leads to muscle hypertrophy and myogenesis (16). In contrast, in liver and adipose tissue, 
increased levels of IL-6 are pro-inflammatory and promote insulin resistance (16, 75). 
Under physiological conditions, nearly 15-35% of circulating IL-6 is produced from 
adipose tissue, therefore, IL-6 is also considered as an adipocytokine (112). However, compared 
to subcutaneous adipose tissue, IL-6 is secreted three times more from the stromal vascular 
fraction of vascular adipose tissue (16, 75). For this reason, IL-6 is considered as a marker for 
visceral adiposity (111). IL-6 has been identified as a key inflammatory molecule during the 
obese chronic inflammatory state (105), as approximately one-third of circulating IL-6 originates 
from adipose tissue (111). Elevated levels of circulating IL-6 have been reported in obese 
subjects (28, 31, 113). Moreover, high levels of IL-6 can be positively correlated with body mass 
and plasma FFA concentrations (101, 105, 114). However, in obese individuals who underwent 
bariatric surgery, subsequent weight loss resulted in low levels of serum IL-6 together with 
improved insulin sensitivity (28, 115). IL-6 has been implicated in the pathogenesis of various 
metabolic diseases including type-1 and type-2 diabetes, coronary heart disease and insulin 
resistance (105, 116). Increased IL-6 levels impair insulin signaling, elevate lipolysis and 
11 
 
augment FFA production (111). The exact mechanism for IL-6 induced impaired insulin 
signaling is not clear. However, it is suggested that IL-6 promotes the increased expression of the 
suppressor of cytokine signaling 3 (SOCS3) which binds and attenuates insulin receptor and 
IRS1 phosphorylation (31, 75). Although, increased plasma concentration of IL-6 is being 
regarded as a predictor for insulin resistance and cardiovascular disease (17, 101, 115, 116), the 
role of IL-6 in mediating insulin resistance is still ambiguous and depends upon metabolic state 
and tissue type. For example, in one IL-6 knockout mouse model, IL-6 was shown to develop 
insulin resistance and obesity, while the same results were not observed with different IL-6 
knockout models (75). Interestingly, IL-6 has modulatory effects on adipokine production (75). 
For example, in human adipocytes, IL-6 was shown to suppress the expression and secretion of 
anti-inflammatory adiponectin and other markers of adipocyte differentiation (116). Thus, IL-6 is 
a pleiotropic cytokine that plays a key role in the pathogenesis of metabolic diseases (111, 116). 
Therefore, understanding its role in regulation of obesity-induced inflammatory states will help 
to counteract the adverse effects arising from obesity. 
 
1.1.4.3 IL-1 
The IL-1 family is a group of related cytokines that play important roles in metabolic 
inflammation and immune responses (115, 117). IL-1α, IL-1β, IL-18 are among the pro-
inflammatory members, whereas, IL-1 receptor antagonist (IL-1Ra) and IL-37 are anti-
inflammatory members of the IL-1 family (115, 117). The inflammatory mediators IL-1α and IL-
1β are potent pyrogens and were among the first identified cytokines with similar structure and 
functional characteristics (118, 119). Both IL-1α and IL-1β are derived from precursor proteins 
(pro-IL-1α and pro-IL-1β) via enzymatic cleavage (119). It is reported that pro-IL-1α is the 
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biologically active form of the protein that is cleaved by calcium–dependent cysteine protease 
calpain to produce mature IL-1α. Both pro-IL-1α and IL-1α remain intracellular and are rarely 
detected in blood and other body fluids, till they are released by dying necrotic cells during 
disease conditions (119, 120). Under normal conditions, IL-1α was found to be a membrane 
bound protein, constitutively expressed at the surface of various cell types such as keratinocytes, 
platelets and epithelial cells as well as by the organs such as liver, kidney and lung (120). IL-1β 
is mainly secreted by blood monocytes, dendritic cells and tissue macrophages (120). 
Interestingly, cytokines such as TNF-α, IL-18, IL-1α and IL-1β itself acts as stimulators for IL-
1β synthesis (120). In addition, compared to pro-IL-1α, IL-1β is first expressed in the form of a 
biologically inactive precursor (pro-IL-β). Pro-IL-1β is then cleaved by an intracellular cysteine 
protease caspase-1 to generate the active 17.5 KDa protein (120). In fact, caspase-1 itself needs 
to be activated via the formation of multimeric cytosolic molecular complex (inflammasome) in 
order to synthesize active and mature IL-β from its inactive precursor pro-IL-1β (119, 120). 
Once secreted, the pro-inflammatory effect of mature IL-1β is mediated with  the help of IL-6 
and C-reactive protein, that is known to be increased during inflammation and pathological 
conditions of hyperlipidemia and atherosclerosis (117). Both IL-1α and IL-1β exert their 
biological effects by binding to their cell surface receptor IL-1 receptor type 1 (IL-1R1), 
expressed by various cell types (119, 120). This in turn activates various downstream signaling 
cascades involving, c-Jun-N-terminal-kinase (JNK), extracellular signal-regulated kinases 
(ERKs), MAPK and NFκB (121). Furthermore, IL-1β has been implicated in the development of 
type-2 diabetes and insulin resistance in both in vitro and in vivo animal model as well as in 
humans (115, 122). In both IL-1α and IL-1β knockout mice, improvement in glucose metabolism 
and suppression of adipose tissue inflammation was observed (117). Thus, these findings 
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indicate that the blocking of IL-1β can be explored for the treatment of insulin resistance and 
obesity. 
 
1.2 Obesity, inflammation and macrophages 
1.2.1 Obesity as a pro-inflammatory state 
Visceral obesity, in particular is a major risk factor for metabolic disorders including 
insulin resistance, diabetes and cardiometabolic complications (1-5, 15, 123-127). The common 
denominator that links obesity with other metabolic disorders is a chronic low grade 
inflammation (9, 10, 18, 24, 26, 27, 31, 71, 75, 77, 128-135). The identification of high levels of 
the pro-inflammatory cytokine TNF-α in adipose tissue of obese individual by Hotamisligil and 
colleagues (1993) provides the link between obesity, inflammation and insulin resistance. The 
subsequent studies demonstrated that an upregulated gene expression of inflammatory 
transcriptional factors and elevated production of various pro-inflammatory cytokines and 
chemokines occurs in hypertrophied adipose tissue (3, 5, 15, 124-127, 136). The exact molecular 
mechanism that leads to the initiation of the inflammatory response under obese conditions is 
largely unknown. However, one of the possible explanations is that due to the excessive 
deposition of fat, expansion of adipose tissue occurs in response to adipocyte hypertrophy and 
hyperplasia. As a consequence, large adipocytes became hypoxic that leads to the induction of 
various inflammatory pathways (67, 128). Obesity induced inflammation triggers overproduction 
of various pro-inflammatory cytokines (IL-1β, IL-6,TNF-α) and chemokines (MCP-1 and MIP1-
α) from adipocytes, macrophages and other cells that play important roles in systemic 
inflammation (3, 5, 15, 124-127, 136) (Figure 1-3). Moreover, the increased macrophage 
infiltration during the inflammatory process was reported to be associated with a macrophage 
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polarization event where macrophages were polarized from an anti-inflammatory M2 to a pro-
inflammatory M1 phenotype (19, 130, 137-140). In addition, during obesity, multiple signaling 
cascades including JNK, inhibitor of κ kinase (IKK), TLR4, NFκB and their downstream 
signaling molecules are activated that contribute to the stimulation of inflammatory processes in 
adipose tissue (69, 99, 141). The systemic inflammation upregulates SOCS proteins that suppress 
insulin receptor signaling and promote endothelial dysfunction (142). Thus, chronic low grade 
inflammation is an underlying mechanism that links obesity with insulin resistance and 
cardiometabolic complications (3, 5, 13-15, 24, 29, 68, 69, 91, 127, 135, 143-150). 
 
Figure 1-3:  Obesity-induced macrophage infiltration and inflammation.  
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Abbreviations: Tumor necrosis factor (TNF-α); Interleukin (IL); Macrophage chemoattractant 
protein (MCP-1); Macrophage inflammatory protein 1 (MIP-1α). 
 
1.2.2 Macrophages and inflammation  
1.2.2.1 Origin, phenotype and function of macrophages 
Macrophages are highly heterogeneous phagocytic cells that play an important role in 
metabolic homeostasis and immune response (137-139, 151-155). Under physiological 
conditions, macrophages contribute to host defense mechanisms, prevent inflammation by 
removing infected cells and pathogens via phagocytosis, contribute to wound healing, tissue 
repair and clearance of dead cells (153, 155) and acts as a link between adaptive and innate 
immunity. However, during the pathological condition of visceral obesity increased macrophage 
infiltration leads to inflammation and insulin resistance (19, 130, 137-140). Interestingly, 
increased numbers of both resident and infiltrated activated adipose tissue macrophages (ATMs) 
have been observed during obesity (137-140). For example, in lean animal models, macrophages 
comprise nearly 10-15% of the stromal cell population (135, 152). However, in obese animal 
models increased macrophage infiltration in adipose tissue increase their population to 
approximately 45-60% (135, 152). As a consequence, increased numbers of activated 
macrophages further elevates the levels of pro-inflammatory mediators including IL-6 and TNF-
α that directly alters insulin signaling and exacerbates adipose tissue inflammation (135, 139, 
154). In addition, ATMs are also involved in adipogenesis, angiogenesis and in hypoxia 




How are macrophages able to mediate both physiological and pathological functions? 
One possible explanation for the diverse function of macrophages arises from their potential to 
exist in different activation states with specific properties (127, 135, 139, 151, 154, 156-160). On 
stimulation with different kinds of stimuli, macrophages gets activated and in turn express 
distinct surface receptors and produce distinct chemokines and cytokines that leads to diverse 
macrophage pro-inflammatory and anti-inflammatory functions (135, 139, 154). Moreover, 
ATMs exhibit a different pattern of surface markers and cytokine profiles and perform distinct 
functions in lean and obese animals (139). Depending upon site, stage and type of tissue insults, 
macrophages generally exhibit different phenotypes; M1 phenotype and M2 phenotype (135, 
139, 154). It is reported that in lean animals, ATMs exhibit an alternative M2 phenotype 
characterized by anti-inflammatory gene expression (IL-10) and enhanced insulin sensitivity 
(139, 154). In contrast, visceral obese ATMs exhibit the classically activated M1 phenotype 
characterized by high expression of pro-inflammatory cytokines such as TNF-α and IL-6 and 
increased inducible nitric oxide synthase (iNOS) activity that inhibits insulin action directly and 
eventually develops adipose tissue insulin resistance (139, 154). Besides M1 and M2 
phenotypes, a mixed M1/M2 phenotype has been observed in obese ATMs that also contribute to 
the chronic inflammatory process (139). 
 
1.2.2.2 Tissue macrophage activation 
In view of the diverse biological functions, activated macrophages possess the ability to 
acquire different phenotypes depending on the type of stimuli and site of insult in the local 
environment (127, 135, 139, 151, 154, 156-160). In response to various pathogens and cytokines 
macrophages may polarize towards the classical M1 phenotype or the alternative M2 phenotype 
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(151, 157, 160) (Figure 1-4). It is suggested that the phenotypic plasticity of macrophages 
resembles the Th1–Th2 polarization of T cells (151, 157). 
 
Figure 1-4:  Schematic representation of macrophage polarization from classical M1 
phenotype to alternative M2 phenotype.  
Abbreviations: Tumor necrosis factor (TNF-α); Interleukin (IL); Interferon-γ (IFN-γ); 
Lipopolysaccharide (LPS), Nuclear factor kappa-B (NFκB); Activator protein-1 (AP-1); Signal 
transducer and activator of transcription 6 (STAT6); Peroxisome proliferator-activated receptor 
gamma (PPARγ). 
 
1.2.2.2.1 Classically activated macrophage (M1 phenotype) 
The M1 phenotype represents classically activated macrophages that participate in the 
immune response. Multiple factors such as interferon gamma (IFN-γ), toll-like receptor (TLR) 
ligands, lipopolysaccharide, granulocyte macrophage colony-stimulating factor (GMCSF) 
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activates the MI phenotype of macrophages. The M1 phenotype possesses microbicidal and 
tumoricidal properties and is characterized by elevated levels of pro-inflammatory cytokines 
such as TNF-α, IL-1β, Il-6, IL-12 and chemokines such as MCP-1 & MIP-1α, high levels of 
reactive oxygen species (ROS) generation and nitrogen intermediates which in turn leads to 
increased oxidative stress (19, 130, 137-140). Furthermore, M1 macrophages function as 
phagocytic cells for intracellular pathogens and can stimulate the Th1 response (156). Studies 
have demonstrated that in obese human and animal models, M1 macrophages mediated high 
levels of pro-inflammatory cytokines induce insulin resistance via the activation of an inhibitor 
of nuclear factor kappa-B kinase-β (IKKβ) and c-Jun N-terminal kinase (JNK)1 signaling 
pathways. These signaling pathways in turn promote inhibitory phosphorylation of IRS1 proteins 
at serine residues and activation of transcriptional factors including NFκB and activator protein 1 
(AP-1) that play important roles in the inflammatory process (19, 132). Overall, classical 
activation of macrophages in response to various stress conditions promotes inflammatory 
responses and insulin resistance. 
 
1.2.2.2.2 Alternative activated macrophage (M2 phenotype) 
Alternatively activated macrophages, represent the M2 phenotype of macrophages that 
contribute to tissue function under physiological conditions (155, 160). M2 macrophages exhibit 
anti-inflammatory properties. M2 macrophages participate in the resolution of inflammation after 
infection or injury, in tissue repair and wound healing, and thus preserve tissue function in 
response to various conditions of stress (155, 160). Furthermore, M2 macrophages promote Th2 
responses and participate in parasite clearance and immunoregulation (157). In general, the M2 
phenotype is stimulated by the Th2 cytokines (IL-4, IL-13), TGF-β, glucocorticoids and immune 
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complexes (151, 160). M2 macrophages are characterized by low levels of pro-inflammatory 
cytokines, high production of anti-inflammatory cytokines (IL-10, IL1rα) and high expression of 
scavenger, mannose and galactose-type receptors (138, 157). Moreover, M2 phenotypic 
macrophages were found to be associated with a high production of the enzyme arginase that is 
known to block inducible nitric oxidase synthase activity which is a characteristic feature of M1 
polarized macrophages (138). Interestingly, it is reported that activation of M2 macrophages in 
response to IL-4 cytokine is accompanied by the stimulation of transcription factors such as 
peroxisome proliferator-activated receptor gamma (PPARγ) and PPARγ coactivator 1β (PGC-
1β) that play roles in lipid oxidative metabolism (138). Taken together, M2 polarized 
macrophages promote tissue repair, exhibit anti-inflammatory effects and exert cytoprotection 
against inflammation and insulin resistance (155, 160).  
 
1.2.3 Mechanisms related to macrophage polarization and plasticity  
Both heterogeneity and plasticity are the key features of macrophages (127, 135, 139, 
151, 154, 156-160). ATMs from lean and obese animals display functional heterogeneity with 
relation to expression of surface markers and cytokine profiles (135, 139, 154). Lean ATMs 
display the anti-inflammatory M2 phenotype that plays important roles in insulin sensitivity, 
while excess nutrient driven obese ATMs are polarized towards the pro-inflammatory M1 
phenotype that contribute significantly in systemic inflammation and associated insulin 
resistance (19, 137, 155). Interestingly, macrophage polarization is a phenomena that is known to 
occur during infection, pathological conditions of chronic inflammation, obesity, insulin 
resistance but also during homoeostatic conditions (19, 137, 155). One important question that 
still remains unanswered is that how does obesity switch the M2 activation state of macrophages 
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to the M1 activation state? At present, very little is understood regarding the mechanism that 
governs macrophage polarization. However, several possible explanations for obesity induced 
macrophage polarization have been postulated by different studies. It is predicted that a wide 
number of signaling molecules associated with different signaling pathways, various 
transcription factors and epigenetic processes are involved in the polarization of macrophages to 
distinct phenotypes (151). It is suggested that activation of the interferon regulatory transcription 
factor (IRF)/STAT  molecular pathway by IFN-γ and TLR ligands via STAT1 favors the M1 
phenotype of macrophage activation, whereas, stimulation by IL-4 and IL-13 via STAT6 activate 
the M2 phenotype of macrophages (151, 161). In addition, activation of macrophages by the 
STAT signaling pathway is governed by the proteins of the SOCS family. For example, IL-4 and 
IFN-γ in combination with TLR stimulation enhance the expression of  SOCS1 and SOCS3 
proteins that  promote the inhibition of STAT1 and STAT3 action (151). In addition to these 
signaling pathways, various transcriptional factors play roles in macrophage polarization. The 
lipid sensing nuclear receptors such as PPARγ and PPARδ and their co-activator PGC-1β also 
mediate the expression of different genes associated with alternative macrophage activation (127, 
151). STAT6 interacts with PPARγ and Kruppel-like factor 4 (proteins that participate in 
macrophage mediated function) to stimulate M2 gene expression and inhibit M1 genes via NFκB 
inhibition (27, 151, 159). In contrast, activation of TLR promote M1 macrophage activation via 
the induction of  the NFκB  signaling pathway and other inflammatory mediators (151). 
Recently, the important role of epigenetic regulation via histone methylation, acetylation and 
non-coding RNAs in macrophage polarization has been identified (151, 160). For example, in 
mice macrophages, IL-4 mediated induction of the histone demethylase was shown to promote 
M2 gene expression via the alterations of chromatin modifications (151). Thus, the physiological 
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and pathological functions of macrophages during normal and diseased states are mainly 
governed by phenotypic switching of macrophages between M1 and M2 activation states. 
 
1.2.4 Macrophage infiltration during obesity  
 Macrophages infiltrate adipose and other tissues during the pathological condition of 
obesity and play direct roles in systemic inflammation and insulin resistance (19, 130, 137-140). 
The number and activation state of resident and infiltrated ATMs is reflective of diseased and 
healthy status of adipose tissue (151, 152). How does obesity promote increased macrophage 
infiltration? It is suggested that in response to excessive fat deposits adipose tissue expands. The 
continuous stress on adipocytes leads to the development of hypoxia, increased endoplasmic 
reticulum (ER) stress, high levels of FFA and ROS generation. This in turn promotes the 
increased production of pro-inflammatory mediators such as TNF-α, IL-6, IL-1β, MCP-1 and 
MIP-1α from adipocytes and other immune cells that result in the accumulation and activation of 
ATMs and various stress responsive signaling pathways (19, 130, 137-140). The activated ATMs 
further produce pro-inflammatory mediators that in turn exacerbate inflammatory responses and 
subsequently lead to the development of insulin resistance (19, 137, 155). The important 
chemoattractants for macrophage recruitment is MCP-1 and MIP-1α (130, 151, 158). It was 
shown that inhibition of MCP-1 and its receptor CCR2 in the obese animal model suppressed 
macrophage infiltration and improved insulin sensitivity (130). In addition, adipocyte necrosis 
observed during obesity might be another important factor that serves as a chemoattractant signal 
for macrophage recruitments (161). For example, in obese human and animal models, crown like 
structures formed by infiltrating macrophages has been observed around necrotic adipocytes 
(161). ATMs from obese humans and mice were reported to exhibit the M1 phenotype along 
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with high TNF-α and iNOS activity, while, ATMs from lean subjects were shown to polarize 
towards the M2 phenotype with high levels of IL-10 and arginase-1 production (138, 151). It is 
possible that with increasing obesity the anti-inflammatory M2 phenotype of macrophages 
switch to the pro-inflammatory M1 phenotype in adipose tissue (27). It is proposed that the pro-
inflammatory cytokines such as TNF-α, IL-1β and TLR associated with M1 phenotype promote 
obesity induced insulin resistance by serine phosphorylation of IRS1 via the activation of IKK 
and JNK signaling pathways and downstream NFκB and AP-1 transcription factors, suggesting 
the pro-inflammatory role of M1 macrophages in obesity-induced inflammation and insulin 
resistance (19, 130, 137-140, 161).  
  
1.3 Obesity and insulin resistance  
Obesity is a major risk factor for insulin resistance (3, 5, 14, 15, 19, 24, 29, 68, 69, 127, 
137, 145-149, 155). Insulin resistance is a state of reduced responsiveness of the metabolic 
tissues (muscle, liver, adipose tissue) to insulin action (135, 162-164). Insulin plays an important 
role in glucose homeostasis (135, 162, 165). In skeletal muscle, liver and adipose tissue, insulin 
increases glucose uptake in cells by activating the translocation of the intracellular glucose 
transporter, GLUT4 to the cell surface via the involvement of multiple signaling pathways (163-
165) and thereby, helps in maintaining normal blood glucose levels. In addition, in adipose tissue 
insulin exerts an anti-lipolytic function by attenuating the release of FFA from adipocytes 
through the suppression of the activity of hormone-sensitive lipase and adipose triglyceride 
lipase (166). Furthermore, insulin decreases the release of hepatic glucose in the circulation 
through the inhibition of the expression of gluconeogenic enzymes and the glycogenolytic 
(breakdown of glycogen to glucose) process (164). Thus, any alteration in normal insulin action 
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and the corresponding insulin signaling pathways would in turn lead to subsequent development 
of insulin resistance in metabolic tissues. 
 
1.3.1 Insulin signaling 
Insulin initiates its metabolic action via its binding to and activation of the insulin 
receptor at the plasma membrane of metabolically active organs (162, 165). The insulin receptor 
is a member of the receptor tyrosine kinase subfamily that consists of insulin like growth factor-1 
(IGF-1) receptor and the insulin receptor-related receptor (IRR) (167). The insulin receptor 
contains two α-subunits and two β-subunits that together form a heterotetrameric complex. 
Insulin binds to the extracellular α-subunits and thereby activates intracellular tyrosine kinase 
domain of β-subunits. This is accompanied by a series of trans-phosphorylation and 
conformational changes of the β-subunits that further leads to enhanced kinase activity (167). 
Insulin signaling involves complex and multiple signaling pathways downstream of the insulin 
receptor. The two important signaling pathways that participate in insulin signaling includes  the 
phosphatidylinositol 3-kinase (PI3K) /protein kinase B (Akt or PKB) signaling pathway and 
MAPK (128). The PI3K/Akt pathway stimulate metabolic responses and governs insulin 
mediated glucose uptake and suppression of gluconeogenesis (128). The MAPK pathway 
activates growth factor-like responses and also governs cell growth and differentiation via 
interacting with the PI3K/Akt pathway (128, 168). The common connecting link between these 
two pathways is IRS proteins that consist of four different intracellular substrate members IRS 1-
4. Out of the four members, IRS1 is the main protein that is susceptible to impaired insulin 
signaling (128). Insulin receptor activation via the binding of insulin at the cell surface promotes 
tyrosine phosphorylation of IRS1/2. Phosphorylated IRS1/2 proteins than activate PI3K that 
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converts phosphatidylinositol (PI) (4,5) bisphosphate (PIP2) to PI (3,4,5) triphosphate 
(PIP3)(162). PIP3 is a bioactive lipid that further activates  3-phosphoinositide dependent protein 
kinase-1/2 (PDK-1/2) which in turn leads to the phosphorylation and activation of downstream 
PI3k-dependent Akt and protein kinase B (PKB) signaling (162). PKB further activates the 
translocation of intracellular GLUT-4 to the plasma membrane to enhance glucose uptake in 
adipose, skeletal and myocardial tissue (128, 167, 168). The tyrosine phosphorylation of IRS-1 
that involves the MAPK pathway activate downstream the extracellular signal-regulated kinases 
(ERK) signaling pathway via the activation of the GTP-binding protein RAS. The activation of 
these signaling pathways thereby, plays an important role in cell growth and remodeling, 
myocardial hypertrophy, cardiac fibrosis and dysfunctional endothelium (128, 167, 168). In 
contrast, the phosphorylation of IRS1 at the serine residue instead of the tyrosine residue 
attenuates insulin signaling via the suppression of insulin mediated tyrosine phosphorylation 
(128, 167, 168). Thus, this inhibitory action of serine phosphorylation acts as a negative 
feedback to insulin signaling and might be a mechanism that interconnects other signaling 
pathways that promote insulin resistance (128, 167, 168). 
  
1.3.2 Inflammation, insulin resistance and obesity: A link 
Both chronic low grade inflammation and insulin resistance are central to obesity related 
diseases such as type-2 diabetes, cardiovascular diseases, dyslipidemia, glucose intolerance and 
chronic kidney diseases (3, 5, 14, 15, 27, 29, 68, 69, 127, 145-149). How does obesity induce 
insulin resistance? The exact underlying mechanism for obesity-induced insulin resistance is 
poorly understood. However, obesity-induced insulin resistance is a complex and multifactorial 
process manifested by nutrient overload, ER stress, hypoxia, elevated levels of 
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cytokines/chemokines, increased ROS generation and chronic inflammation (164, 169). It is 
suggested that the stressful condition of obesity induces various stress-responsive molecules and 
their counter-regulatory signaling pathways such as JNK, ERK, and IKKβ that inhibit insulin 
signaling via the serine phosphorylation of IRS thus, suppressing insulin action (164, 169). In 
addition, abnormal secretion of pro-inflammatory cytokines (IL-6, IL1-β, TNF-α) and the 
chemokines (MCP-1, MIP-1α) from hypertrophied adipose tissue were reported to be the 
possible cause for the induction of systemic insulin resistance (156, 162, 164) (Figure 1-5). In 
particular, the pro-inflammatory cytokine TNF-α produced by activated macrophages is a major 
adipokine that links inflammation and insulin resistance (3-5, 58, 82-84, 86, 88, 164, 170). TNF-
α acts in a paracrine manner and has a direct inhibitory effect on insulin-receptor signaling 
through the activation of JNK and IKK signaling pathways. In addition, activation of AP-1 and 
NFκB further exacerbates pro-inflammatory cytokine production (24, 99, 163, 171, 172).  
Thus, elevated levels of pro-inflammatory mediators, in response to the inflammatory 
signal initiated by hypertrophied adipose tissue and infiltrated macrophages, leads to the 
abrogation of insulin sensitivity and acts as a link between obesity induced inflammation and 
insulin resistance (Figure 1-5). 
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Figure 1-5   Obesity mediated alterations in adipokines secretion and the development of 
subsequent insulin resistance.  
Abbreviations: Tumor necrosis factor (TNF-α); Interleukin (IL); Free fatty acids (FFAs). 
 
1.3.3 Cardiac insulin resistance 
Insulin resistance in the heart occurs independent of systemic insulin resistance (168), 
however, systemic insulin resistance participates in impaired cardiac insulin signaling (3, 5, 13-
15, 24, 29, 68, 69, 127, 143-149, 168). The factors that contribute to dysfunctional insulin 
signaling in cardiac tissue include elevated levels of FFA, increased oxidative stress and aberrant 
production of pro-inflammatory cytokines/chemokines (128, 167, 168). Obesity leads to the 
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deposition of increased levels of FFA, diacylglycerol, ceramides and triglycerides in myocardial 
tissue that result in cardiac insulin resistance through the stimulation of kinases that promotes 
serine phosphorylation of the IRS1 protein. Moreover, it is proposed that increased oxidative 
stress activates ROS sensitive kinases, and angiotensin-II signaling that favors IRS1 
phosphorylation at serine residues and contributes to insulin resistance (168, 173). Similarly, 
increased myocardial ROS production by mitochondria also contributes to impaired insulin 
signaling (168, 174). In addition, ER stress through the activation of MAPK/JNK has been 
shown to induce insulin resistance in cardiac tissue (168, 174). Furthermore, increased 
macrophage infiltration, elevated levels of IL-6, TNF-α, and decreased production of the insulin 
sensitizing hormone adiponectin, in response to pericardial adiposity contributes to the 
development of insulin resistance in cardiac tissue. Interestingly, TNF-α and IL-6 activates 
MAPK, PKC and SOCS3 that leads to the degradation of IRS1 protein (168, 175). The activation 
of the renin-angiotensin-aldosterone system (RAAS) might be another mechanism that 
contributes to insulin resistance in the heart during various pathological conditions of heart 
failure and myocardial infarction (168, 176). Besides angiotensin-II, increased secretion of IL-6 
and TNF-α from expanded adipose tissue also stimulate aldosterone secretion from adrenal 
glands. Aldosterone and angiotensin-II in turn elevate ROS generation in cardiac vascular 
smooth muscle cells via the activation of nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase enzymes. As a consequence, ROS sensitive protein kinases are activated that 
phosphorylates serine residues in IRS1 and leads to the development of insulin resistance in the 





1.4 Obesity and oxidative stress   
1.4.1 Role of reactive oxygen species (ROS) in obesity 
Oxidative stress is a condition of an imbalance between the levels of ROS and 
antioxidant defense systems (178, 179). ROS like the superoxide anion, hydrogen peroxide and 
hydroxyl radical are highly reactive molecules which are produced during normal biological 
processes or in response to different stress conditions (178, 179). Moreover, interaction between 
ROS and nitric oxide generate peroxynitrite that induce nitrosative stress and suppress nitric 
oxide bioavailability and thereby contribute to endothelial dysfunction (178-180). Increased 
oxidative stress has been implicated to play an important role in the pathogenesis of obesity, 
insulin resistance, diabetes and cardiovascular diseases (3, 5, 124, 178, 181-215). It is well 
documented that obesity is associated with increased ROS generation and reduced production of 
antioxidants (20, 178, 214, 216). It has been suggested that during obesity, adipose tissue is the 
main site for free radicals generation and contribute towards obesity related cardiometabolic 
complications (3, 5, 124, 178, 181-215). The exact mechanism responsible for dysfunctional 
adipose tissue and oxidative damage is not clear. However, increased fatty acid oxidation, 
impaired mitochondrial metabolism and decreased production of antioxidant enzymes might be 
possible mechanisms that lead to elevated ROS production during obesity (179, 215). It is 
suggested that increased accumulation of lipids in adipose tissue leads to adipocyte hypertrophy 
and hypoxia that contribute to oxidative stress (178, 215). Increased levels of FFA facilitate ROS 
generation via the stimulation of NADPH oxidase and attenuation of antioxidant enzymes (178, 
215, 217). Elevated ROS in adipose tissue in turn contribute to enhanced inflammatory processes 
via the induction of redox sensitive NFκB (179, 215, 217), increased production of pro-
inflammatory cytokines (215, 218) and attenuation of insulin sensitizing anti-inflammatory 
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adiponectin (219-223). Moreover, macrophage that play key roles in the chronic inflammatory 
processes also participate in ROS generation (135, 139, 154). In addition, local RAAS in 
adipocytes might be another possible mechanism that contributes to obesity mediated oxidative 
stress (168, 177, 215). Thus, oxidative stress in adipose tissue participates in the systemic 
inflammation process which in turn causes endothelial dysfunction and subsequent development 
of insulin resistance and cardiometabolic complications. The proposed mechanism by which 
elevated oxidative stress leads to obesity mediated insulin resistance involves the stimulation of 
JNK and NFκB signaling pathways that phosphorylates the insulin receptor and IRS proteins at 
serine residues (69, 99, 141, 178). Increased serine phosphorylation of IRS deactivates IRS-1 and 
impairs insulin signaling. This in turn, suppresses glucose uptake by GLUT-4 via the inactivation 
of IRS-1 and PI3k/Akt and eventually leads to the development of insulin resistance (168, 177, 
178). Taken together, increased oxidative stress and systemic inflammation serves as a 
connecting link between obesity, insulin resistance and cardiovascular diseases. 
 
1.4.2 8-isoprostane 
Isoprostanes are a biologically active family of prostaglandin (PG)-like compounds that 
play important pathophysiological roles in the pathogenesis of several disorders associated with 
elevated oxidative stress (224-228). Importantly, isoprostanes are potent vasoconstrictors formed 
by a non–enzymatic process of peroxidation of phospholipid-bound arachidonic acid in response 
to increased superoxide radicals (224, 225). This is followed by a phospholipase mediated 
cleavage process and finally release to the circulation and excretion in the urine (224, 225). 
Since, isoprostanes are the most stable products of lipid peroxidation compared to other 
products, they are easily detectable in urine and plasma samples (224, 225). Therefore, 
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isoprostanes are now considered as authentic markers of oxidative stress under various 
pathological conditions (224-228). Among isoprostanes, 8-isoprostane is the stable downstream 
product of lipid peroxidation released during oxidative stress (225, 226). The levels of 8-
isoprostanes are generally measured in plasma and urine samples (226). 8-isoprostane is a potent 
vasoconstrictor and a modulator of platelet activation. The basal level of 8-isoprostanes was 
found to be elevated in the pericardial fluid of patients with severe heart failure (227). Similarly, 
elevated levels of 8-isoprostane were found during various pathological conditions including 
obesity (228) reno-vascular hypertension (229) and diabetes (225). Thus, therapeutic tools that 
can reduce the levels of 8-isoprostane will be indicative of a strong antioxidant capacity and 
suppressors of oxidative stress. Thus, the measurement of 8-isoprostane in biological fluids 
might serve as a non-invasive marker for lipid peroxidation and will be helpful in determining 




Endothelin (ET) is a vasoconstrictor peptide that plays a role in blood pressure and fluid 
homeostasis (230-232). Clinical studies demonstrated the pathophysiological role of the 
endothelin system in various disease conditions such as hypertension, diabetes, atherosclerosis, 
coronary artery disease, heart and renal failure (26, 230-235). The ET family comprises three 
structurally similar 21 amino acid peptides namely ET-1, ET-2 and ET-3. ET-1 is the most 
abundant and potent peptide of the ET family with respect to its biological effect (26, 230-235). 
ET-1 is produced by endothelial cells of the vascular system (232). In general, ET-1 functions in 
an autocrine or paracrine manner and the biological action of ET-1 is mediated by two distinct 
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G-coupled receptors ETA and ETB (179, 230). ET-1 via the stimulation of ETA receptors 
exhibits its vasoconstrictor, proliferative and hypertrophic effects (232, 235). It is reported that 
stimulation of the ETA receptor, predominant in vascular smooth muscle of arteries contributes 
to vasoconstriction via the increase in intracellular calcium levels (179, 231, 232), while, 
activation of the ETB receptor in the veins, pulmonary vessels and endothelial cells leads to 
vasodilation through the synthesis of NO and prostacyclin (179, 232). Various stimuli such as 
angiotensin-II, epinephrine, thrombin, insulin, vasopressin, cytokines and hypoxia acts as a 
trigger for ET-1 production (231-233).  ET-1 is known to modulate other vasoactive molecules 
that play key roles in various biological functions (231-233). For example, ET-1 through its ETA 
receptor regulates angiotensin converting enzyme activity during obesity (231-233). ET-1 
potentiates the action of noradrenaline and serotonin and thereby, contributes to increased 
vasoconstriction in hypertensive subjects (232, 236). High levels of ET-1 is associated with a 
parallel increase in ROS generation. In the DOCA-salt hypertensive rat model, increased 
generation of ET-1 leads to a high production of superoxide in vascular tissue that ultimately 
leads to endothelial dysfunction and reduced NO bioavailability (232, 234, 235). Likewise, in 
vascular smooth muscle of rat aorta as well as in humans, high secretion and expression of ET-1 
was found to be associated with increased intracellular ROS production (232, 234). It is 
suggested that ET-1 potentiates ROS generation through the activation of signaling pathways 
including p38MAPK, JNK and ERK (232, 234, 237, 238). Overproduction of ROS in turn leads 
to an increased inflammatory response via the activation of the NFκB signaling pathway (69, 99, 
179, 239, 240). Both increased ROS and inflammation acts as an underlying mechanism for the 
pathogenesis of cardiometabolic disorders and serves as a link between obesity and 
cardiovascular diseases (3, 5, 14, 15, 26, 27, 29, 68, 69, 127, 145-149, 161, 241). 
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ET-1 plays a major role in the pathogenesis of obesity and associated complications (26, 
230-235). A positive correlation exists between elevated ET-1 plasma levels and obesity (26, 
179, 232). For example, high levels of ET-1 in the circulation have been detected in normal 
obese and obese individuals with hypertension (179, 232). Moreover, in experiments done with 
mice fed on a high fat diet, increased expression of ET-1 at both molecular and cellular levels 
has been observed (179). One of the possible explanations for the obesity mediated increase in 
ET-1 levels is the interplay between ET-1 and the RAAS system (179, 232, 237). During obesity, 
increased production of angiotensin-II (a potent pro-inflammatory molecule), in response to the 
elevated RAAS system, stimulates high expression and production of ET-1 in the vascular 
system that leads to increased vasoconstriction (179, 232, 237). Moreover, increased production 
of ET-1 in response to leptin might be another mechanism for high ET-1 generation during 
obesity (242). The elevated ET-1 mediated vasoconstriction during obesity leads to the inhibition 
of endothelium dependent vasodilation and contributes to the pathological condition of 
hypertension, atherosclerosis, heart failure and related disorders (26, 179, 232). 
High levels of ET-1 have been implicated in cardiac hypertrophy, fibrosis and vascular 
remodeling (231, 232, 235, 238). The ETA receptor plays a central role in the modulation of 
vascular activity (231). During the pathological conditions of heart failure, coronary artery 
disease, hypertension and endothelial dysfunction, high expression of ETA receptor has been 
observed (26, 230-235). Studies done with the hypertensive DOCA–salt animal model (235) and 
aldosterone-infused rats support the involvement of the ETA receptor in the pathogenesis of 
cardiac injury and remodeling. Blocking of the ETA receptor reduced oxidative stress, attenuated 
hypertrophic remodeling and fibrosis (231, 232, 235, 238). It is proposed that the mechanism for 
the ETA mediated inflammatory response in cardiac tissue involves NFκB activation, 
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stimulation of cell adhesion molecules and growth factors (231, 232, 235). NFκB is sensitive to 
increased oxidative stress and is stimulated in response to the NADPH oxidase-derived ROS (69, 
99, 179, 239, 240). It is reported that ET-1 promotes cardiac hypertrophy through the stimulation 
of NADPH oxidase enzyme that produces ROS and activates the MAPK signaling pathway (26, 
234, 238). The vasoconstrictor effect of ET-1 in cardiac tissue can be extended to renal tissue as 
well. ET-1 can modulate both vascular and tubular function in renal tissue and play a role in 
sodium homeostasis (230). Increased glomerular expression of ET-1 and prolonged stimulation 
of the ETA receptor may contribute to the progression of chronic kidney disease (230, 243). ET-
1 via its ETA receptor has been reported to alter renal function by modulating the glomerular 
filtration rate and increasing albuminuria (230). Moreover, stimulation of the ETA receptor 
promotes phenotypic changes on the podocytes and contributes to hyperplasic lesion formation 
(230, 243). However, neutralization of ETA receptors by the ETA antagonist not only protected 
against diabetes induced renal injury, but also prevented fibrosis and atrophy of the kidney and 
improved renal function (230, 243). Collectively, ET-1 has inflammatory, hypertrophic and 
fibrotic effects in cardiac and renal tissue. Thus, blocking of ET-1 and its receptors would have 
therapeutic effects against obesity and cardiovascular complications. 
 
1.5 Obesity and cardiomyopathy (See Appendix A for more details) 
Visceral adiposity is an independent risk factor for progression and development of 
cardiovascular diseases (1, 3-5, 10, 14, 15, 23, 62, 71, 75, 123, 127, 150, 244-254). Obesity itself 
is associated with multiple pathological conditions which themselves serve as important risk 
factors for various metabolic disorders including insulin resistance, type-2 diabetes, 
dyslipidemia, cardiovascular  and renal diseases (3, 5, 14, 15, 24, 27, 29, 58, 68, 69, 127, 149, 
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255-257). The dysfunctional adipose tissue is a key feature that links obesity and 
cardiometabolic complications (1-5, 15, 18, 72, 75, 124-127). Initially, under the normal 
physiological state, deposition of excessive fat takes place in non-ectopic tissue such as 
subcutaneous adipose tissue (1, 6, 72, 258). However, during conditions of obesity, once the 
maximal limit of subcutaneous adipose tissue is achieved, the later deposition of excess fat 
occurs in ectopic tissue sites including heart, liver, kidney and the vasculature (1, 6, 72, 75, 79, 
258). Thus, this ectopic fat (perivascular, epicardial and myocardial fat) exerts adverse effects on 
cardiac tissue and vasculature in both an endocrine and paracrine manner (1, 6, 7, 72, 253, 258). 
In general, pericardial fat depots were found along the large coronary arteries and on the surface 
of cardiac tissue. Furthermore, the ectopic fat deposition in the heart is the spread of epicardial 
fat into the atria and ventricles (1, 6, 72, 253, 258). This in turn causes structural and 
hemodynamic alterations of cardiac tissue as well as endothelial dysfunction, eventually leading 
to the development of obesity induced cardiomyopathy (1, 6, 7, 72, 75, 79, 150, 253, 258).  
 
1.5.1 Mechanisms responsible for obesity associated cardiomyopathy 
How does obesity induce cardiomyopathy? The exact mechanism responsible for obesity 
associated cardiovascular disorders is not completely understood. However, different 
mechanisms such as increased FFA levels, increased hemodynamic preload and afterload,  
insulin resistance, cardiac hypertrophy and fibrosis that correlate obesity and cardiovascular 
disease have been proposed (1, 6, 7, 72, 150, 253, 258, 259). It is proposed that excessive 
hypertrophy of adipocytes in response to chronic nutrient overload alters normal metabolic 
functions of adipose tissue and generates various stress responsive molecules and signals to 
neighboring cells. This in turn produce adipocytes apoptosis, local hypoxia, as well as ER stress 
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and leads to the abnormal secretion of adipokines and increased macrophage infiltration to the 
inflamed site (1, 3, 5, 15, 67, 76). As a consequence chronic low grade inflammation, increased 
oxidative stress and adipose tissue fibrosis alters insulin signaling and eventually leads to the 
development of insulin resistance (72, 150, 175, 260, 261). Thus, defective insulin signaling and 
subsequent insulin resistance is an important mechanism that links visceral obesity to 
cardiomyopathy (3, 5, 14, 15, 24, 29, 68, 69, 127, 145-150). Insulin plays a regulatory role in 
substrate metabolism in the heart (259, 262). Excess accumulation of lipids in cardiac tissue 
elicits adverse endocrine, paracrine and immune responses (259, 262). This results in increased 
production of inflammatory/ROS mediators, increased fatty acid oxidation, altered response to 
insulin and decreased glucose uptake that altogether contribute to an impaired IRS1/PI3K/Akt 
insulin signaling and subsequent development of insulin resistance in cardiomyocytes (259, 263, 
264). As a consequence, the development of left-ventricular hypertrophy, cardiac tissue 
remodeling, diastolic and systolic dysfunction eventually contribute to obesity induced 
cardiomyopathy and predispose to heart failure (129, 248, 265) (Figure 1-6). Moreover, obesity 
is also a contributing factor for hyperinsulinemia and hyperglycemia that leads to altered cardiac 
structure and function. It is proposed that hyperglycemia participates in cardiac injury via the 
enhanced production of ROS that leads to apoptosis of myocardial cells (129, 248, 265, 266). In 
addition, hyperglycemia-mediated generation of advanced glycation end-products and excessive 
remodeling of ECM proteins contribute to compromised cardiac function (129, 248, 265, 266).  
Another possible mechanism that contributes to obesity related cardiomyopathy is an 
altered RAAS system in response to dysfunctional adipose tissue metabolism (1, 13, 66, 91, 129, 
132, 248, 265, 267-277). It is reported that adipose tissue has been implicated in the production 
of components of the RAAS system including angiotensinogen, angiotensin-converting-enzyme 
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(ACE) and AT-1 (1, 254, 271, 276-279). Angiotensinogen is an important component of the 
RAAS system that is catalytically cleaved by renin to AT-I and subsequently to AT-II by the 
action of ACE. AT-11 acts as a growth factor for myocardial cells and contributes to different 
cellular process including hypertrophy, apoptosis, cell proliferation, fibrosis and cardiac 
dysfunction (129, 248, 265). In addition, during obesity abnormal activation of the RAAS system 
accompanied by upregulated renin activity and elevated aldosterone levels contribute to increase 
volume overload, vasoconstriction and insulin resistance  and the subsequent development of 
hypertension, myocardial and renal dysfunction (1, 66, 254, 271, 276-280).  
 
Figure 1-6: Schematic representation of the link between increased visceral adiposity, 




Abbreviations: Tumor necrosis factor (TNF-α); Interleukin (IL); Macrophage chemoattractant 
protein-1 (MCP-1); Macrophage inflammatory protein -1α (MIP-1α). 
 
1.5.2 Altered cardiac structure and function in obesity (See appendix D 3 for more details) 
 Obesity has various pathophysiological consequences affecting the cardiovascular 
system (1, 14, 23, 71, 129, 244-252, 265). Deposition of excess fat in ectopic and non-ectopic 
tissue adversely effects metabolic homeostasis and induces various structural adaptations and 
alterations in cardiac structure and function which may altogether contribute to cardiovascular 
diseases (1, 6, 72, 253, 258, 263). 
A recent study demonstrated that excessive fat accumulation in the body induces cardiac 
structural and functional changes as a beneficial adaptive response in order to maintain body 
homeostasis (60). This adaptive response during the initial phase of obesity is characterized by 
increased cardiac output and stroke volume in response to elevated plasma volume along with 
reduced peripheral resistance (60). However, with increasing duration and stage of obesity this 
beneficial adaptive response switches to a harmful maladaptive pathological response of obesity 
and associated cardiometabolic complications (1, 14, 23, 71, 244-252). With increasing duration 
of obesity, elevated plasma and blood volume shifts Frank-Starling curves to the left due to 
increased cardiac load (60, 129, 254). As a consequence, cardiac overload induces left-
ventricular remodeling characterized by increased left-ventricular wall thickness and left-
ventricular cavity enlargement. This ultimately leads to the development of left-ventricular 
hypertrophy which is an important predictor of heart failure (60, 129, 254, 281).  
Left-ventricular hypertrophy, myocardial fibrosis as well as increased cross linking of 
collagen are risk factors that contribute to altered diastolic and systolic function (60, 129, 248, 
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254, 265, 266, 281). The altered cardiac function in turn elevates myocardial oxygen demand 
(281-283) accompanied by increased apoptosis and necrosis of myocardial cells as well as 
accumulation of advanced glycation end-products in the myocardium. These pathological 
changes result in elevated myocardial inflammation and endothelial dysfunction that eventually 
predisposes to heart failure (60, 129, 254, 281, 283). The exact mechanism responsible for 
myocardial dysfunction needs further explanations. However, both volume and pressure load 
dependent alterations were suggested as the underlying mechanism for obesity induced cardiac 
dysfunction (10, 284). In addition, it was demonstrated that during the condition of excess 
accumulation of FFA in the cardiac tissue, there is a parallel increase in β-oxidation of FFA 
(254). When the deposition of FFA exceeds the capacity of the myocardium to further oxidize 
FFA, lipotoxicity occurs leading to cardiac dysfunction (10, 285), indicating that impaired 
myocardial metabolism plays an important role in obesity induced cardiac dysfunction (60, 129, 
254, 281, 283). 
 
1.5.3 Myocardial remodeling and fibrosis  
 Myocardial remodeling and fibrosis is an important pathophysiological process that leads 
to structural and functional changes in the heart in response to increased pressure and volume 
load and cardiac injury (129, 248, 265, 281, 283, 286). This process has been implicated in the 
development of left-ventricular hypertrophy and is associated with a chronic inflammatory 
process (129, 287-290). The heart is composed of various kinds of cells including endothelial 
cells, vascular smooth muscle cells, mast cells and cardiomyocytes surrounded by extracellular 
matrix (ECM) (6, 286, 287). Cardiomyocytes nearly comprise 70-80% of the heart mass and is 
composed of bundles of myofibrils that contain sarcomeres as repeating micro-anatomical units 
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(6, 286, 287). Under normal conditions, cardiomyocytes are surrounded by a network of collagen 
fibers that provide mechanical support. The ECM also contributes to maintain the elliptical shape 
of the heart and thickness and thereby, provides tensile strength to myocytes and blood vessels 
(291, 292). During the physiological condition of increased hemodynamic load, cardiomyocytes 
exhibit a homogenous hypertrophic response and undergo expansion by the synthesis of new 
contractile proteins (286, 287, 293). However, during pathological conditions of chronic 
overload, the fine network of collagen fibers is disrupted by the inhomogeneous abnormal 
deposition of interstitial collagen and overexpression of ECM proteins such as TGF-β and 
fibronectin leading to mechanical stiffness of cardiac tissue with subsequent diastolic 
dysfunction that can progress to impaired systolic function (286, 292). 
Various molecular, mechanical and biochemical stimuli including mechanical stress, 
neurohormonal activation, endothelin, inflammation and increased ROS generation has been 
implicated in the excessive synthesis of collagen from fibroblasts and vascular smooth muscle 
cells that leads to the remodeling and fibrosis of cardiac tissue (1, 66, 129, 254, 271, 276-280, 
286, 292). This in turn cause either apoptosis or necrosis of cardiomyocytes that induces the 
release of growth factors in the connective tissue to form new fibroblasts and ECM proteins. The 
abnormal increase in fibrosis, ECM synthesis and apoptosis of cardiomyocytes contribute to 
decreased contractile force, myocardial stiffness and compromised cardiac function (129, 248, 
265, 281, 283, 286, 292). In addition, chronic activation of the RAAS system via aldosterone and 
the sympathetic nervous system also contribute to cardiac tissue fibrosis and the development of 
left-ventricular hypertrophy during obesity (1, 66, 129, 254, 271, 276-280, 292). Thus, increased 
myocardial stiffness and reduced contractility in response to pathological cardiac remodelling 




1.5.4 Markers of heart failure 
1.5.4.1 Osteopontin 
Osteopontin (OPN) is a glycosylated phosphoprotein first isolated in 1986 from 
mineralized bone matrix (294). As the name implies, OPN is the main component of bone, 
however, it is produced by several cell types and tissues including osteocytes, chondrocytes, 
fibroblasts, macrophages, arterial smooth muscle cells, skeletal muscle, endothelial cells, brain  
and kidney (295-297). OPN exists as both an extracellular and intracellular protein and can be 
found as soluble protein in body fluids such as plasma, urine and milk (295-297). OPN has been 
implicated to play a pathophysiological role in various biological processes such as 
inflammation, fibrosis, bone mineralization, tissue modeling and obesity (294, 295, 297-308). 
 
1.5.4.1.1 Osteopontin and inflammation 
Mounting evidence suggests that OPN has been implicated in the pathogenesis of 
diseases related to chronic inflammation including obesity, diabetes, insulin resistance and 
cardiovascular disease (294, 295, 297-308). OPN is expressed by inflammatory macrophages and 
is highly activated in response to various inflammatory molecules such as LPS,TNF-α, IFN-γ, 
TGF-β, angiotensin-II, nitic oxide, IL-1β (295, 297, 299). The exact regulatory mechanism that 
governs OPN secretion from inflammatory macrophages is still not clear. It is proposed that 
stimulation of PI3K, ERK and JNK signaling cascade activate OPN expression in LPS induced 
macrophages (295, 299, 300, 303, 306). OPN plays a role in the macrophage infiltration process 
to the site of inflammation (295, 299, 300, 303, 306). Studies conducted using genetic 
approaches or through the use of neutralizing antibodies has shown that blocking of OPN 
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attenuates the recruitment of monocytes, macrophages and leukocytes to the inflamed tissue 
(295, 300). Moreover, the OPN promoter possesses the binding sites for pro-inflammatory 
transcriptional factors including AP-1 and NFκB and hence can modulate the expression of 
various inflammatory proteins (295, 301). OPN also plays an important role in tissue remodeling 
by stimulating the expression of matrix metalloproteinase (MMP) such as MMP-2 and MMP-3 
that degrades matrix and facilitates cell migration (295, 302). Interestingly, OPN favors 
inflammatory cytokine IL-12 induction and attenuates anti-inflammatory IL-10 cytokine 
production by macrophages during inflammation (295, 300). Taken together, OPN plays 
important roles in the expression of different cytokines and transcriptional factors and is a key 
player in the inflammatory process.  
 
1.5.4.1.2 Osteopontin and obesity 
OPN plays a key role in the pathogenesis of adipose tissue inflammation and insulin 
resistance (295, 300, 303-305). OPN expression is strongly elevated in adipose tissue of 
genetically obese mice or in the high fat diet induced obese mouse model (295, 298, 303). 
Similarly, in obese individuals as well as in obese diabetic and insulin resistant patients, the OPN 
levels in circulation and its expression in adipose tissue is highly upregulated (295, 298, 303). In 
contrast, blunting of the OPN expression by antibodies and deficiency of the OPN gene in mice 
improved insulin sensitivity, glucose tolerance and suppressed inflammation via the reduction of 
adipose tissue mediated IL-6, TNF-α, MCP-1 and iNOS expression (295, 303, 304). The exact 
mechanism for upregulation of OPN expression in inflammatory adipose tissue is not clear. It is 
proposed that the primary source for high OPN expression under obese conditions are adipose 
tissue macrophages in response to high glucose, TLR4 activation, IL-6 and IL-18 factors (295, 
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303). A recent study demonstrated that the glucose dependent insulinotropic peptide (GIP) an 
incretin hormone that plays an important role in the process of adipogenesis also induce OPN 
expression in adipocytes (295, 305). OPN in turn, activates several inflammatory signaling 
cascades such as Akt, p38 MAPK, and ERK, increases the expression of TNF-α and MCP-1 in 
macrophages that leads to the subsequent development of adipose tissue mediated insulin 
resistance and diabetes (295, 306). Thus, OPN is implicated as an important component in the 
development of obesity associated inflammation and insulin resistance.  
 
1.5.4.1.3 Osteopontin and myocardial disorder 
Under physiological conditions, the expression of OPN in the myocytes, fibroblasts and 
endothelial cells of cardiac tissue is low at a basal level. However, pathophysiological conditions 
such as hypertrophy and factors such as endothelin-1, angiotensin-II, IFN-γ and cytokine like IL-
1β triggers a strong expression of OPN in cardiac tissue (294, 298, 307). Angiotensin-II is 
regarded as a potent inducer of OPN in the vasculature during the atherosclerotic process (297). 
It is reported that in myocytes, high expression of OPN is stimulated in response to increased 
myocyte apoptosis and impaired myocardial function (294, 298, 307). In contrast, in various 
models of cardiac hypertrophy and heart failure, deficiency of the OPN gene is related to 
decreased myocardial fibrosis and myocyte apoptosis (294, 298, 307). In patients with heart 
failure, high levels of OPN in plasma is found compared to their normal counterparts (308). The 
elevated OPN expression in cardiac tissue and in the circulation can be related to myocyte 
hypertrophy, myocardial dysfunction and the severity of heart failure (294, 308). Recently, it was 
demonstrated that increased OPN activity in heart failure patients was associated with a parallel 
increase in the activity of lysyl oxidase (an enzyme involved in extra-cellular protein 
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remodeling) and collagen deposition (308). Furthermore, increased plasma levels of OPN during 
pulmonary hypertension was associated with altered right ventricle function and tissue 
remodeling (294, 298, 307). These findings suggest that elevated expression of OPN in 
circulation and in cardiac tissue is a predictor of impaired cardiac function and remodeling and 
subsequent heart failure. 
 
1.5.4.2 Osteoprotegerin 
Osteoprotegerin (OPG) is a secreted glycoprotein of the tumour necrosis factor receptor 
(TNFR) super family (309, 310). It plays an important regulatory role in bone turnover and 
inhibits osteoclast differentiation. OPG exerts its effect via binding to two ligands, RANKL 
(receptor activator of NFκB ligand) and TRAIL (TNF related apoptosis inducing ligand). 
RANKL is a cytokine produced by osteoblasts and bone marrow stromal cells that with the help 
of its receptor RANK induces osteoclast differentiation (311, 312). OPG blocks RANKL-RANK 
ligation, thereby inhibiting osteoclastogenesis (310). OPG is reported to be constitutively 
expressed by smooth muscle and endothelial cells in the vasculature (309, 310). In addition, 
various growth factors and pro-inflammatory cytokines such as TNF-α, IL-1β, platelet derived 
growth factor (PDGF) and angiotensin-II can stimulate the OPG expression during inflammatory 
processes in both vascular smooth muscle cells and endothelial cells (309, 310). Activation of 
endothelial cells by TNF-α and IL-1β, might be one of the mechanisms for high plasma levels of 
OPG in patients with cardiovascular complications and is a contributing factor for  endothelial 
cell dysfunction (309, 311). OPG induces migration and adhesion of immune cells (leukocyte, 
macrophages, lymphocytes) (310), a primary step of endothelial dysfunction through the 
activation of various endothelial adhesion molecules including ICAM-1 (intercellular adhesion 
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molecule-1), VCAM-1 (vascular cell adhesion molecule-1), and E-selectin as well as stimulation 
of metalloproteinase activity in the vasculature (309). OPG promotes remodeling of ECM by 
potentiating the induction of expression of profibrotic proteins such as TGF-β, fibronectin and 
collagen type I, III and IV (309, 310). A recent study proposed that a vicious cycle prevails 
between TGF-β and OPG, as TGF-β mediated activation of smooth muscle cells results in the 
high production of OPG in response to PDGF and angiotensin II (310). 
The role of bone regulatory protein OPG in cardiovascular physiology is a topic of much 
interest. OPG is known to play key pathophysiological roles in cardiovascular disease and 
exhibit inflammatory and proliferative effects (309-312). OPG is a critical regulator of arterial 
calcification during the atherosclerotic process that leads to the development of cardiovascular 
disease (309-312). Infact, the RANKL/RANK/OPG system participates in the inflammation 
related atherosclerotic process (309). Despite these findings, the actual mechanism that 
interrelates inflammation, OPG and cardiovascular events still needs to be clarified. However, 
OPG can serve as an important biological marker for cardiovascular diseases and heart failure. 
 
1.6 Atrial natriuretic peptide (ANP) (See Appendix D 4 for more details) 
ANP is a peptide hormone mainly secreted by the heart atria (313-316). It belongs to a 
structurally related hormone family composed of brain natriuretic peptide (BNP) and the C-type 
natriuretic peptide (CNP) (313-316). Under physiological and pathophysiological conditions, 
ANP can function as an autocrine and paracrine factor in different organs including, heart, 
kidney, lung, thymus and liver (315-317). ANP plays an important role in the immune response 
and contributes to innate immunity (315-324). ANP plays important roles in blood pressure 
homeostasis and exhibits anti-inflammatory, natriuretic and diuretic effects (315-324).  
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Moreover, ANP attenuates cardiac hypertrophy (314, 316, 324), promotes peripheral 
vasodilation and has a modulatory role in cardiac and vascular remodeling (315, 317). It 
suppresses total peripheral resistance via its inhibitory effect on the release of rennin, vasopressin 
and aldosterone (315). ANP also possess anti-proliferative properties (315, 317). It is suggested 
that in vascular and cardiac cells, ANP promotes anti-proliferative effects via the reduction of 
intracellular adenosine 3', 5'-cyclic monophosphate (cAMP) levels and inhibition of MAPK and 
protein kinase G signaling pathways (315, 317). 
 
1.6.1 Obesity and ANP 
Mounting evidence confers that an inverse relationship exists between obesity and 
natriuretic peptide levels in the circulation (319, 320, 325). Interestingly, increased ANP levels 
due to genetic polymorphism in the ANP promoter region was found to be associated with 
reduced blood pressure, BMI and lower risk for obesity and metabolic syndrome (319-321, 326, 
327). Moreover, increased levels of natriuretic peptide are accompanied by reduced VAT and 
ectopic fat deposition in metabolic organs (319). In obese individuals, the circulating levels of 
natriuretic peptides is highly reduced compared to lean subjects that can be restored by physical 
exercise done for long duration (319). In addition, in obese individuals an altered secretion of 
myocardial natriuretic peptide has been observed (321). One of the possible reasons for 
decreased natriuretic peptide levels might be the degradation of natriuretic peptide by neutral 
endopeptidase neprilysin and NPRC receptor in obese individuals (319). It is demonstrated that 
in obese individual with hypertension, higher expression of NPRC is observed in adipose tissue 
compared to their normal counterparts (319). In human adipocytes and monocytes, NPRC 
expression was increased in response to hyperinsulinemia (319). 
46 
 
ANP plays a major role in lipid metabolism. ANP acts as a stimulator for lipolysis in 
adipose tissue (319, 321, 328).  ANP-induced lipolysis in turn promotes FFA release which 
serves as a substrate for metabolic tissues and results in increased lipid oxidation via the β-
oxidation pathway in adipose tissue (319). It is observed that short term administration of 
intravenous ANP for a enhanced lipid oxidation in normal individuals (328). More investigation 
to delineate the initial steps of the mechanism responsible for ANP-induced enhanced lipid 
oxidation and mitochondrial biogenesis may help to design novel targets for the treatment of 
obesity related metabolic diseases. 
 
1.7 Adiponectin (See Appendix D 5 for more details) 
1.7.1 Adiponectin and obesity 
Adiponectin is an anti-inflammatory adipokine that plays a major role in the regulation of 
tissue inflammation, lipid metabolism and cardiovascular homeostasis (219, 220, 222, 329-339). 
It serves as a key molecule that links obesity to insulin resistance and cardiovascular disease 
(220, 329, 334, 336, 337). Compared to other adipokines, adiponectin exhibits diverse biological 
functions owing to its anti-diabetic, antioxidant, anti-atherogenic and insulin sensitizing effects 
(219, 220, 222, 329-338). Adiponectin is vasoprotective and demonstrated to be beneficial 
against pathological conditions of obesity, inflammation, insulin resistance, type-2 diabetes and 
atherosclerosis (219, 220, 222, 329-338). Studies conducted on a knockout mice model revealed 
that compared to wild type, adiponectin-knockout (Adipo-KO) mice fed a high fat diet exhibited 
dysfunctional insulin signaling, high levels of TNF-α in both plasma and adipose tissue and were 
highly insulin resistant (219, 332). However, administration of adiponectin via adenovirus 
transfer improved insulin sensitivity in these Adipo-KO mice (219). Adiponectin is mainly 
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secreted from adipocytes; however, it is produced by cardiomyocytes as well (329, 340). It is 
interesting to know that although, adipose tissue is the main site for adiponectin production, 
reduced levels of adiponectin is associated with obesity (219-223). The exact mechanism 
responsible for this is not clear. It is suggested that obesity-induced hyperinsulinemia and 
overproduction of pro-inflammatory cytokines such as TNF-α and IL-6 exert reciprocal effects 
on adiponectin expression that results in reduced systemic levels of adiponectin during obesity 
(222). Moreover, ER stress-induced impaired processing of adiponectin protein might be another 
reason for reduced adiponectin levels during obesity (222, 335). In addition, the size of 
adipocytes and insulin sensitivity are the driving force for adiponectin production. For example, 
adipocytes that are large and are insulin resistant secrete less adiponectin (222, 335). 
In general, the physiological levels of circulating adiponectin is found to be nearly, 0.5-
30 µg/ml, which is about 0.01% of total plasma proteins (333). An inverse relationship has been 
observed between circulating levels of adiponectin and various pathological conditions of 
obesity and cardiovascular disease (219, 221, 222, 331, 332, 334). It is reported that low plasma 
levels of adiponectin are found in obese humans and in obese animal models with insulin 
resistance (219-221). Moreover, reduced circulating levels of adiponectin were reported in 
patients with type-2 diabetes, coronary artery disease, hypertension, dyslipidemia and during 
excessive oxidative stress conditions (219-221). In contrast, during chronic heart or renal failure, 
elevated levels of adiponectin were reported (219). However, the underlying mechanism 
responsible for high levels of adiponectin during these disease conditions is still not clear. 
Taken together, these studies support that adiponectin plays a pivotal regulatory role in 





1.8 Heme oxygenase (HO) system (Refer Appendix B and Appendix C for more details)  
Section 1.8 (Shuchita et al., Curr Pharm Des. 2014; 20(9):1354-69) has been reformatted 
from the original version of the manuscript, co-authored with my supervisor Joseph Fomusi 
Ndisang for inclusion in the thesis. In this review article, as primary author, I was responsible for 
the first draft of the manuscript and revised the manuscript as suggested by the supervisor.  
  
1.8.1 Overview of HO system 
HO is an evolutionarily conserved stress-responsive protein that protects from several 
immune-mediated inflammatory diseases and restores cellular homeostasis upon exposure to 
various stimuli. HO is the rate-limiting enzyme that catalyzes the degradation of the heme 
molecule generating an equimolar ratio of carbon monoxide (CO), biliverdin (IXa) isomer and 
free iron. Biliverdin is subsequently converted to bilirubin, another cytoprotective compound, via 
the action of biliverdin reductase and free iron is promptly sequestered into ferritin, an 
antioxidant (34, 35, 341, 342). The downstream products of HO possess important antioxidant, 
anti-inflammatory properties through which HO exhibits its cytoprotective function depicted in 
Figure 1-8 (3-5, 32-54). Thus the HO system generates a tetrad of cytoprotective molecules, 
suggesting that compounds like HO inducers that enhance HO activity could have a 








The Heme oxygenase system 
 
Figure 1-8: Schematic representation of cytoprotective role of the heme oxygenase system. 
Adapted and reformatted from Shuchita et al., Curr Pharm Des. 2014; 20(9):1354-69. 
Abbreviations used; CO (carbon monoxide), Biliverdin Reductase (BVR); Fe2+ (Iron); HO-
1(heme oxygenase-1); NADPH (Nicotinamide adenine dinucleotide phosphate) 
 
1.8.2 Distribution and isoforms of HO 
The HO enzyme consists of three isoforms, the inducible HO-1, also known as heat shock 
protein (hsp 32), the constitutive HO-2 and HO-3, a pseudo-derivative of HO-2 (41, 341, 342). 
HO-1 (~32 KDa), encoded by the HMOX1 gene, is induced by a broad spectrum of 
pharmaceutical agents (35) and stimuli with widespread tissue distribution, including liver, 
kidney and lung. The constitutively synthesized HO-2 (~36 KDa) encoded by the HMOX2 gene 
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is localized primarily in the brain, testis, and the vascular endothelium (37, 44, 343). Still poorly 
understood HO-3 (33 KDa) is a constitutively expressed pseudogene derived from HO-2 
transcripts, with very little demonstrable activity and unknown function (344, 345). Both HO-1 
and HO-2 catalyzes the heme degradation pathway and are similar in respect to mechanism of 
heme oxidation, cofactors and substrate specificities (5, 35, 52).  
 
1.8.3 Cytoprotective role of HO and its by-products 
Upregulation of HO-1 by a number of agonistic stress stimuli plays beneficial roles and is 
associated with potential clinical applications in various pathological states including 
atherosclerosis, transplant rejection, hypertension, acute renal injury hypoxia, ischemia and 
inflammation (3-5, 32-54). HO-1 is induced by both heme and non-heme products including 
hydrogen peroxide, ultraviolet (UV) radiation, heavy metals, hypoxia, nitic oxide, shear stress, 
endotoxin, cytokines, growth factors and oxidized low-density lipoprotein (LDL)(36, 43, 343, 
346). A plethora of studies have demonstrated that the induction of HO-1 and the subsequent 
metabolites of heme catabolism play vital roles in regulating important biological responses 
including inflammation, oxidative stress, cell survival, and cell proliferation (3-5, 32-54). The 
proposed mechanisms by which HO-1 exerts its biological effects include its ability to degrade 
the pro-oxidative heme (derived from various ubiquitously distributed heme proteins), the release 
of biliverdin and subsequent conversion to bilirubin, both of which have antioxidant properties 
and the generation of carbon monoxide, which has vasodilatory, anti-proliferative, and anti-
inflammatory properties (38, 39, 44, 205, 347-352). HO-1-derived bilirubin is an efficient 
scavenger of reactive oxygen and nitrogen species (RONS) (38-40, 205, 347-351). The 
beneficial role of induction of HO-1 expression resulting in anti-hypertension, anti-diabetes and 
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reno-protection has been reported in various animal models (3-5, 32-54). Although, mechanisms 
underlying HO-1 induction is still not unveiled completely, it is demonstrated that the regulation 
of HO-1 is complex and essentially regulated at the transcriptional level which is cell and tissue 
specific (352, 353).  
 Taken together, these findings have led to the notion that the HO and its catabolic 
products could be used as a promising therapeutic target against vascular dysfunction, 
inflammatory disease states and cardiovascular diseases. 
 
1.9. Summary  
Collectively, the introductory material above gives a detailed picture of the current state 
of knowledge related to obesity and cardio-metabolic complications (see appendices for more 
detailed description). In general, obesity is associated with various health consequences 
including insulin resistance, type-2 diabetes, cardiomyopathy, nephropathy and hypertension (1, 
11, 14, 15, 27, 57-60, 62, 64, 65, 68, 69). Visceral obesity, like pericardial adiposity, is an 
established risk factor for cardiovascular diseases (6-8, 12, 354). Moreover, elevated 
inflammation, increased oxidative stress, altered lipid metabolism, insulin resistance, impaired 
glucose metabolism and excessive ECM deposition are among the possible mechanisms which 
are implicated in altered cardiac structure and function (13-15, 27, 29, 30, 58, 68, 69, 149, 150) 
and links obesity with cardiomyopathy. Since the cytoprotective role of HO is well 
acknowledged (3-5, 32-54) in the present thesis the effects of upregulating HO with hemin on 
cardiomyopathy in obese ZF rats was investigated and the mechanism by which HO improves 




1.10 Rationale  
Visceral obesity is an established cardiovascular risk factor and a serious health issue 
worldwide (1-12, 14, 15, 80, 123, 129, 248). In obesity, high levels of pro-inflammatory 
cytokines/chemokines, increased oxidative stress and excessive infiltration of macrophages (1, 3, 
5, 15, 16, 20, 67, 76, 150, 175) constitute a major damaging force for tissue homeostasis. In 
obese individuals, vital organs including the heart are exposed to incessant inflammatory and 
oxidative insults that ultimately leads to cardiac dysfunction and impaired insulin signaling. If 
this conditions persist, heart failure and other cardiovascular complications may arise (6, 12, 26, 
135, 150, 265, 355, 356).  
Generally, heart failure is characterized by elevated levels of osteopontin (294, 297, 298, 
308), osteoprotegerin (311, 357, 358), endothelin-1 (230-232, 234), 8-isoprostane (224, 227) and 
ECM/profibrotic factors such as TGF-𝛽, collagen, and fibronectin (21, 286, 292, 293), pro-
inflammatory cytokines (TNF-𝛼, IL-6, IL-1𝛽) (1, 3, 5, 15, 24, 67, 76, 115) and chemokines 
(MCP-1 and MIP-1α) (16, 19, 132). Interestingly, these inflammatory/oxidative mediators are 
elevated during obesity (2, 16, 26, 30, 75, 83, 131, 132, 179, 217, 232, 257, 298) that would act 
in concert to further exacerbate cardiac injury and compromising cardiac function. Thus, there is 
need for new therapeutic strategies with novel mechanisms of action that can be used clinically 
to counteract the adverse effects associated with obesity and cardiomyopathy. An upregulated 
HO can be used as an alternative approach to combat obesity and associated cardiovascular 
comorbidities. Our lab and other clinical studies have acknowledged the beneficial role of the 
HO system in response to various pathophysiological stress conditions (3-5, 32-54). However, 
the activation of HO by different stress stimuli under pathophysiological conditions only results 
in the transient increase in HO activity that falls below the optimum level required for the 
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stimulation of downstream signaling components through which the HO system confers 
cytoprotection. Hence, to activate the HO system above the threshold levels, HO inducers like 
hemin may be needed for cardioprotection (4, 53, 54, 195, 196, 359).  
Our lab recently reported the anti-diabetic and insulin sensitizing effects of the HO 
inducer hemin in different animal models such as the spontaneously hypertensive rat model, 
deoxycorticosterone acetate-salt hypertensive rat model and Goto-Kakizaki rat model (53, 192, 
195, 201, 202). However, so far no systemic study has been carried out to demonstrate the effects 
of an upregulated HO system by hemin on macrophage polarization and its effects on insulin 
signaling and cardiomyopathy in ZF rats, an obese rat model characterized by insulin resistance, 
hyperinsulinemia, glucose intolerance, hypertriglyceridemia, hypercholesterolemia, and 
cardiomyopathy. Similarly, the effect of the HO system on pericardial adiposity in ZF rats 
remains to be elucidated. Furthermore, no study has been done on the effects of hemin therapy 
on the markers of heart failure such as osteopontin and osteoprotegerin in cardiac tissue of ZF 
rats. Moreover, the effects of an upregulated HO system on cardiac ANP or adiponectin in obese 
ZF rats need to be elucidated. It is important to investigate, if an upregulated HO system by 
hemin would alleviate the aberrant insulin signaling and impaired glucose metabolism in obese 
ZF rats and attenuates cardiomyopathy. 
 
1.11 General hypothesis  
Based on the above background knowledge, it is hypothesized that upregulation of the HO 





1.12 Thesis objectives: The main objectives of my thesis work are 
 to determine the effect of hemin on HO-1 concentration in the left ventricle tissue of  ZF 
rats. 
 to investigate the effects of hemin on pro-inflammatory cytokines and chemokines in the 
left ventricle tissue of  ZF rats. 
 to investigate whether hemin treatment attenuates macrophage infiltration and to analyze 
its effects on pro-inflammatory M1-phenotype and anti-inflammatory M2-phenotype 
markers in cardiac tissue of ZF rats.  
 to assess whether hemin treatment suppresses oxidative stress in ZF rats. 
 to determine if hemin treatment exhibits protection against excessive deposition of 
extracellular matrix and profibrotic proteins in the left ventricle tissue of ZF rats. 
 to investigate whether an upregulated HO system potentiates important proteins of the 
insulin signal transduction pathway in obese and insulin resistant ZF rats. 
 to study the effects of hemin on glucose intolerance and insulin resistance in ZF rats.  
 to investigate whether hemin treatment enhances ANP and adiponectin in ZF rats. 
 to assess whether hemin treatment attenuates cardiac lesions in ZF rats. 
 to investigate whether treatment with hemin improves cardiac function by measuring 
various echocardiographic and hemodynamic parameters and suppresses the markers of 




The results of this thesis has been published as two manuscripts 
 
CHAPTER 2 
The risk of heart failure and cardiometabolic complications in obesity may be 
masked by an apparent healthy status of normal blood glucose  
 
Shuchita Tiwari, Manish Mishra, Ashok Jadhav, Courtney Gerger†, Paul Lee,  
Lynn Weber† and Joseph Fomusi Ndisang  
 
This chapter has been published as a research paper in 
 
 
Oxidative Medicine and Cellular Longevity Volume 2013, Article ID 253657, 16 
pages 
 
My contribution to this paper: (Shuchita et al., Oxid Med Cell Longev. 2013; 2013:253657) 
was co-authored with Manish Mishra, Ashok Jadhav, Courtney Gerger, Paul Lee, Lynn Weber, 
and my supervisor Joseph Fomusi Ndisang. This chapter describes the role of an upregulated HO 
system by hemin on cardiomyopathy in ZF rats and the multifaceted mechanisms by which 
hemin therapy improves insulin signaling, glucose metabolism and cardiac function.  Moreover, 
this chapter suggests that perturbations in insulin signaling and cardiac function may be 
forerunners to overt hyperglycemia and heart failure in obesity. The experimental approach was 
designed in accordance with objectives as described in chapter 1. In this study, I was responsible 
for performing all experiments, collection of all data, statistical analyses, making figures and 
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tables. As primary author, I drafted the first version of the manuscript, given all major 
interpretations, synthesized information, and revised the manuscript with input from all co-
authors. My supervisor Joseph Fomusi Ndisang conceived the idea for the work and provided 
critical input towards my experimental protocol and manuscript writing. 
 
2.1 Abstract 
Although, many obese individuals are normoglycemic and asymptomatic of 
cardiometabolic complications, this apparent healthy state may be a misnomer. Since heart 
failure is a major cause of mortality in obesity, we investigated the effects of heme-oxygenase 
(HO) on heart failure and cardiometabolic complications in obese normoglycemic Zucker-fatty-
rats (ZF rats).Treatment with the HO-inducer, hemin reduced markers of heart failure such as 
osteopontin and osteoprotegerin, and abated left-ventricular hypertrophy/fibrosis, extracellular 
matrix/pro-fibrotic proteins including collagen-IV, fibronectin, TGF-β1, and reduced cardiac 
lesions. Furthermore, hemin suppressed inflammation by abating macrophage chemoattractant 
protein-1, macrophage-inflammatory protein-1 alpha, TNF-α, IL-6 and IL-1β but enhanced 
adiponectin, atrial-natriuretic-peptide (ANP), HO-activity, insulin sensitivity and glucose 
metabolism. Correspondingly, hemin improved several hemodynamic/echocardiographic 
parameters including left-ventricular -diastolic wall-thickness, left-ventricular -systolic wall-
thickness, mean-arterial pressure, arterial-systolic pressure, arterial-diastolic pressure, left-
ventricular -developed pressure, +dP/dt and cardiac output. Contrarily, the HO-inhibitor, 
stannous-mesoporphyrin nullified the hemin-effect, exacerbating inflammatory/oxidative insults 
and aggravated insulin resistance (HOMA-index).  
We conclude that perturbations in insulin-signaling and cardiac function may be 
forerunners to overt hyperglycemia and heart failure in obesity. Importantly, hemin improves 
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cardiac function by suppressing markers of heart failure, left-ventricular hypertrophy, cardiac 
lesions, extracellular matrix/pro-fibrotic proteins, inflammatory/oxidative mediators, while 
concomitantly enhancing the HO-adiponectin-ANP axis. 
 
2.2 Introduction 
The recent escalation of obesity in every segment of the population including children, 
adolescences and adults poses a great health challenge of considerable socioeconomic burden 
(61, 360). The impact on healthcare systems may become unsustainable given the numerous 
chronic diseases such as type-2 diabetes, dyslipidemia, hypertension and other related 
cardiometabolic complications associated with obesity (61, 360, 361). Cardiac complications 
including heart failure is among the major causes of mortality in obese individuals. Obesity 
causes lipotoxicity and adipose tissue dysfunction with excessive production of adipokines like 
tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), IL-1β, all of which are implicated in heart 
failure and related cardiometabolic complications (206, 254). However, obesity may not always 
translate into increased risk for these comorbidities (362). Some obese individuals dubbed 
‘metabolically healthy’ are protected against obesity-related metabolic diseases. These 
‘metabolically healthy’ obese individuals are insulin-sensitive with normal lipid metabolism and 
cardiac function similar to healthy lean individuals, which is in stark contrast to ‘metabolically 
unhealthy’ obese individuals with high risk of developing cardiometabolic complications (80, 
362). However, the apparent state of good health in ‘metabolically healthy’ obese sub-phenotype 
may be a misnomer because the development of several characteristics of metabolic syndrome is 
now being observed in many adults who previously manifested the healthy obese phenotype 
(363), suggesting that individuals with a healthy obese phenotype may not remain healthy for 
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their entire lives. Several parameters including environmental and behavioral factors may modify 
obesity sub-phenotypes, and the transition from healthy to unhealthy. Whether healthy obese 
individuals can maintain insulin sensitivity during the entire life or whether healthy obesity 
simply represents delayed onset of obesity related cardiometabolic complications has to be 
clarified.  
In obesity, excessive oxidative stress, intense inflammatory activity, insulin resistance, 
deregulated lipid metabolism, altered glucose metabolism and impaired mitochondrial biogenesis 
are among the pathophysiological driving forces that precede the early stages of cardiac 
dysfunction. Many cardiac complications have the common denominator of elevated 
inflammation due to the infiltration of macrophage M1-phenotype (364). Generally, 
macrophages exhibit two different forms dubbed “classical” or M1-phenotype and “alternative” 
or M2-phenotype (364), and each phenotype express distinct patterns of surface receptors when 
responding to different stimuli. The M1-phenotype stimulates inflammation while the M2-
phenotype blunts inflammation (364). During macrophage infiltration, the M1-phenotype is 
stimulated by different chemokines  including macrophage inflammatory protein-1 alpha [(MIP-
1α), chemokine (C-C motif) ligand-3 (CCL3)] and macrophage chemoattractant protein-1 
[(MCP-1) (158), chemokine (C-C motif ligand-2 (CCL2)] (158). The activation of the 
macrophage M1-phenotype is generally associated with elevated levels of pro-inflammatory 
cytokines including TNF-α, IL-6 and IL-1β (5, 365, 366). Moreover, the levels of macrophage 
M1-phenotype, MCP-1, TNF-α, IL-6 and IL-1β are elevated in obesity and insulin resistance (3, 
158, 365), and these factors play a major pathophysiological role in heart failure (254). In 
obesity, markers of heart failure such as osteopontin (367) and osteoprotegerin (357) are elevated 
(306, 358). Similarly, the levels of extracellular matrix/profibrotic proteins like transforming 
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growth factor beta (TGF-β), collagen and fibronectin are elevated in obesity (368). Therefore, in 
obesity elevated chemokines, cytokines and increased macrophage-M1 infiltration would act in 
concert with elevated extracellular matrix/profibrotic and heart-failure proteins to exacerbate 
cardiac tissue destruction and compromise heart function. Thus, novel strategies capable of 
selectively suppressing macrophage M1-phenotype, pro-inflammatory cytokines/chemokines and 
extracellular matrix/profibrotic proteins are needed. 
In many pathophysiological conditions, various stress-response immune-regulatory 
proteins, including heme oxygenase (HO-1) are activated as an innate defense mechanism (369-
372).  However, the pathophysiological activation of HO-1 may only result in a transient or 
marginal increase of HO-activity that falls below the threshold necessary to activate the 
downstream signaling components through which the HO system elicits its cytoprotective 
effects, so a robust and surmountable increase of HO-activity with HO-inducers like hemin may 
be needed for cardio-protection (193, 201, 202, 207, 373). Generally, HO is composed of two 
main isoforms (HO-1 or inducible) and (HO-2 or constitutive), which are largely responsible for 
the anti-oxidant and anti-inflammatory effects of HO (205). We recently reported the 
cardioprotective effects of the HO system in Zucker diabetic fatty rats (ZDFs) (3), a model 
characterized by obesity, insulin resistance and overt hyperglycemia. However, because ZDFs 
are hyperglycemic, their pathophysiological profile is not reflective of individuals dubbed 
‘metabolically healthy’, a subtype of obesity characterized by normoglycemia (363). Given that 
the incidence of cardiometabolic complications is increasing in many adults who previously 
manifested the metabolically healthy obese phenotype (363), novel studies with animal models 
that closely mimic the pathophysiological profile of metabolically healthy obese subtype are 
needed. Therefore, this study will investigate the effects of the HO system on cardiometabolic 
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complications in Zucker fatty rats (ZF rats), an obese model with normoglycemia and 
cardiometabolic complications (374) that closely mimic the pathophysiological profile of 
metabolically healthy obese individuals with normoglycemia and an apparent state of good 
health. Although the HO system is cytoprotective, its effects on cardiomyopathy in ZF rats 
remain to be elucidated. 
Since, dysfunctional insulin signaling, obesity, elevated inflammation and cardiac 
hypertrophy are forerunners to heart failure, this study will also investigate the multifaceted 
mechanisms by which the HO system preserves cardiac function in ZF rats. Whether, an 
upregulated HO system by hemin is capable of modulating macrophage polarization towards the 
M2-phenotype that blunts inflammation, while suppressing the pro-inflammatory M1-phenotype 
will be assessed. As macrophage infiltration is stimulated by chemokines like MIP-1α and MCP-
1 (158), and the effects of the HO system on these chemokines in ZF rats have not been reported, 
this study will also determine left-ventricular MIP-1α and MCP-1 and correlate changes of these 
chemokines to the expression of the pro-inflammatory macrophage-M1-phenotype in the left 
ventricle of ZF rats. Similarly, the effect of hemin therapy on important markers of heart failure 
such as osteopontin (357) and osteoprotegerin (306) will be investigated. Importantly, no study 
has reported the levels of expression of osteopontin and osteoprotegerin in myocardial tissue of 
ZF rats. Therefore this study will unveil the multifaceted mechanisms by which hemin therapy 







2.3 Materials and Methods 
2.3.1 Animals, treatment groups and biochemical parameters 
Our experimental protocol was in conformity with the Guide for Care and Use of 
Laboratory Animals stipulated by the Canadian Council on Animal Care and the National 
Institutes of Health (NIH Publication No. 85-23, revised 1996), and was approved by University 
of Saskatchewan Animal Ethics Committee. Male ZF rats (12 weeks old) and sex/age-matched 
Zucker lean (ZL) rats were purchased from Charles River Laboratories (Willington, MA). The 
animals were housed at 21C with 12-hour light/dark cycles, fed with standard laboratory chow 
and had access to drinking water ad libitum.  
The HO-inducer, hemin (30 mg/kg i.p., Sigma, St Louis, MO), and HO-blocker stannous-
mesoporphyrin [(SnMP) 2 mg/100 g body weight i.p.] were purchased from Porphyrin Products 
(Logan, UT), and prepared as we previously reported and administered biweekly for 8 weeks (3, 
124, 200). At 16 weeks of age, the animals were randomly assigned to the following 
experimental groups (n=6 per group): (A) controls (ZF and ZL), (B) hemin-treated ZF and ZL, 
(C) ZF+Hemin+SnMP and (D) ZF+vehicle dissolving hemin and SnMP.  
During the treatment period body-weight and glucose were monitored on a weekly 
routine. Body-weight was measured using a digital balance (Model Mettler PE1600, Mettler 
Instruments Corporation, Greifensee, Zurich, Switzerland). At the end of the 8-week treatment 
period, the animals were 24 weeks of age. A day prior to killing, the animals were fasted in 
metabolic cages for 24-hr urine collection and weighed. Systolic blood pressure was determined 
by non-invasive tail-cuff method, while a Millar Mikro-Tip ultra-miniature tip sensor pressure 
transducer catheter (Model SPR-407, Harvard Apparatus, Montreal, Canada) for invasive 
hemodynamic parameters. In addition, a Vevo 660 high frequency ultrasound machine (Visual 
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Sonics, Markham, ON, Canada) equipped with B-mode imaging was used for echocardiographic 
measurements as we previously reported (3).  After anaesthetizing the animals with pentobarbital 
sodium (50 mg/kg i.p.), blood was collected by cardiac puncture, and the pericardial fat pad and 
the heart isolated, cleaned and weighed with an analytical balance  as previously reported (187). 
The atria were removed from the heart and the right ventricle free wall separated from the left 
ventricle including the septum as we previously reported (187).  
Left-ventricular HO activity was evaluated spectrophotometrically as we previously 
reported (187, 200). ELISA kits were used for HO-1 (Stressgen-Assay Design, Ann Arbor, MI, 
USA), adiponectin (Phenix Pharmaceuticals, Inc, Burlingame, CA, USA), TNF-α, IL-6 and IL-
1β (Immuno-Biological Laboratories Co Ltd, Gunma, Japan), MIP-1α and MCP-1 (OmniKine™, 
Assay Biotechnology Company Inc, Sunnyvale, CA, USA) (203, 375), while EIA kits for 8-
isoprostane, ANP, ET-1, cGMP and kits for cholesterol and triglyceride were purchased from 
Cayman following the manufacturers’ instructions as we reported (3, 187, 200). Intraperitoneal 
glucose tolerance test (IPGTT) and homeostasis model assessment of insulin resistance (HOMA-
IR) were done as we previously reported (200). 
 
2.3.2 Histological, morphological and immunohistochemical analyses of left ventricle 
Histological and morphometric analyses were done as we previously described (186). 
Sections of 5 μm were cut and stained with hematoxylin and eosin for histological analysis. 
Masson's Trichrome staining detected left-ventricular collagen deposition. Morphometrical 
evaluation of left-ventricular longitudinal myocytes thickness was done by randomly measuring 
30 cardiac muscle fibers from each experimental group by a blinded researcher using a 
microscope (Aperio Scan Scope Model CS, Aperio Technologies Inc, Vista, CA, USA) and 
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analyzed using Aperio Image Scope V11.2.0.780 software (Aperio, e-Pathology Solution, Vista, 
CA, USA). Morphologic assessment of collagen deposition in left-ventricular sections was 
accessed using Aperio Image Scope (Aperio Technologies Inc, Vista, CA, USA). Each left-
ventricular section was magnified at 200X, and 20 random snaps were taken per slide (20 x 6 = 
120 images per group) subsequently scored semi-quantitatively by a blinded researcher as we 
previously reported (3, 186).  
Immunohistochemistry was done as we previously reported (188). Sections of 5 μm of 
left-ventricular tissue were treated with bovine serum albumin in phosphate buffered saline to 
block non-specific staining, and incubated overnight with ED1 (1:500 dilution sc-59103, Santa 
Cruz Biotechnology, CA). The sections were later treated with with goat anti-mouse IgG for 30 
min (1:200 dilution; Jackson Immuno-Research Laboratories, Inc., ME, USA). 
Immunohistochemical staining was done using the standard avidin-biotin complex method with 
the chromogen 3, 3’-diaminobenzidine (DAB) at the final detection step. Sections of heart tissue 
were scanned using virtual microscope (Aperio Scan Scope Model CS, Aperio Technology Inc, 
Vista, CA, USA). Quantitative assessment of ED1 was done by a blinded researcher who 
randomly examined 20-22 fields of each left-ventricular section magnified at 200X.  
Macrophages which were positively stained with ED1 (brown from immune-stained sections) 
were quantified by manually counting the ED1-stained cells around the blood vessels and 
interstitial spaces of myocardium. 
 
2.3.3 Western Immunoblotting 
Pericardial fat and left-ventricular tissues were homogenized as previously reported (3, 
124, 186, 187, 200). Primary antibodies [(Santa Cruz Biotechnology, Santa Cruz, CA, USA), 
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ED-1 (CD68), sc-59103), ED-2 (CD163) (sc-58956), CD-14 (sc-9150), CD-206 (sc-48758), CD-
36 (sc-9154), osteopontin (sc-21742), osteoprotegerin (sc-11383), PI3K (sc67306), IRS-1 (sc-
559), collagen-IV (sc-11360), fibronectin (sc-18825), TGF-β1/2/3 (sc7892)] and GLUT4 (ab 
654, Abcam Inc, Cambridge, MA, USA) were used. Densitometric analysis was done with UN-
SCAN-IT software (Silk Scientific Inc, Orem, Utah, USA). G6PDH antibody (A9521, Sigma St 
Louis, MO, USA) was used as a control to ascertain equivalent loading.  
 
2.3.4 Statistical Analysis 
  All data are expressed as means  SEM from at least four independent 
experiments unless otherwise stated. Statistical analyses were done using two-way ANOVA, 
using Statistical Analysis System (SAS), software Version 9.3 (SAS Institute Inc., Cary, NC, 




2.4.1 Hemin therapy upregulates the HO system to improve cardiac function 
To investigate the mechanisms underlying the improvement of cardiac function in obese 
insulin-resistant ZF rats, we measured the concentration of HO-1 and HO activity. In ZF-control 
rats, the basal level of HO-1 concentration and HO-activity were significantly lower than in ZL-
control (Figs. 2-1A and 2-1B). However, hemin administration increased HO-1 and HO-activity 
in ZF by 8.4- and 11.3-fold respectively. The enhanced HO activity would increase endogenous 
carbon monoxide that would in turn stimulate cGMP (187, 200). Both cGMP and carbon 
monoxide are known to enhance insulin signaling and glucose metabolism (376). Accordingly, 
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we detected a 3.4-fold increase of cGMP in hemin-treated animals (Fig.2-1C). In contrast, the 
co-administration of the HO-blocker, SnMP and the HO-inducer, hemin abolished the hemin-
induced increase of HO-1 and HO-activity, with corresponding reduction of cGMP levels (Fig.2-
1C). Hemin therapy also enhanced HO-1, HO-activity and cGMP levels in ZL-control rats 
(Fig.2-1A, 2-1B and 2-1C). In hemin-treated ZLs, HO-1, HO-activity and cGMP were enhanced 
by 3.1-, 2.8-, 2.4-fold respectively as compared to 8.4-, 11.3- and 3.4-fold respectively in hemin-
treated ZF rats, suggesting greater selectivity of hemin to the HO system in unhealthy ZF rats 
characterized obesity, insulin resistance and cardiomyopathy (374).    
Since cardiac hypertrophy is amongst the forerunners to heart failure, we investigated the 
effects of hemin on cardiac hypertrophy. Our results indicate that hemin therapy significantly 
reduced cardiac hypertrophy in ZF, whereas the co-administration of hemin and SnMP nullified 
the effect (Table 2-1).  Echocardiography was used to further assess left-ventricular hypertrophy. 
Our hemodynamic data obtained during catheterization of the left side of hearts from ZF rats 
showed association between elevated myocardial hypertrophic response and obesity. A 
significant 2-fold increase in left-ventricular free wall thickness, an important index of cardiac 
hypertrophy (377) was observed during diastole and systole, and interestingly these were abated 
by hemin by 33.3 % and 15.6 % respectively (Figure 2-9 & 2-10) (Table 2-2). Other 
hemodynamic deficiencies in ZF rats including abnormalities in left-ventricular end-diastolic 
volume, left-ventricular end-systolic volume, stroke volume and cardiac output which were 
reduced by 17.5%, 16%, 8.3%, 7.7% respectively (Table 2-2), were increased by hemin therapy 
by 15.2%, 27.3%, 13.6% and 12.4% respectively. Hemin therapy also improved cardiac 
hemodynamics by lowering arterial-systolic pressure, arterial-diastolic pressure, mean-arterial 
pressure and total-peripheral resistance by 12.4%, 11.4% and 12.2%, 17.6% respectively, with 
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corresponding reduction of +dp/dt (the maximal-rate of increase in left-ventricular pressure), 
left-ventricular developed pressure and heart rate.  
Treatment with hemin and SnMP caused loss of body-weight in ZL-controls and ZF rats, 
which however did not exceed 9% (Table 2-1). The loss of weight may not be due to toxicity as 
we recently showed that several indices of toxicity including plasma gamma-
glutamyltransferase, aspartate aminotransferase and alanine aminotransferase were within 
normal range (200). Although ZF rats had normoglycemia, hemin and SnMP affected blood 
glucose.  In hemin-treated animals, there was a slight but significant reduction of glycemia, 
whereas in SnMP-treated animals a slight increase was observed (Table 2-1). Similarly, hemin 
therapy slightly reduced glycemia in ZL-controls. The vehicle dissolving hemin and SnMP had 
no effect on the measured parameters.  
 
2.4.2 Hemin therapy abates MCP-1, MIP-1α, TNF-α, endothelin-1, 8-isoprostane but 
enhanced ANP in ZF rats 
Since 8-isoprostane stimulates ET-1 (378), and both ET-1 and 8-isoprostane are involved 
in the oxidative destruction of tissue, we measured ET-1 and 8-isoprostane. ET-1 in untreated ZF 
rats were markedly elevated as compared to ZL-controls (Fig.2-2A), but were significantly 
abated by hemin. In contrast, the co-administration of hemin and the HO-blocker, SnMP 
annulled the effect of hemin (Fig.2-2A). Because elevated oxidative stress is linked to impaired 
insulin-signaling and cardiac dysfunction, we measured urinary 8-isoprostane, an important 
marker of oxidative stress (379). In ZF rats, the basal levels of 8-isoprostane were significantly 
elevated (Fig.2-2B), but were reduced by hemin, whereas co-treatment of hemin with SnMP 
nullified the effects. Given that ET-1 and ANP are known to interact reciprocally (380), we 
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investigated whether the hemin-dependent suppression of ET-1 (Fig.2-2A) would be associated 
with a parallel potentiation of ANP. In ZF rats, the basal ANP levels were markedly depressed 
by 1.7-fold (Fig.2-2C), but interestingly were robustly enhanced by hemin by 3.3-fold. In 
contrast, the co-administration of hemin with SnMP abolished the effects of hemin.  
We also investigated the effects of hemin on MIP-1α and MCP-1 since these chemokines 
trigger macrophage infiltration (158). In ZF rats, the basal MCP-1 levels were significantly 
increased by 4.6-fold (Fig.2-2D), but were attenuated by hemin by 2.8-fold, whereas the co-
administration with SnMP nullified the effects of hemin (Fig.2-2D). Although hemin therapy 
greatly attenuated MCP-1 by 64% in ZF, however comparable levels as observed in the ZL-
controls were not reinstated.  Hemin therapy was also effective in suppressing MIP-1α (Fig.2-
2E). In ZF rats, the basal MIP-1α levels were significantly elevated by 4.9-fold, but were 
reduced by hemin by 3.5-fold, whereas the co-treatment of hemin with SnMP nullified the 
effects (Fig.2-2E). Since TNF-α is implicated in macrophage infiltration (158), we also assessed 
the effects of hemin on TNF-α. In ZF rats, the basal levels of TNF-α were elevated by 3.5-fold, 
but were significantly attenuated by hemin by 2.6-fold (Fig.2-2F), whereas co-treatment with 
SnMP abolished the effect of hemin. 
 Hemin therapy also affected ET-1, 8-isoprostane, ANP, MCP-1, MIP-1α in ZL-controls, 
although the magnitude of effect was smaller than in ZF rats (Fig.2-2). 
 
2.4.3 Hemin selectively abated the pro-inflammatory macrophage M1-phenotype, but 
enhanced the anti-inflammatory M2-phenotype in the left ventricle of ZF rats   
After having observed the hemin-dependent reduction of cytokines/chemokines 
implicated in macrophage infiltration such as MIP-1α, MCP-1 and TNF-α, we investigated 
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whether the suppression of these chemokines/cytokines in the left ventricle of ZF rats would be 
accompanied by the selective attenuation of the pro-inflammatory macrophage M1-phenotype 
using a specific marker such as ED1 (381) to quantify the expression of the pro-inflammatory 
M1-phenotype in left-ventricular tissue, and other markers for the assessment of anti-
inflammatory M2-phenotype including ED2 (381), CD14 (382, 383), CD206 (364), CD36 (384, 
385). 
Our Western immunoblotting and relative densitometry revealed that the basal expression 
of the pro-inflammatory macrophage M1-phenotype marker, ED1, in ZF rats was markedly 
elevated by 4.8-fold as compared to ZL-controls (Fig.2-3A), but was significantly reduced by 
hemin by 3.5-fold, although control levels were not attained. On the other hand, the basal 
expression of several markers of the anti-inflammatory macrophage M2-phenotype including 
ED2, CD206, CD36 and CD14 were significantly depressed in ZF rats by 2.1- , 5.7-, 3.6- and 
2.9-fold respectively (Figs.2-3B, 2-3C, 2-3D and 2-3E). Interestingly, hemin therapy greatly 
enhanced the depressed ED2, CD206, CD36 and CD14 in ZF rats by 3.8-, 4.1-, 2.3- and 2.6-fold 
respectively, suggesting that a novel mechanism by which hemin therapy blunts inflammation is 
by selectively modulating the polarization of macrophage toward the M2-phenotype that 
dampens inflammation.  
 
2.4.4 Hemin therapy suppressed macrophage infiltration in the left ventricle of ZF rats 
Following the observation from our Western blot experiment that hemin therapy reduced 
left-ventricular ED-1, a marker of macrophage infiltration, we use the ED-1 antibody to further 
confirm macrophage infiltration in the left ventricle by immunohistochemistry (Fig.2-4A). Our 
results reveal that left-ventricular sections from ZL-control rats were almost devoid of the dark 
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brown ED1 positive staining. However, in untreated ZF-control rats, a greater number of ED1-
positively stained dark brown cells were observed, indicating increased macrophage infiltration. 
Interestingly, in hemin-treated ZF rats, there was a marked reduction in the number of dark 
brown stained macrophages, suggesting reduction of macrophage infiltration. Correspondingly, 
hemin therapy significantly reduced the quantitative ED1 score (Fig.2-4B). 
    
2.4.5 Hemin therapy enhanced insulin signaling but suppressed extracellular matrix and 
profibrotic proteins implicated in cardiac injury  
Since visceral adiposity and elevated inflammation impairs insulin signaling (8), we 
investigated the effects of hemin therapy on the expression of important components of the 
insulin signal transduction pathway including IRS-1, PI3K and GLUT4. In ZF rats, the basal 
expression of IRS-1, PI3K and GLUT4 were significantly reduced by 11.2-, 2.5- and 2.3-fold as 
compared to the ZL-control (Figs.2-5A, 2-5B and 2-5C), but were enhanced by hemin by 5.7-, 
4.01- and 1.9-fold respectively. To further confirm the anti-hypertrophic effect of hemin therapy, 
we measured collagen-IV an important protein implicated in cardiac hypertrophy and fibrosis 
(186). In ZF rats, the basal expression of left-ventricular collagen-IV was significantly elevated 
by 6.9-fold, but was abated by hemin by 2.8-fold (Fig.2-5D). Given that excessive deposition of 
extracellular matrix/profibrotic proteins and inflammation due to macrophage infiltration are 
cardinal pathophysiological events implicated in cardiac insult (8, 386), while atrial natriuretic 
peptide (ANP) and adiponectin are known to suppress fibrosis caused by the deposition of 
extracellular matrix (387, 388), we investigated whether the concomitant potentiation of ANP, 
adiponectin and the HO-system by hemin would abate TGF-β. In ZF rats, the basal expression of 
TGF-β was significantly elevated by 4.6-fold, but was markedly attenuated by hemin by 3.4-fold 
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(Fig 2-5E). Since TGF-β mobilizes the extracellular matrix by stimulating fibronectin and 
collagen to cause fibrosis and cardiac injury (21, 387), we also measured the expression of 
fibronectin. In ZF rats, the basal expression of fibronectin was increased by 7.5-fold, but was 
markedly attenuated by hemin therapy by 4.5-fold (Fig.2-5F). 
 
2.4.6 Hemin improved glucose tolerance, enhanced the insulin-sensitizing protein, 
adiponectin but abated insulin resistance  
After having observed the hemin-induced potentiation of insulin signaling, to further 
confirm the role of hemin therapy on glucose metabolism, we assessed the effects of hemin on 
glucose tolerance, insulin resistance and the insulin-sensitizing protein, adiponectin in ZF rats, an 
obese model with elevated inflammation. Since inflammation due to macrophage infiltration is 
implicated in insulin resistance and cardiomyopathy (8, 386), and ZF rats are characterized by 
insulin resistance (374), we investigated whether the hemin-dependent suppression of 
macrophage infiltration would be accompanied by improved glucose metabolism. In untreated 
ZF rats, IPGTT analysis showed marked increase in glycemia as compared to ZL-controls and 
hemin-treated ZF rats at all time-points tested (Fig.2-6A), suggesting improved glucose tolerance 
in hemin-treated ZF rats. Although ZF rats were hyperinsulinemic with elevated basal glycemia, 
when challenged with a bolus injection of glucose, only to a meagre glucose-stimulated insulin 
release was observed (Fig.2-6B), suggesting glucose intolerance. On the other hand, glucose 
challenge to ZL-controls and hemin-treated ZF rats greatly stimulated insulin release (Fig.2-6B), 
suggesting improved glucose tolerance. Hemin also reduced the elevated insulin resistance 
HOMA-IR in ZF rats (Fig.2-6C), whereas co-administration with SnMP reversed the effects of 
hemin (Fig.2-6C).   
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We also investigated the effects of hemin therapy on adiponectin, an anti-inflammatory, 
insulin sensitizing and cardioprotective protein (389, 390). Interestingly, hemin therapy 
significantly enhanced the depressed basal adiponectin levels in ZF rats, whereas treatment with 
SnMP abolished and further reduced the depressed levels of adiponectin (Fig.2-6D). Hemin 
therapy also reduced HOMA-IR index in ZL-controls and enhanced adiponectin, although the 
effect was less-intense as compared to ZF rats.  
 
2.4.7 Hemin therapy suppressed left-ventricular fibrosis, cardiomyocyte hypertrophy and 
longitudinal cardiac myofibril thickness in ZF rats 
Histological and morphometric analyses using Masson’s trichrome and hematoxylin and 
eosin staining were done to further confirm the cardio-protection by hemin. Cardiomyocytes 
appeared as dark reddish while extracellular matrix, such as collagen, stained blue (Fig.2-7A). 
Left-ventricular sections from ZL-controls appeared morphologically normal, with scanty 
interstitial collagen deposition. In contrast left-ventricular images from ZF rats showed moderate 
to severe fibrosis, with scarring of cardiomyocytes, and interstitial and perivascular collagen 
depositions (Fig.2-7A). Interestingly, hemin therapy attenuated the severity of scarring, and 
intestinal and perivascular collagen deposition, evidenced by reduced extracellular and 
perivascular blue staining (Fig.2-7A). Correspondingly, semi-quantitative analysis showed that 
hemin therapy significantly abated the elevated collagen deposition and perivascular fibrosis in 
ZF rats, reinstating comparable levels to ZL-control (Fig.2-7B). 
Hemin therapy was also effective against cardiomyocyte hypertrophy (Fig.2-7C). In ZF 
rats, cardiomyocytes were enlarged with increscent nuclei and the inner myofibril spaces were 
decreased, as compared to normal cardiomyocytes in ZL-controls (Fig.2-7C). In ZF rats, the 
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longitudinal cardiac myofibril thickness was 37% higher than ZL-controls (Fig.2-7D), but was 
reduced by 27% in hemin-treated ZF rats. Although ZL-control values were not reinstated, 
hemin increased inter-myofibril spaces in ZF rats close to the levels observed in ZL-controls 
(Fig.2-7D). 
 
2.4.8 Hemin therapy suppressed the elevated expression of markers of heart failure in the 
left ventricle of ZF rats 
To further confirm the cardioprotective effects of an upregulated HO-system, we 
investigated the effects of hemin therapy on important markers of heart failure such as 
osteopontin (367) and osteoprotegerin (357). Since left-ventricular hypertrophy is associated 
with heart failure (391), we determined whether the hemin-dependent suppression of left-
ventricular hypertrophy in ZF rats would be accompanied by the reduction of markers of heart 
failure. Our results indicate that, in ZF rats, the basal expression levels of osteopontin and 
osteoprotegerin were significantly elevated by 4.6- and 7.1-fold respectively as compared to ZL-
controls (Fig.2-8A and 2-8B). Interestingly, treatment with hemin attenuated the expressions of 
osteopontin and osteoprotegerin by 3.5- and 3.3-fold respectively (Figs.2-8A and 2-8B).  
 
2.5 Discussion 
The present study indicates that the multifaceted mechanisms by which hemin therapy 
improves cardiomyopathy in obesity includes: (i) the suppression of visceral adiposity, (ii) the 
reduction of macrophage M1-phenotye, (iii) the attenuation of markers of heart failure, (iv) the 
reduction of extracellular matrix/profibrotic proteins and (v) the amelioration of insulin 
resistance, with corresponding enhancement of glucose metabolism. In ZF rats, excessive 
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visceral adiposity, increased macrophage infiltration and the elevated levels of 8-isoprostane, 
MIP-1α, MCP-1, TNF-α, IL-6, IL-1β, ET-1, proteins of heart failure and extracellular-matrix 
deposition are among the complex molecular processes that characterize the intricate relationship 
between inflammation, oxidative stress, cardiac fibrosis, and the progressive development of 
insulin resistance and cardiomyopathy (8, 206, 386, 387, 392-394). Importantly, the present 
study unveils that hemin therapy selectively enhance the anti-inflammatory macrophage M2-
phenotype in pericardial fat and left-ventricular tissue of ZF rats while concomitantly abating the 
pro-inflammatory M1-phenotype, suggesting that a novel mechanism by which hemin therapy 
suppress cardiac inflammation in obesity is by selectively favoring the polarization of the 
macrophage towards the M2-phenotype that ablate inflammation. Correspondingly, hemin 
therapy abated several chemokine and cytokines that promotes macrophage infiltration including 
MIP-1α, MCP-1, TNF-α, IL-6 and IL-1β (158, 365, 366). Interestingly, the suppression of 
visceral adiposity and inflammation in hemin-treated ZF rats was accompanied by reduced 
insulin resistance and improved glucose intolerance, and the potentiation of important 
components of the insulin signal transduction pathway including IRS-1, PI3K and GLUT4, 
which in addition to the hemin-dependent enhancement of adiponectin, an anti-inflammatory, 
insulin sensitizing and cardioprotective protein (389, 390) may account for improved glucose 
metabolism in obese conditions.  
Hemin therapy also reduced left-ventricular hypertrophy, cardiac fibrosis, cardiomyocyte 
longitudinal muscle-fiber thickness, a pathophysiological feature of cardiomyocyte hypertrophy 
(186),  with corresponding suppression of markers of heart failure such as osteopontin and 
osteoprotegerin (357, 367), as well as the reduction of extracellular matrix protein like TGF-β, 
fibronectin and collagen which are implicated in cardiac hypertrophy and fibrosis (387, 394). 
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Since TGF-β mobilizes the extracellular matrix by stimulating fibronectin and collagen causing 
tissue damage and hypertrophy (387, 394), the concomitant reduction of TGF-β, fibronectin and 
collagen-IV in ZF rats may account for reduced cardiac lesions. Another mechanism by which 
the HO system suppress extracellular matrix and pro-fibrotic agents like TGF-β and ET-1 may be 
due to the HO-dependent potentiation of ANP, a substance known to suppress extracellular 
matrix (380, 395) . Generally, ANP and ET-1 have opposing effects (322). For example, ANP 
reduces fibrosis by inhibiting TGF-β and fibronectin (380), while ET-1 acts in conjunction with 
TGF-β to stimulate the synthesis of fibronectin (395). Similarly, ANP suppress inflammation to 
reduce insulin resistance (322), while ET-1 stimulates inflammatory/oxidative insults causing 
insulin resistance (396). On the other hand, ANP stimulates the production of adiponectin (397), 
a  protein with insulin sensitizing and anti-inflammatory effects (389).  The effects of ANP are 
largely mediated by cGMP (398), and adiponectin is also known to enhance cGMP (399). 
Moreover ANP and the HO system have mutual stimulatory effects. Accordingly, ANP enhance 
HO (400, 401), and similarly, the HO system has been shown to upregulate ANP and adiponectin 
(196, 202). Therefore, the synergistic potentiation of the HO-adiponectin-ANP axis and insulin 
signaling with corresponding ablation of extracellular matrix/heart failure proteins, the reduction 
of oxidative stress and inflammation mediators such as macrophage M1-phenotype, MIP-1α and 
MCP-1, TNF-α, IL-6, IL-1β, ET-1 and 8-isoprostane are among the multifaceted mechanisms by 
which hemin therapy improved cardiac function. Thus, novel strategies capable of potentiating 
the HO-adiponectin-ANP axis would improve cardiomyopathy and insulin signaling in obesity. 
Cardiomyocyte hypertrophy and myocardial fibrosis are early microscopic changes in 
heart failure. Subsequently, macroscopic alterations including increased left-ventricular wall 
thickness, diastolic/systolic dysfunction and impaired cardiac hemodynamics become evident. 
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Interestingly, hemin therapy modulated several hemodynamic and echocardiographic parameters 
to improve cardiac function. These include the reduction of left-ventricular diastolic wall-
thickness, left-ventricular systolic wall-thickness, mean-arterial pressure, arterial-systolic 
pressure, arterial-diastolic pressure, left-ventricular developed pressure, +dP/dt and total-
peripheral resistance, with corresponding enhancement of stroke volume and cardiac output, and 
thus improved cardiac function in hemin-treated ZF rats. The improved myocardial function in 
hemin-treated ZF rats was also associated with the reduction of total-cholesterol, triglycerides 
and pericardial fat. Moreover, pericardial adiposity is associated with left-ventricular diastolic 
dysfunction (12). Hemin therapy also enhanced the HO system, cGMP, adiponectin and ANP, 
and abated 8-isoprostane, MCP-1, MIP-1α, TNF-α, IL-6, IL-1β, ET-1 and lowered HOMA-IR 
index in ZL-control rats, although the magnitude was smaller as compared to ZF rats with 
depressed HO-activity. The reasons for this selective effect of HO are not fully understood. 
However, it is possible that as ZL-controls are healthy animals with normal/functional insulin-
signaling, the HO system may be more stable as compared to ZF rats which have deregulated 
HO system with depressed HO-1 and HO-activity. Importantly, the selectivity of the HO system 
in diseased conditions could be explored against the co-morbidity of insulin-resistant diabetes 
and obesity 
Although we recently reported the cardioprotective effects of the HO system in ZDFs (3), 
a model characterized by obesity, insulin resistance and overt hyperglycemia, pathophysiological 
profile of ZDF is not reflective of the metabolically healthy individuals who are characterized by 
obesity and normoglycemia (363). In contrast, ZF rats closely mimic the pathophysiological 
profile of metabolically healthy obese individuals with normoglycemia, so our findings may be 
applicable to this subtype of obese individuals. Moreover, with the rising incidence of 
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cardiometabolic complications in many adults who previously manifested the metabolically 
healthy obese phenotype (363), novel studies with animal models that closely mimic the 
pathophysiological profile of metabolically healthy obese subtype are needed. Therefore, 
studying the effects of the HO system on ZF rats may offer new perspective in the 
pathophysiology of cardiometabolic complications, and especially the progressive deterioration 
of cardiac function which may eventually lead to heart failure given the elevated levels of 
proteins of heart failure detected in untreated ZF rats.  
Collectively, our study unveils the beneficial effect of upregulating the HO system in the 
co-morbidity of obesity and insulin resistance, and suggest that the suppression of oxidative 
mediators, macrophage-M1-phenotye infiltration and extracellular matrix/remodeling proteins 
are among the multifaceted mechanisms by which the HO system maintains enhance insulin 
signaling and counteract diabetic cardiomyopathy. These data suggest that although ZF rats are 
normoglycemic, perturbations of insulin signaling and cardiac function may be forerunners to 
overt hyperglycemia and heart failure in obesity.  
 
2.6 Conclusion 
The novelty of our study includes: (i) the hemin-induced selective enhancement of the 
anti-inflammatory M2-phenotype in pericardial fat and left-ventricular tissue of ZF rats, and 
parallel reduction of the pro-inflammatory macrophage M1-phenotype and MIP-1α, a chemokine 
implicated in macrophage infiltration; (ii) the hemin-dependent suppression of heart failure 
proteins such as osteopontin and osteoprotegerin;  (iii) the suppression of pericardial adiposity 
and reduction of inflammatory cytokines in ZF rats; and (iii) the hemin-induced reduction of 
insulin resistance and improvement of cardiac function in ZF rats. This study also suggests a 
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possible paracrine and inter-organ cross-talk between the heart and pericardial fat. Importantly, 
the concomitant modulation of macrophage polarization in pericardial adipose tissue and left 
ventricles towards the anti-inflammatory M2-phenotype alongside the parallel reduction of pro-
inflammatory cytokines and chemokines implicated in macrophage infiltration and tissue 
destruction may be indicative of a putative inter-organ cross-talk and the movement of 
inflammatory mediators from the pericardial fat to the myocardium or vice versa, and this may 
be particularly important in the progressive development of cardiomyopathy, insulin resistance 
and related cardiometabolic complications. Although this linkage has to be established, this study 
would set the stage for further exploration of the putative inter-organ communication between 
pericardial fat and the heart. 
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Figure 2-1: Effects of the HO inducer, hemin and the HO inhibitor, SnMP on HO-1, HO-activity 
and cGMP in the left ventricle of ZLs and ZF rats. (A) Hemin enhanced HO-1, whereas SnMP 
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nullified the effects of hemin. (B) Hemin increased HO-activity, while SnMP abolished the 
hemin effect. (C) Hemin enhanced cGMP, which however was abolished by SnMP.  Bars 
represent means ± SEM; n=6 rats per group (*p<0.01 vs ZL-Control; †p<0.05 vs ZL-Control; 
@p<0.01 vs ZF+Hemin+SnMP or ZF-control).  
 
Figure 2-2: Effects of the HO inducer, hemin and the HO inhibitor, SnMP on endothelin-1, 
ANP, MCP-1, MIP1-α and TNF-α in left-ventricular tissue from ZLs and ZF rats. Hemin therapy 
(A) reduced endothelin-1, (B) attenuated 8-isoprostane, (C) increased ANP, (D) suppressed 
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MCP-1, (E) abated MIP-1α and (F) reduced TNF-α, whereas SnMP abolished the hemin effects.  
Bars represent means ± SEM; n=6 rats per group (*p<0.05, **p<0.01 vs ZL-Control; †p<0.05, 



























































































































































































Figure 2-3: Effects of hemin on ED1, ED2, CD206, CD36 and CD14 in left-ventricular tissue 
from ZLs and ZF rats.  Hemin therapy (A) abated ED1, but (B) enhanced ED2, (C) increased 
CD206, (D) enhanced CD36, and (E) increased CD14 in ZF rats. Bars represent means ± SEM; 






































Figure 2-4: Representative photomicrographs of cross-sections of the left ventricle showing 
macrophage infiltration (ED1-positive cells stained dark brown) (magnification×200). (B) 
Quantitative analyses of macrophage infiltration per field indicating that in ZF rats the number of 
ED1-positive dark-brown cells (macrophage infiltration) was markedly elevated as compared to 
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ZL-control, but interestingly were significantly attenuated by hemin therapy. Bars represent 






















































































































































































































Figure 2-5: Effects of hemin on the expression of important proteins of the insulin signal 
transduction pathway such as IRS-1, PI3K, GLUT4 and the expression of 
profibrotic/extracellular matrix proteins including, collagen-IV, TGF-α and fibronectin in left-
ventricular tissue from ZLs and ZF rats.  Representative Western immunoblotting and relative 
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densitometry of the expressed proteins normalized by G6PHD indicates that hemin therapy 
significantly (A) enhanced IRS-1, (B) increased PI3K, (C) upregulated GLUT4,  but (D) abated  
Collagen-IV,  (E) reduced TGF-β, and  (F) suppressed  fibronectin in ZF rats. Bars represent 



































































































Figure 2-6: Effects of hemin on glucose tolerance, insulin resistance (HOMA-IR index) and 
adiponectin. Hemin therapy (A) improved glucose tolerance (IPGTT), (B) increased glucose-
stimulated insulin release, (C) reduced insulin resistance and (D) increased adiponectin. Bars 
represent means ± SEM; n=6 rats per group (*p<0.05, **p<0.01 vs ZL-Control; †p<0.01 vs. ZL-




Figure 2-7: Effect of hemin on histological lesions in the left ventricle of ZLs and ZF rats. (A) 
Representative Mason’s trichrome-stained images revealing severe cardiac muscle scaring and 
collagen deposition in ZF rats. (B) Semi-quantitative evaluation showed that hemin therapy 
reduced collagen deposition in ZF rats. (C) Representative hematoxylin and eosin-stained images 
revealing severe longitudinal muscle-fiber thickness in ZF rats. (D) Quantitative evaluation 
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showed that hemin reduced longitudinal muscle-fiber thickness. ± SEM; n=6 rats per group 
(*p<0.05, **p<0.01 vs all groups). 
 
Figure 2-8: Effect of hemin on markers of heart failure such as osteopontin and osteoprotegerin  
in the left ventricle of ZLs and ZF rats. (A). Representative Western immunoblotting and relative 
densitometry of the expressed proteins normalized by G6PHD indicates that hemin therapy 
significantly (E) abated osteopontin and (F) reduced osteoprotegerin in ZF rats. Bars represent 





Figure 2-9: Hemin therapy suppressed left-ventricular free wall thickness in ZF rats (A). B-
Mode image of left ventricle in the long axis view - Diastolic (B) Quantitative analyses indicates 
that hemin therapy suppressed left ventricle free wall thickness in ZF rats. Bars represent means 





Figure 2-10: Hemin therapy suppressed left-ventricular free wall thickness in ZF rats (A). B-
Mode image of left ventricle in the long axis view - Systolic (B) Quantitative analyses indicates 
that hemin therapy suppressed left ventricle free wall thickness in ZF rats. Bars represent means 











ZL Control ZL + Hemin ZF Control ZF + Hemin ZF + 
Hemin + SnMP
ZF + Vehicle
Body weight (g) 472.9  9.7 445.5  11.6
† 746.8  21.5 685.9  14.7$ 691.4  15.2$ 702.8  24.6
Fasting glucose
(mmo/L)
7.2  0.6 6.5  0.3* 8.2  0.5 6.9  0.4* 8.5  0.4 * 8.1  0.4
Heart weight (g) 1.5  0.03 1.1  0.02
† 3.4  0.06 2.0  0.04$ 3.0  0.03$ 3.1  0.04
Cardiac hypertrophy  
(g/Kg body weight)




†p<0.05 vs ZL; $p<0.05 vs ZF; §p<0.05 vs ZL Control; *p<0.05, **p<0.01 vs ZF-control or ZL-
Control, n=6 per group 
 
Table 2-1: Effect of hemin and stannous mesoporphyrin (SnMP) on physiological and 







Parameters Experimental groups P-value




Effect of hemin 
on ZF
Arterial systolic pressure (mmHg) 153  5.2 124  3.4 # 134  6.3 * 0.001 0.018 Reduced by 12.4 % 
Arterial diastolic pressure (mmHg) 109  3.2 92  2.5 # 96  4.7 * 0.003 0.024 Reduced by 11.9 %
Mean arterial pressure (mmHg) 123  3.8 102  2.7 # 109  5.2 * 0.002 0.022 Reduced by 11.4 %
Total peripheral resistances 
(mmHg.min/mL)
1.7  0.1 1.4  0.1 1.4  0.1 0.060 0.080 Reduced by 17.6%
LV developed pressure (mmHg) 161  4.1 136  8.0 # 140  5.8 * 0.012 0.030 Reduced by 13.0 %
+ dp/dt(max) (mmHg/sec) 3634  127 3050  200 
# 3050  169 * 0.027 0.027 Reduced by 16.1 %
Heart rate (beats/min) 328  9.2 331  7.2 289  14.2 * 0.814 0.020 Reduced by 11.9 %
LV diastolic wall thickness(mm) 2.7  0.1 1.7  0.1 # 1.8  0.1 * 0.0001 0.0001 Reduced  by 33.3%
LV systolic wall thickness (mm) 3.2  0.1 2.1  0.1 # 2.7  0.1 * 0.0001 0.007 Reduced by 15.6 %
LV end diastolic volume (ml) 0.33  0.01 0.40  0.04 0.38  0.02 0.075 0.169 Increased by 15.2%
LV end systolic volume (ml) 0.11  0.01 0.16  0.01 # 0.14  0.01 0.001 0.089 Increased by 27.3 %
Stroke volume (ml) 0.22  0.01 0.24  0.02 0.25  0.02 0.564 0.311 Increased by 13.6 %
Cardiac output (ml/min) 72.8  3.6 78.9  9.0 81.8  9.8 0.519 0.412 Increased by 12.4 %
 
 
Table 2-2: Effect of hemin therapy on Hemodynamic and Echocardiographic Parameters. 
Values for each echocardiography and hemodynamic end-point were averaged for each rat and 
the mean values used in statistical analyses, with n = number of rats. Differences among 
treatment groups were compared using 1-way ANOVA followed by Fisher’s Least Square 
Difference (LSD) posteriori tests. Differences of p<0.05 were considered statistically significant. 
Values are means ± SE; n = 6 per group. *P < 0.05 vs. control ZF rats,
 
#P < 0.05 vs. control ZL 
rats. n=6 per group 
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Cardiac function is adversely affected by pericardial adiposity. We investigated the 
effects of the heme-oxygenase (HO) inducer, hemin on pericardial adiposity, macrophage 
polarization and diabetic-cardiomyopathy in Zucker-diabetic-fatty rats (ZDF). 
Echocardiographic, quantitative-RT-PCR, Western-blot, EIA and spectrophotometric analysis 
were used. In ZDF-rats, hemin administration increased HO-activity, normalized glycaemia, 
potentiated insulin-signaling by enhancing insulin-receptor-substrate-1 (IRS-1), 
phosphatidylinositol-3-kinase (PI3K) and protein-kinase-B (PKB), suppressed pericardial 
adiposity and reduced several pro-inflammatory/oxidative mediators including, NF-κB, c-Jun-N-
terminal-kinase (c-JNK), endothelin (ET-1), TNF-α interleukin (IL)-6, IL-1β, activating-protein 
(AP-1) and 8-isoprostane, whereas the HO-blocker, stannous-mesoporphyrin (SnMP) nullified 
the hemin-effects. Furthermore, hemin reduced the pro-inflammatory macrophage-M1-
phenotype, but enhanced M2-phenotype that dampens inflammation. These were associated with 
improved ejection-fraction and cardiac-output, but reduced total peripheral resistance. 
Interestingly, the hemin effects were less pronounced in Zucker-lean rats with healthy status, 
suggesting greater selectivity of HO in unhealthy ZDF-rats. Since NF-κB activates TNF-α, IL6 
and IL-1β, while TNF-α, JNK and AP-1 impair insulin-signaling, and the high levels of these 
cytokines in obesity/diabetes would create a vicious cycle that together with 8-isoprostane and 
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ET-1 exacerbates cardiac injury, compromising its function. Therefore, the concomitant 
reduction of pro-inflammatory cytokines and macrophage infiltration coupled to increased 
expression of IRS-1, PI3K, PKB and cardiac hemodynamics may account for enhanced glucose 
metabolism and improved cardiac function. The preferential polarization of macrophages 
towards anti-inflammatory M2-phenotype in cardiac tissue, suppression of pericardial adiposity 
and hemin-dependent improved cardiac function in ZDF-rats are novel findings. Collectively, 
our study unveils the beneficial effects of hemin on pericardial-adiposity, impaired insulin-
signaling and diabetic-cardiomyopathy, and suggests that the multifaceted mechanisms include 
the suppression of inflammatory/oxidative mediators. 
 
3.2 Introduction 
The inflammatory and metabolic systems have been evolutionarily well-conserved in 
species, and are fundamental for survival (402). However, these systems can be offset by obesity 
or nutrition-overload leading to inflammation in metabolic sites like the adipose tissue and 
skeletal muscles. Generally, obesity and insulin resistance are closely associated with a state of 
low-grade inflammation due to incessant activation of a wide variety of inflammatory mediators 
including nuclear-factor kappa B (NF-κB), tumor-necrosis factor-alpha (TNF-α and c-Jun-N-
terminal kinase (JNK) (5, 76, 92, 136, 403-410).  Moreover, NF-κB  stimulates TNF-α, 
interleukin (IL)-6 and IL-1β, which in turn may activate JNK to create a vicious cycle that may 
aggravate insulin resistance and tissue damage (5). These destructive processes may be further 
exacerbated by macrophage infiltration, an event characterized by elevated levels of ED-1 (ED-1 
is the primary antibody for activated macrophages (411). Generally, macrophages express 
distinct patterns of surface receptors when responding to different stimuli. Currently, two distinct 
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polarization states of macrophages, “classical” or M1 and “alternative” or M2 have been 
characterized (5, 412). While the M1 phenotype promotes inflammation, the M2 phenotype 
dampens inflammatory events. Therefore, the concomitant reduction of M1 phenotype, NF-κB, 
TNF-α, JNK, IL6 and IL-1β would limit tissue insults and decrease the oxidative destruction of 
important metabolic regulators like adiponectin and insulin in type-2 diabetes (T2D)  (413, 414). 
Emerging evidence indicates that adipocytes from different body compartments have 
distinct inflammatory phenotypes based on their anatomical location (415). Generally, 
pericardial or ectopic adiposity is more malignant than subcutaneous adiposity, although they are 
both implicated in the pathogenesis of obesity-related cardio-metabolic complications like 
insulin resistant T2D and coronary artery disease in lean and obese individuals (8, 415). 
Although we recently reported the insulin sensitizing effects of the heme oxygenase (HO) 
inducer, hemin, in Zucker diabetic Fatty rats (ZDF) (200), the effects of the HO system on 
pericardial adiposity remains largely unclear. Similarly, the effect of upregulating the HO system 
with hemin on macrophage polarization in cardiac tissue has not been reported. Whether hemin 
therapy will improve cardiac function in ZDF after suppressing the M1 phenotype, NF-κB, TNF-
α, JNK, IL6 and IL-1β in the left ventricle will be investigated. Therefore this study was 
designed to investigate the role of hemin on pericardial adiposity and the mechanisms by which 
hemin ameliorates diabetic cardiomyopathy in ZDF, an insulin-resistant T2D model with 
diabetic cardiomyopathy (374, 416).  
3.3 Materials and methods  
3.3.1 Animal treatment and biochemical assays  
Our experimental protocol was approved by the University of Saskatchewan Standing 
Committee on Animal Care and Research Ethics, which is in conformity with the Guide for Care 
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and Use of Laboratory Animals stipulated by the Canadian Council on Animal Care and the 
National Institutes of Health (NIH Publication No. 85-23, revised 1996). Twelve-week-old male 
ZDF rats, a genetically obese leptin receptor-deficient (fa/fa) animal model of T2D and their 
corresponding age/sex-matched Zucker-lean (ZL) littermates were purchased from Charles River 
(Willington, MA, USA). The animals were housed at 21C with 12-hour light/dark cycles, fed 
with standard laboratory chow and had access to drinking water ad libitum. The drugs used for 
this study were hemin, an inducer of HO (30 mg/kg i.p., Sigma, St Louis, MO) and stannous-
mesoporphyrin (SnMP), a blocker of HO (2 mg/100 g body weight i.p, Porphyrin Products, 
Logan, UT). The doses of SnMP and hemin used in this study have been shown to be effective in 
previous studies (48, 192, 200, 202, 417). Hemin and SnMP were prepared as we previously 
reported and were given biweekly for eight weeks (48, 187, 192, 200, 202, 417). Hemin has been 
approved by the FDA against porphyria (56), while SnMP has successfully completed phase-III 
clinical trials (418).  At 14 weeks of age, the animals were randomly assigned to five 
experimental groups (n=6-14 per group): (A) controls (ZDF and ZL), (B) hemin-treated ZDF 
and ZL, (C) ZF+Hemin+SnMP, (D) ZDF+SnMP and (E) ZF+vehicle dissolving hemin and 
SnMP.  
During the treatment period glucose was monitored weekly after 6 hrs of fasting in 
metabolic cages with a glucose-meter (BD, Franklin Lakes, NJ, USA). Body weight was also 
measured on a weekly basis. At the end of the 8-week treatment period, the animals were 22 
weeks of age. A day prior to sacrifice, the animals were fasted in metabolic cages for 24-hr urine 
collection and weighed. Systolic blood pressure was determined by non-invasive tail-cuff 
method (Model 29-SSP, Harvard Apparatus, Montreal, Canada). Plasma was collected by intra-
cardiac puncture and the pericardial fat pad and the heart were isolated, cleaned and weighed 
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using an analytical balance (Precisa Instruments Ltd, Switzerland). The atria were removed from 
the heart and the right ventricle free wall separated from the left ventricle including the septum 
as we previously reported (187). 
Left-ventricular HO activity was evaluated spectrophotometrically as bilirubin production 
using our established method (187, 196, 200, 202), while HO-1 (Stressgen-Assay Design, Ann 
Arbor, MI, USA), TNF-α, IL-6, IL1-β (Immuno-Biological Laboratories Co Ltd, Takasaki-shi, 
Gunma, Japan) were measured by commercially available ELISA kits. Other biochemical 
parameters such as left-ventricular 8-isoprostane and endothelin-1 were measured by EIA 
(Cayman Chemical, Ann Arbor, MI) as we previously reported (187, 196). 
 
3.3.2 Measurement of cardiac hemodynamic parameters (invasive hemodynamic 
measurements) 
The animals were anesthetized with isoflurane through inhalation using a vaporizer. The 
vaporizer was set at 5.0% isoflurane/L O2 (g) to induce, and 2.0%/L O2 (g) for maintenance of 
anesthesia.  To measure the hemodynamic parameters, a Millar Mikro-Tip ultra-miniature tip 
sensor pressure transducer catheter (SPR-407) with a catheter size of 1.5 French was inserted 
through the right carotid artery and advanced into the left-ventricular chamber to measure the 
left-ventricular hemodynamic parameters. After positioning of the pressure transducer into the 
left ventricle, the rat was allowed to stabilize for 10 minutes before the left-ventricular 
hemodynamic measurements were recorded.  Arterial blood pressure was subsequently recorded 
by pulling the catheter out of the ventricular chamber into the aorta. Central venous pressure was 
measured by inserting the miniature tip sensor pressure transducer catheter into the superior vena 
cava through the right jugular vein.  Data was acquired on a Biopac Data Acquisition system and 





Echocardiographic evaluation was done in rats using a Vevo 660 high frequency 
ultrasound machine (Visual Sonics, Markham, ON) equipped with B-mode imaging. For 
consistency, all measurements were done by the same investigator and all ultrasound procedures 
did not exceed 30 minutes for each rat. Prior to ultrasound experiments, anesthesia was induced 
with 5% isoflurane, maintained at 0.5-1% isoflurane (Abbott Laboratories, Saint-Laurent, QC), 
and the rats placed with the ventral side up on an electrocardiogram (ECG) plate (Visual Sonics, 
Markham, ON) with each paw covered with electrode cream (Sigma Crème, Parker Laboratories, 
Fairfield, NJ) and secured to ECG contacts with surgical tape in order to monitor heart rate 
throughout each experiment. A temperature probe was inserted rectally to maintain internal body 
temperature at 37C. To prevent artifact with this high resolution ultrasound system, the animal 
was depilated by wiping from the chest area with depilatory cream (Nair, New York, NY). 
Thereafter, Eco Gel 200 (Eco-Med Pharmaceuticals, ON) was then applied to the thorax for 
ultrasound.  
A RMV 710B scan head was used to gather all parasternal short and long-axis views of 
the rat ventricle in B-mode. The areas of three different short axis views along the ventricle were 
measured and designated as A1, A2, A3 while the ventricular length of one long axis view was 
measured and divided by four to give ventricular height (h). Using different short axis views at 
different levels of the ventricle compensates for irregularities in ventricular shape and greatly 
increases accuracy of chamber volume measurements (283). All of these values were measured 
at both systole and diastole using Visual Sonics software (Markham, ON). With these values, 
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end systolic and diastolic volumes in units of cm3 (equivalent to ml) were each calculated for the 
left ventricle using: (Equation I) V = (A1+A2) h + ((A3h)/2) + (/6(h3)) 
End systolic volume was subtracted from end diastolic volume to give stroke volume 
(VS) in milliliters. Heart rate in beats per minutes for each rat was recorded at three different 
times throughout one imaging period and then averaged. Cardiac output (CO) in 
milliliters/minute was then determined using heart rate (fH) and stroke volume (VS): (Equation II) 
CO = fH * VS. Ejection fraction (%) for each rat was also calculated using stroke volume (VS) 
and end diastolic volume (EDV): (Equation III) Ef = VS /EDV   
In order to measure left-ventricular free wall thickness, a clip in parasternal long axis 
view was obtained for all experimental groups. At least three individual images were exported 
from the clip at both systole and diastole using Premiere Elements 2.0 (Adobe, San Jose, CA) 
and then left-ventricular wall thickness determined using ImagePro 6.0 software (Bethesda, 
MD). Heart rate (fH in beats per minute) was calculated from ECG traces during the blood 
pressure experiment.  
 
3.3.4 Total RNA isolation and quantitative RT-PCR for NF-κB, AP-1 and JNK 
 
The left ventricle was homogenized and quantitative RT-PCR done as we previously reported 
(187, 200, 202). Briefly, triplicate samples of 1 µl of cDNA each was ran using a template of 3.2 
pmol of primers for NFκB (forward, 5'CATGCGTTTCCGTTACAAGTGCGA-3' and reverse 
5'TGGGTGCGTCTTAGTGGTATCTGT-3'), AP-1 (forward,5'AGCAGATGCTTGAGTTGAG 
A G CCA3' and reverse 5'TTCCATGGGTCCCTGCTTTGAGAT-3'), JNK (forward 
5′AAGCAGCAAGGCTACTCCTTCTCA-3′ and reverse 5′ATCGAGACTG CTGTCTGTGTCT 
GA-3′) and glyceraldehyde-3-phosohate dehydrogenase (5'TCTGGGATGGAATTGTGAGGGA 
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GA-3') in a final volume of 25 µl. Sequences of all primers were confirmed by the National 
Research Council of Canada, Saskatoon. 
 
3.3.5 Western immunoblotting  
The left-ventricular tissue was homogenized and centrifuged as previously described 
(187, 199, 200, 202). Primary antibodies (Santa Crutz Biotechnology, CA, USA) including ED-2 
(sc-58956), ED-1 (sc-59103), phosphatidylinositol-3-kinase (PI3K) (sc67306), protein kinase-B 
(PKB) (sc9118) and insulin-receptor-substrate-1 (IRS-1) (8299) were used. Densitometric 
analysis was done with UN-SCAN-IT software (Silk Scientific, Utah, USA). GAPDH antibody 
(Sigma St Louis, MO, USA) was used as a control to ascertain equivalent loading.  
 
3.3.6 Left-ventricular histology 
The middle portion (midpapillary level) of the left ventricle of heart was separated, fixed 
in 10 % formalin phosphate buffer for 48 hrs., processed and paraffin embedded as we 
previously reported (187). Then sections of 5 μm thicknesses were cut and stained with 
hematoxylin and eosin for histological analysis. The left-ventricular sections were obtained from 
the middle portion of the left ventricle to avoid differences in regional cardiomyocyte size in 
different regions of the left ventricle. The cardiac sections were scanned using a microscope 
(Aperio Scan Scope Model CS, Aperio Technology Inc, CA, USA) and analyzed using Aperio 
Image Scope V11.2.0.780 software (Aperio, e-Pathology Solution, CA USA). Left-ventricular 
myocyte width longitudinal myocyte thickness was measured randomly in 20-30 cardiac muscle 
fibers from each left-ventricular tissue section. Muscle fiber thickness was quantified and 
analyzed between different groups. For consistency, myocytes were positioned perpendicularly 
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to the plane of the section with a visible nucleus and cell membrane clearly outlined. Unbroken 
areas were selected for measurement. All sections were imaged at 40X zoom (40X; 0.50 
µm/pixel) in Aperio Image Scope using length measurement tool (µmeter). 
 
 Statistical analyses 
All data were expressed as means  SEM from at least six independent experiments 
unless otherwise stated. Statistical analyses were done using unpaired Student’s t-test and 
analyses of variance in conjunction with Bonferroni test for repeated measures where 
appropriate. Group differences at the level of p<0.05 were considered statistically significant. 
 
3.4 Results 
3.4.1 Hemin therapy abated pericardial adiposity and restored normoglycemia in ZDF rats 
ZDF rats were severely hyperglycemic with fasting glucose levels of 24.6 ± 3.1 mmol/L 
(Table 3-1), whereas their age/sex matched littermates’ control-ZL were normoglycemic (7.2 ± 
0.8 mmol/L). The 8-week regimen of hemin to ZDF reduced the elevated glycemia to 
physiological levels (24.6 ± 3.1 vs. 6.8 ± 1.3 mmol/L; p<0.01), whereas the co-treatment of 
hemin and the HO-blocker, SnMP abolished the effect of hemin, suggesting a role of the HO 
system on glucose homeostasis.  Similarly, hemin treatment significantly reduced pericardial 
adiposity (1.85 ± 0.2 vs. 0.79 ± 0.13 g/Kg body weight, p <0.01) and cardiac hypertrophy (3.8 ± 
0.3 vs. 2.4 ± 0.14 g/Kg body weight; p<0.01) in ZDF, whereas the co-administration of hemin 
and SnMP nullified the effect, suggesting a role of the HO system on the regulation of 
pericardial adiposity and cardiac hypertrophy. The vehicle dissolving hemin and SnMP had no 
effect on blood glycemia, pericardial adiposity and heart weight (Table 3-1).   
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Hemin therapy also affected ZL rats though less intensely. A slight but significant 
reduction of blood glucose, cardiac hypertrophy and pericardial adiposity was observed in ZL 
rats. These effects were abolished by SnMP (Table 3-1). In hemin-treated ZDF rats, blood 
glucose, cardiac hypertrophy and pericardial adiposity were reduced by 72.3, 36.8 and 57% 
respectively whereas in ZL rats these same parameters were reduced by 11.1, 14.8 and 25.4% 
respectively, suggesting greater selectivity of the actions of hemin in diseased conditions like the 
situation in ZDF rats, whereas less active in healthy status as in the case of ZL rats.  
The HO inducer, hemin and HO blocker, SnMP also affected body weight. A slight body-
weight loss (<10%) was observed in hemin- and SnMP-treated animals (Table 3-1). In 
ZL+Hemin, ZDF hemin, and ZF+Hemin+SnMP the loss of body weight was 2.5, 5.3 and 8.1% 
respectively. Although body-weight loss can affect blood glucose levels, it is unlikely in this case 
since the slight body-weight loss in hemin- and SnMP-treated were accompanied by opposite 
effects on glucose levels (Table 3-1). Accordingly, we observed a decrease of glucose levels in 
hemin-treated animals, but an increase in SnMP-treated animals suggesting that the HO system 
may be endowed with intrinsic anti-diabetic effects. The loss of body weight may not be due to 
toxicity as we recently showed that several indices of toxicity including plasma gamma-
glutamyltransferase (GGT), aspartate aminotransferase (AST) and alanine aminotransferase 
(ALT) were within normal range (200).   
Hemin therapy also improved cardiac hemodynamics (Table 3-2). In hemin-treated ZDF, 
systolic blood pressure was reduced by 13.95%, while cardiac output increased by 8.2%. 
Interestingly, the lowering of systolic blood pressure was associated with a 12.2% decrease in 
total peripheral resistance, suggesting reduced afterload to the left ventricle (420). 
Correspondingly, a reduction of 8.9% in the rate of left-ventricular pressure development 
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(+dP/dt) was observed (Table 3-2). Furthermore, hemin increased the left-ventricular ejection 
fraction by 5.4%, and this effect was accompanied by a 2.2 % reduction of left-ventricular 
systolic pressure (LVSP). Therefore, increased cardiac output coupled to the concomitant 
reduction of total peripheral resistance, +dP/dt and LVSP are indicative of improved cardiac 
function in hemin-treated ZDF.    
 
3.4.2 Hemin therapy enhanced HO-1 and HO activity but abated ET-1 and 8-isoprostane in 
the left ventricle of ZDF rats 
To investigate the role of the HO system in the improved cardiac function and insulin-
signaling in ZDF, we measured HO activity, ET-1 and 8-isoprostane. Our results indicate that the 
basal levels of HO-1 and HO-activity in control-ZDF were significantly reduced by 2.13- and 
1.98-fold respectively as compared to control-ZL rats. Hemin therapy markedly increased the 
depressed levels of HO-1 and HO activity in ZDF rats by 8.1- and 10.56-fold respectively (Figs. 
3-1A and 3-1B), whereas the co-treatment with the HO inhibitor, SnMP nullified the effects of 
the HO inducer, hemin. Similarly, treatment with SnMP alone depleted the basal levels of HO-1 
and HO activity (Figs.3-1A and 3-1B). Hemin therapy also enhanced the levels of HO-1 and HO 
activity in ZL rats, although a greater increment was observed in hemin-treated ZDF animals 
(Figs. 3-1A and 3-1B). The higher magnitude of HO-signaling may be responsible for the more 
intense reduction of glycemic levels in ZDF rats as compared to ZL rats (Table 3-1). 
Alternatively, the less-preponderant increase of HO activity in ZL rats may suggest greater 
stability of the HO system in healthy conditions.  
Given that elevated oxidative stress is among the causative factors of insulin resistance 
and cardiac dysfunction, we measured 8-isoprostane, an important marker of oxidative stress 
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(379). In ZDF rats, the basal levels of left-ventricular 8-isoprostane were markedly elevated, 
suggesting enhanced oxidative stress (Fig. 3-1C). Interestingly, hemin therapy significantly 
reduced 8-isoprostane by 57.6%. Contrarily, in SnMP+ZDF treated animals, the effect of hemin 
on 8-isoprostane was annulled and 8-isoprostane was reversed to comparable levels as observed 
in control-ZDF rats. On the other hand, in SnMP-treated animals, the levels of left-ventricular 8-
isoprostane were further increased, suggesting that oxidative stress is further potentiated by 
blockade of basal HO activity (Fig. 3-1C). Hemin therapy also reduced 8-isoprostane in ZL rats, 
although less-intensely as compared to ZDF as only a 28.9% reduction was observed in hemin-
treated ZL rats as compared to 57.6% hemin-treated ZDF rats. 
Since 8-isoprostane stimulates ET-1 (378), and both ET-1 and 8-isoprostane are involved 
in the oxidative destruction of tissue, we also assessed ET-1 in the left ventricle. Our results 
indicate that the levels of ET-1 in ZDF rats were 2.7-fold higher than in control-ZL rats. 
Interestingly, hemin therapy greatly attenuated the elevated levels of left-ventricular ET-1 in 
ZDF rats, while SnMP abolished the effect of hemin (Fig. 3-1D). Hemin therapy also reduced 
ET-1 levels in ZL rats albeit to a lesser extent as compared to ZDF rats. Accordingly, a reduction 
of 25.2% of ET-1 was observed in hemin-treated ZL rats as compared to 54.2% hemin-treated 
ZDF rats.  
Therefore, the preponderant increase of HO activity in hemin-treated ZDF as compared 
to hemin-treated ZL (Figs. 3-1A), coupled to the more accentuated reduction of left-ventricular 
8-isoprostane (Fig. 3-1C) and ET-1 (Fig. 3-1D) may account for the greater anti-diabetic effect 




3.4.3 Hemin therapy suppressed pro-inflammatory cytokines that deregulate glucose 
metabolism cardiac function 
TNF-α, IL-6 and IL-1β are cytokines that impair cardiac function and glucose 
metabolism (5, 421, 422), so we investigated whether the improvement in cardiac function and 
glucose metabolism in hemin-treated ZDF would be accompanied by reduction of these 
cytokines. Our results indicate that the levels of TNF-α, IL-6 and IL-1β in the left ventricle of 
control-ZDF rats were significantly elevated by 4.5-, 9.1- and 2.5-fold respectively as compared 
to control-ZL rats (Fig. 3-2). Treatment with hemin markedly reduced TNF- -6 and IL-
by 71.2, 51.3 and 56.8% respectively. In contrast, the co-application of the HO-inhibitor, SnMP 
with hemin reversed the effects of hemin (Fig. 3-2A, 3-2B and 3-2C), suggesting a role of the 
HO system in the regulation of these inflammatory cytokines. Hemin therapy also reduced the 
levels of TNF-α, IL-6 and IL-1β in the ZL rats, although less intensely. A reduction of 35.4, 
37.0, 28.5% of TNF-α, IL-6 and IL-1β respectively was observed in hemin-treated ZL rats as 
compared to 71.2, 51.3 and 56.8% in hemin-treated ZDF rats. 
 
3.4.4 Hemin abated transcription factors that impair insulin-signaling and cardiac function 
Many inflammatory and oxidative transcriptions factors including NF-κB, AP-1 and JNK 
are implicated in tissue damage and insulin resistance (414, 423). In ZDF rats, quantitative real-
time RT-PCR analyses indicated that the levels of NF-κB, AP-1 and JNK in the left ventricle 
were strikingly elevated (Fig. 3-3). Treatment with hemin reduced NF-κB and AP-1 by 2.5- and 
2.9-fold respectively, while the HO inhibitor, SnMP, nullified the effects of hemin (Fig. 3-3A 
and 3-3B). Moreover, treatment with SnMP alone further enhanced NF-κB and AP-1 in ZDF 
rats by 20% and 31.9% respectively, suggesting the involvement of basal HO activity in the 
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regulation of these oxidative/inflammatory mediators. Furthermore, in ZDF rats, the basal 
expression of left-ventricular JNK, a substance that suppresses insulin biosynthesis (414), was 
markedly increased by 4.75-fold, but was abated by hemin (Fig. 3-3C). Hemin therapy also 
reduced NF-κB, AP-1 and JNK in ZL rats by 30.5, 24.8, and 26.1% respectively which were 
less-intense as compared to hemin-treated ZDF where the reduction of NF-κB, AP-1 and JNK 
were 59.3, 65.6 and 57.8%, suggesting greater selectivity of hemin in the diseased condition. 
 
3.4.5 Hemin therapy abated inflammation but potentiated insulin-signaling agents   
Given that macrophages are amongst the fundamental sources of many of the circulating 
inflammatory molecules in obesity, and are postulated to be causal in the development of insulin-
resistant T2D (5, 412), we used specific markers (ED1 and ED2) to quantify the M1 pro-
inflammatory phenotype (ED1) and the M2 anti-inflammatory phenotype (ED2). Our Western 
immunoblotting and relative densitometric analyses indicated that the expression of the pro-
inflammatory M1 phenotype in control-ZDF was significantly elevated (Fig. 3-4A), but 
interestingly was abated by 40.1% by hemin therapy. On the other hand, the anti-inflammatory 
phenotype, M2, was significantly reduced in control-ZDF (Fig. 3-4B), but interestingly was 
enhanced by 61.3% by hemin therapy, suggesting that hemin may preferentially favor 
macrophage polarization towards the M2 anti-inflammatory phenotype as an alternative 
mechanism to counteract tissue insult. 
Given that IRS1, PI3K and PKB are important proteins implicated in the insulin signal 
transduction pathway (Ndisang, 2010), we investigated the effect of hemin therapy on these 
proteins. Our results indicate that the expression of IRS1 in control-ZDF was depressed (Fig. 3-
4C). However, hemin therapy greatly enhanced the expression of IRS1 bv 2.3-fold. Similarly 
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hemin therapy significantly increased the expressions of PI3K (Fig. 3-4D) and PKB (Fig. 3-4E) 
by 3.5-and 2.8-fold respectively. 
 
3.4.6 Hemin therapy reduced longitudinal muscle fiber thickness in ZDF rat 
Longitudinal muscle fiber thickness is a common pathophysiological feature of cardiac 
myocyte hypertrophy (187, 424, 425). In untreated ZDF rats, enlarged cardiomyocytes with 
increscent nuclei were evident, as compared to normal cardiomyocytes in ZL-control rats (Fig. 
3-5A). The inter myofibril space was reduced in ZDF-control rats as compared to the age/sex-
matched ZL rats (Fig. 3-5A). Indeed, a 44 % increase in cardiomyocyte longitudinal fiber 
thickness was observed in the ZDF-control rats as compared to ZL rats (21.9 ± 0.89 vs 15.2 ± 
0.49 µmeter, p<0.01, n=6) (Fig. 3-5B). Interestingly, hemin treatment reduced cardiomyocyte 
longitudinal fiber thickness by 25 % as compared to ZDF control (18.1 ± 0.76 vs 21.9 ± 0.89 
µmeter, p<0.05, n=6). However, this reduction did not reach the basal level of cardiomyocyte 
longitudinal thickness of the ZL rats (15.2 ± 0.49 µmeter) (Fig. 3-5B). 
 
3.5 Discussion 
The present study demonstrates for the first time that upregulating the HO system with 
hemin preferentially favors macrophage polarization towards the M2 phenotype that dampens 
inflammation, while suppressing the M1 pro-inflammatory phenotype. Another novel 
observation is that hemin therapy suppresses pericardial adiposity in ZDF rats, a model of insulin 
resistance, dyslipidemia and hyperglycemia (200). Pericardial adiposity is associated with 
elevated inflammatory/oxidative insults and dyslipidemia that adversely affect cardiac function, 
especially in individuals co-morbid with obesity and insulin resistance (8, 381, 415). 
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Interestingly, hemin therapy significantly reduced pericardial adiposity, attenuated macrophage 
infiltration and pro-inflammatory/oxidative mediators, such as NF-κB, AP-1 JNK, TNF-α, IL-6 
and IL-1β (5, 414, 421-423), but enhanced important proteins involved in the insulin signal 
transduction pathway such as IRS-1, PI3K, and PKB (5), with corresponding reduction of 
hyperglycemia in ZDF.  
Although one study had previously reported the role of HO-1 promoter in macrophage 
polarization (426), the expression levels of M1 and M2 phenotypes were not measured, so our 
study provides solid evidence on the role of the HO system on macrophage polarization. 
Importantly, the preferential enhancement of the M2 phenotype may be considered an alternative 
anti-inflammatory mechanism through which the HO system counteracts inflammatory insult. 
Interestingly, the HO system may reduce tissue inflammation through other mechanisms 
including the suppression of inflammatory cytokines like TNF-α, IL-6 and IL-1β (5, 421, 422). 
Consistently, in hemin-treated ZDF rats, TNF-α, IL-6 and IL-1β were markedly reduced. 
Similarly, other pro-inflammatory/oxidative mediators such as 8-isoprostane, NF-κB, AP-1 and 
JNK (414, 423) were greatly attenuated by hemin therapy, whereas the HO inhibitor, SnMP, 
nullified the hemin effects and exacerbated oxidative/inflammatory insults causing further 
impairment in glucose metabolism.   
Hemin therapy also improved cardiac hemodynamics. In particular, systolic blood 
pressure was significantly lowered while cardiac output increased in hemin-treated ZDF. The 
lowering of systolic blood pressure and LVSP observed were accompanied by the reduction of 
total peripheral resistance, and these effects would reduce the afterload to the left ventricle and 
thus prevents the onset of ventricular dysfunction (420, 427, 428).  An abnormal left-ventricular 
function would affect the cardiac performance and contribute to the symptoms associated with 
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cardiac failure (429). With the reduction of systolic blood pressure in hemin-treated ZDF, left-
ventricular cardiomyocytes would contract less vigorously. This was evidenced by the reduction 
of +dP/dt. Therefore, by not generating a high pressure gradient to maintain adequate blood 
circulation, the workload and oxygen consumption of the left ventricle would be reduced and the 
risk of cardiovascular related morbidity and mortality would be curtailed (420, 427-429).  
Another beneficial effect of hemin treatment to ZDF rats was the increase in left-ventricular 
ejection fraction. Interestingly, this was accompanied by a reduction of LVSP.  Thus, the 
concomitant increase in ejection fraction and cardiac output accompanied by the parallel 
reduction of systolic blood pressure, LVSP, +dP/dt and total-peripheral resistance would 
translate into improved cardiac function in hemin-treated ZDF. 
Several mechanisms may be responsible for the improvement of cardiac hemodynamic 
parameters by hemin. These include vascular contractility (430), ventricular contractility (80), 
and the reduction of cardiac damage by hemin (185, 187, 193, 424, 425). In the present study, 
hemin therapy significantly reduced longitudinal muscle fiber thickness, a common 
pathophysiological feature of cardiac myocyte hypertrophy (187, 424, 425). Similarly, an 
upregulated HO system by hemin has been shown to correspondingly reduce cardiac 
histopathological lesions such as longitudinal muscle fiber thickness, cross-sectional muscle 
fiber thickness, scarring, muscular hypertrophy, coronary arteriolar thickening and fibrosis, (185, 
187, 193) which would result in a healthier heart with improved ventricular contractility and 
improved hemodynamics (80). Furthermore, the HO system generates a vasodilator like carbon 
monoxide, a stimulator of cGMP that modulates both vascular contractility (80, 430) and 
ventricular contractility thus hemodynamics (80).  
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Generally, cardiac function is influenced by multiple factors and contractility is only one 
of such factors (420). By keeping after-load constant, any increase in cardiac function will 
increase left-ventricular force development (increase in +dp/dt).  An increase in ejection fraction 
or cardiac output resulting from improvement in cardiac function can be accompanied by a 
subsequent decrease in pre-load (427). This is particularly true when the increase in cardiac 
function is accompanied by a decrease in after-load (total-peripheral resistance).  The decrease in 
pre-load will cause a decrease in the resting fiber (sarcomere) length and reduce the ventricular 
force development which is manifested by the decrease of left-ventricular +dp/dt (max) (420, 
427). Although the present study indicates that upregulating the HO system with hemin 
significantly reduced total-peripheral resistance and lowered systolic blood pressure in ZDF rats, 
the other hemodynamic parameters measured such as cardiac output, ejection fraction, LVSP and 
+dP/dt were improved by 8.26, 5.37, 2.28 and 8.94% respectively, and significance was not 
attained. Therefore the hemodynamic data presented in this study should be cautiously 
interpreted, and future investigations would be needed for a more comprehensive understanding 
on the effects of hemin therapy on cardiac hemodynamics. Nevertheless, the HO system has been 
shown to modulate vascular contractility and ventricular contractility (80, 430) and improve 
ejection fraction (431), whereas blockade of the HO system resulted to a decrease in cardiac 
output and an increase in total-peripheral resistance (432). Collectively these studies and the 
present findings strongly suggest that the HO system may contribute towards the improvement of 
cardiac hemodynamics and cardiac function.   
Hemin therapy also enhanced the HO system and abated NF-κB, AP-1 JNK, TNF-α, IL-6 
and IL-1β in ZL-control rats, although the magnitude was smaller as compared to ZDF rats with 
depressed HO-activity. The reasons for this selective effect of HO are not fully understood. 
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However, it is possible that since ZL rats are healthy animals with normal/functional insulin-
signaling, the HO system may be more stable as compared to ZDF which have depressed HO 
activity. Importantly, the selectivity of the HO system in diseased conditions could be explored 
against the co-morbidity of insulin-resistant diabetes and obesity. Nevertheless, future studies 
will be done to investigate the selective effects of the HO system on ZL-control rats. Although 
we previously reported the insulin sensitizing effect of hemin in the gastrocnemius muscle of 
ZDF, tissue-specific response is a well-known phenomenon in the pathophysiology of insulin 
resistance and impaired glucose metabolism, and different tissues may respond distinctly to the 
same stimuli, indicating that a physiological response in one tissue may not necessarily be the 
same in another tissue  (433, 434). Whether the reported effects were unique for the 
gastrocnemius muscle or universal for other tissues is critical for understanding the role of hemin 
in insulin resistance and glucose metabolism. Therefore, studying the effect of an upregulated 
HO system in the left ventricle of ZDF rat is important for the advancement of knowledge in this 
area. Moreover, the effects of hemin therapy on left-ventricular IRS-1, PI3K and PKB in ZDF-
rat, a model with diabetic cardiomyopathy (374, 416) remains poorly understood.  Interestingly, 
the present study unveils that the restoration of normoglycemia in hemin-treated ZDF was 
accompanied by the concomitant potentiation of left-ventricular IRS-1, PI3K and PKB, and the 
improvement of cardiac function. 
 
3.6 Conclusion 
Collectively, our study unveils the beneficial effect of the HO system on pericardial 
adiposity, impaired insulin-signaling, diabetic cardiomyopathy and suggest that the suppression 
of inflammatory/oxidative mediators are among the multifaceted mechanisms by which the HO 
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system maintains homeostasis in physiological milieu. Given that NF-κB activates TNF-α, IL6 
and IL-1β (5), while TNF-α, JNK and AP-1 impair insulin-signaling (5), the high levels of these 
cytokines and inflammatory/oxidative mediators in the chronic conditions of obesity and 
diabetes would create a vicious cycle that when added to the oxidative insults generated by 8-
isoprostane and ET-1 (435) would exacerbate tissue insult and compromise its function. 
Therefore, the concomitant reduction of pro-inflammatory cytokines and macrophage infiltration 
coupled to the potentiation of insulin-signal transduction agents such as IRS-1, PI3K, PKB and 
the improved cardiac hemodynamics may account for enhanced glucose metabolism and 
improved cardiac function in hemin-treated ZDF. Importantly, the novel findings of our study 
includes: (i) the preferential polarization of macrophages towards anti-inflammatory M2-
phenotype in cardiac tissue as evidenced by increased expression levels of the M2-phenotye and 
the parallel reduction of the M1-proinflammatory phenotype; (ii) the suppression of pericardial 
adiposity; and (iii) the hemin-induced improvement of cardiac function in ZDF rat, a model of 
obesity, insulin resistance, type-2 diabetes with cardiomyopathy (374, 416). 
With the escalation of obesity, diabetes and hypertension in industrialized and developing 
countries, the incidence of cardio-metabolic complications including diabetic cardiomyopathy 
and heart failure will increase. Cardio-metabolic complications are multifactorial diseases and a 
wide variety of different pathophysiological factors including inflammatory/oxidative insults are 
involved. The present study highlights the ability of hemin therapy to suppress 
inflammatory/oxidative mediators and improve insulin-signaling in T2D. Impaired insulin-
signalling is not only an important etiological factor in the pathogenesis of T1D and T2D, but 
also an important patho-physiological driving force that is capable of dictating the dynamics and 
progression of the disease as well as its ultimate evolution in to complications like diabetic 
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cardiomyopathy. Therefore, the findings reported here could serve as a useful tool for the 
formulation of novel therapeutic agents against diabetes, pericardial adiposity and related 
complications like diabetic cardiomyopathy. Interestingly, our study may have great translational 
potential as the drugs used (hemin and SnMP) may have therapeutic application. Both hemin and 
SnMP may have application in clinics as hemin has been approved by the FDA against porphyria 
(55, 56), while SnMP has successfully completed phase-III clinical trials for possible use against 
neonatal jaundice (436-438). 
 
Acknowledgements 
This work was supported by the Heart & Stroke Foundation of Saskatchewan of Canada 





























































Figure 3-1: Effects of the HO inducer, hemin and the HO inhibitor, SnMP, on left-ventricular 
HO-1, HO activity, 8-isoprostane and ET-1 of ZDF and ZL rats. (A) The basal HO-1 levels in 
ZDF rats were lower as compared to ZL-control rats. Hemin therapy increased HO-1 
concentration, while the HO blocker, SnMP annulled the hemin effect. Hemin also enhanced HO 
activity in ZL rats, but less intensely as compared to ZDF rats. (B) The basal HO activity in ZDF 
rats was depressed as compared to ZL-control rats, but was enhanced by hemin while the HO 
blocker, SnMP annulled the hemin effect. Hemin also enhanced HO activity in ZL rats, but less 
intensely as compared to ZDF rats. Hemin reduced (C) 8-isoprostane and (D) abated ET-1 in 
ZDF and ZL-control rats, but SnMP abolished the effect. The vehicle dissolving hemin and 
SnMP had no effect on HO activity, 8-isoprostane and ET-1. Bars represent means ± SE; n=6 













































Figure 3-2: The effects of hemin and the HO inhibitor, SnMP, on left-ventricular inflammatory 
cytokines.  Hemin therapy reduced (A) TNF-α, (B) IL-6 and (C) IL-1β, in ZDF rats and ZL-
controls, while SnMP nullified the effects of hemin. Bars represent means ± SE; n=6 rats per 











































Figure 3-3: The effects of hemin and the HO inhibitor, SnMP, on left-ventricular NF- -1 
and JNK. Quantitative real-time RT-PCR indicated hemin therapy suppressed the elevated basal 
mRNA expression of (A) NF-κB, (B) AP-1 and (C) JNK in ZDF and ZL rats, but SnMP 
annulled the hemin effect. Bars represent means ± SE; n=6 rats per group (*p<0.05, **p<0.01 

















































































































Figure 3-4: Effect of hemin on left-ventricular ED-1, ED-2, IRS-1, PI3K and PKB in ZDF rats. 
Representative Western immunoblots and relative densitometry indicates that hemin therapy (A) 
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suppressed ED-1, but enhanced (B) ED-2, (C) IRS-1, (D) PI3K and (E) PKB in ZDF. Bars 








Figure 3-5: Effect of hemin on longitudinal muscle fiber thickness is ZDF. (A) Representative 
images of histological sections revealed that hemin therapy attenuated longitudinal muscle fiber 
thickness is in ZDF. In untreated ZDF rats, enlarged cardiomyocytes with increscent nuclei were 
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evident as compared to normal cardiomyocytes in age/sex-matched the ZL-control rats. (B) 
Semi-quantitative analyses revealed that hemin therapy markedly reduced longitudinal muscle 
fiber thickness is ZDF rats. Bars represent means ± SE; n=4 rats per group (*p<0.05 vs. control-

















Figure 3-6: Schematic representation of the actions of hemin. Hemin therapy enhances HO-1, 
which in turn reduces adiposity and pro-inflammatory cytokines including IL6, IL-1β, NF-κB, 
TNF-α, JNK and M1-phenotype macrophage infiltration. Correspondingly, insulin sensitivity 







Control ZL ZL+ Hemin Control ZDF ZDF + Hemin ZDF + Hemin
+SnMP
Body weight (g) 363.7  5.4 354.5  9.5 383.6  5.4 363.4  6.5
† 352.5  8.2#




2.7 0.2 2.3  0.1* 3.8  0.3 2.4  0.14** 3.4  0.3#
Pericardial adiposity  
(g/Kg body weight)
1.3  0.1 0.97  0.05* 1.85  0.2 0.79  0.13** 1.72  0.5#
 
 
†p<0.05 vs controls; *p<0.05 vs Control ZDF or control ZL, #p<0.05 vs ZDF + Hemin n=8 per 
group 
 
Table 3-1: Effect of hemin and stannous mesoporphyrin (SnMP) on physiological variables in 






Table 3-2: Echocardiographic and invasive hemodynamic measurements 
1 The negative percentage changes in left-ventricular systolic pressure (LVSP) and left-
ventricular pressure development (+dP/dt) are well correlated to the reduction of total peripheral 
resistance and systolic blood pressure, all of which are indicative of improved cardiac function 









































































1.16 ± 0.08* 
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General discussion  
The research presented in this thesis strongly underscore the novel and beneficial effects 
of an upregulated HO system by hemin against impaired insulin signaling and cardiomyopathy in 
obese ZF rats and the mechanisms by which HO improves dysfunctional insulin signaling, 
glucose metabolism, pericardial adiposity and altered cardiac structure and function (Chapter 2-
3). The potentiation of ANP and adiponectin by hemin-induced upregulated HO in cardiac tissue 
of ZF rats is an important and novel cardio-protective mechanism for attenuation of 
inflammatory and oxidative mediators, suppression of pro-inflammatory M1 macrophage 
phenotype, attenuation of ECM/profibrotic proteins and the improvement in impaired cardiac 
hemodynamic and echocardiographic parameters. Therefore, this chapter includes a general 
discussion about overall research results in terms of their importance in understanding the novel 
and beneficial role of the hemin-induced upregulated HO system against obesity and 
cardiomyopathy. The present study for the first time highlights the novel role of the HO system 
on macrophage polarization in the cardiac tissue of ZF rats. Importantly, my thesis work 
provides novel insights on the beneficial effects of concomitant potentiation of HO, ANP and 
adiponectin against cardiomyopathy and obesity in ZF rats.  
Although, the beneficial role of hemin-induced upregulated HO against inflammation, 
insulin resistance, oxidative stress, pericardial adiposity and cardiac hypertrophy are discussed 
briefly, several challenging questions remain to be addressed. Some of these questions will be 




4.1 Is obesity induces inflammatory events as primary response or is it a consequence of 
insulin resistance?  
Chronic low-grade inflammation and oxidative stress are common denominators that 
links obesity with diabetes, insulin resistance, dyslipidemia and cardiovascular diseases (14, 15, 
27, 29, 58, 68, 69, 133, 149, 150, 175, 178, 215). The inflammatory response induced during the 
obese condition is quite distinct from classical inflammation that is elicited as a defense 
mechanism against various tissue insults (24). Under the obese state, a metabolic inflammatory 
trigger is induced in response to increased levels of glucose, oxidized low-density lipoproteins 
and FFA. This metabolic trigger is detected by adipocytes and they respond by activating 
inflammatory pathways that lead to an impaired metabolic homeostasis, a reduced metabolic rate 
and disruption of insulin signaling (1, 5, 14, 76, 77, 124, 133, 142, 186, 439-441). However, it is 
still not very clear exactly how obesity elicits an inflammatory response. It is still not clear 
whether obesity induced inflammation is a primary response or is it a consequence of insulin 
resistance. It is suggested that inflammatory signals are initiated within the adipose tissue itself 
by adipocytes and other immune cells, as adipocytes are the very first cells that are affected by 
excess body fat (142). But how do these hypertrophied adipocytes elicit inflammatory signals? 
Several mechanisms have been proposed to explain this query. The mechanism for obesity-
induced inflammation might be by the altered metabolic signals produced by hypertrophied 
adipose tissue in response to excess glucose, low-density lipoproteins and FFA. As a 
consequence, the metabolic function of adipose tissue is compromised due to the overproduction 
of pro-inflammatory cytokines and chemokines such as TNF-α, IL-6, IL-1β, MCP-1 (1, 5, 15, 76, 
77) and inflammatory transcription factors such as NFκB and JNK by resident and recruited 
macrophages (1, 5, 14, 77, 124, 134, 142, 186, 439-441). This leads to localized inflammation in 
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adipose tissue followed by the development of systemic inflammation and other obesity-related 
complications including insulin resistance and cardiovascular diseases (14, 15, 27, 29, 58, 68, 69, 
149). Another mechanism that has been proposed is increased infiltration of macrophages into 
fatty adipose tissue that contributes to the increased production and expression of pro-
inflammatory mediators that propagate inflammatory signaling cascades (137-139). Moreover, 
increased macrophage infiltration during the inflammatory process was reported to be associated 
with a macrophage polarization event where macrophages polarizes from the anti-inflammatory 
M2 to the pro-inflammatory M1 phenotype (19, 130, 137-140). In addition, it is suggested that 
enlarged adipose tissue became hypoxic which in turn triggers inflammatory signaling cascades 
(134, 137-139). Another important factor that contributes to inflammation in obesity is oxidative 
stress. The condition of over nutrients in adipose tissue leads to high levels of intracellular ROS 
generation which in turn activates inflammatory pathways and subsequent endothelial injury 
(178, 214, 215). It is proposed that obesity induces stress signals inside adipocytes that leads to 
the deposition of misfolded proteins inside the ER. The ER stress generated stimulate the 
unfolded protein response pathway and activates an inflammatory signaling cascade through the 
activation of JNK and NFκB pathway along with the suppression of the IKK-β pathway (1, 3, 5, 
15, 67, 76). This altogether results in the elevated production of pro-inflammatory cytokines and 
chemokines that leads to the gradual deterioration of insulin sensitivity (1, 5, 15, 67, 77). It is 
interesting to know that blocking of inflammatory mediators such as TNF-α and JNK provides 
protection against insulin resistance in obese human and obese animal models (145). Based on 
these findings, it can be concluded that obesity contributes to both chronic low-grade 
inflammation and insulin resistance and inflammation is not just the consequence of obesity but 
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rather is a primary event for obesity related insulin resistance, hyperglycemia, and 
hyperlipidemia (145). 
 
Modulatory effects of HO, ANP and adiponectin 
The highlight of the present study is the beneficial role of an upregulated HO, ANP and 
adiponectin by hemin in ameliorating obesity induced inflammatory/oxidative insults and 
associated cardiometabolic complications in obese ZF rats (Chapter 2). An interplay exists 
between HO, ANP and adiponectin, as mutual stimulatory effects have been reported between 
HO and ANP (196, 359, 442). Furthermore, both ANP and HO have been shown to stimulate 
adiponectin (202, 319, 397, 443, 444). Interestingly, ANP has inhibitory effects on inflammatory 
cytokines such as TNF-α, IL-6, IL-1β (322). In addition, adiponectin was shown to attenuate 
macrophage infiltration by abating NFκB and TNF-α and promote macrophage polarization 
towards the anti-inflammatory M2 phenotype (334, 336). Furthermore, both ANP and HO 
exhibit endogenous cytoprotective effects by virtue of their anti-inflammatory, anti-oxidant and 
anti-proliferative properties (3-5, 32-54, 319, 322, 324). Together, these evidence strongly 
suggest that the therapeutic agents that can potentiate the HO-ANP-adiponectin axis would be of 
great benefit, as they have potential to counteract the adverse effects of inflammatory/oxidative 
insults and insulin resistance associated with obesity and cardiomyopathy.  
 
4.2 Mechanisms underlying the suppression of visceral adiposity by hemin  
Visceral adiposity is an independent risk factor for progression and development of 
cardiovascular disease (1-12, 14, 15, 80). Initially, under the normal physiological state 
deposition of excessive fat takes place in non-ectopic tissue such as subcutaneous adipose tissue 
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(7, 71-73). However, during obesity, once the maximal limit of subcutaneous adipose tissue is 
achieved, increased FFA and other lipids than start to deposit in ectopic tissue such as heart, 
liver, kidney, muscles and the vasculature (1-5, 77, 241, 258). Thus, the deposition of 
perivascular, pericardial, and epicardial ectopic fat in heart exerts adverse effects in both an 
endocrine and paracrine manner (72, 253). Visceral adiposity like pericardial fat due its close 
anatomical location to coronary circulation has more serious consequences compared to 
subcutaneous fat and is a greater risk factor for heart disease and associated complications (12, 
355, 356). As a consequence, excess pericardial fat eventually results in elevated myocardial 
inflammation, increased oxidative stress, cardiac hypertrophy and excessive deposition of 
ECM/profibrotic proteins and the subsequent development of insulin resistance in cardiac tissue 
(72, 75, 79, 81, 129, 150, 253, 260, 261, 265, 287-289). This suggests that agents that reduce 
visceral adiposity, inflammation and attenuates oxidative stress would be beneficial to counteract 
obesity induced cardiometabolic complications. 
As a parallel project to the research outlined in Chapter 2 our study provides another 
novel observation that hemin therapy suppressed pericardial adiposity in obese ZDF (Chapter 3) 
and ZF rat models (54). The data presented in our most recent publication (330) showed that 
treatment with hemin improves pericardial adipocyte morphology and function in obese ZF rats 
as evidenced by elevated adiponectin levels and reduced levels of inflammatory and oxidative 
mediators, reduced expression of osteopontin and TGF-β as well as attenuation of pericardial 
adipocyte hypertrophy. Interestingly, hemin-mediated potentiation of proteins of repair and 
regeneration such as beta-catenin, Oct3/4, and Pax2 is suggestive of another important novel 
mechanism for the restoration of adipocyte morphology and function in the pericardial adipose 
tissue of obese ZF rats.  
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In this prospective study, I showed for the first time that HO-1 induction by hemin 
polarizes macrophages towards the anti-inflammatory M2 phenotype and suppresses the M1 pro-
inflammatory phenotype and thereby contributes towards the suppression of inflammation in 
cardiac tissue of ZF rats (Chapter 2 and Chapter 3). Interestingly, our study demonstrated that 
administration of hemin to ZF rats and ZDF rats and to their counterpart ZL rats increased HO 
activity, HO-1 concentration and cGMP levels in cardiac tissue. In contrast, co-administration of 
the HO inhibitor SnMP and HO inducer hemin suppressed HO-1 and HO activity and reduced 
cGMP levels. This suggests that increased cardiac HO-1 concentration, HO activity and cGMP 
levels were associated with a corresponding downregulation of inflammatory/oxidative 
mediators. In addition, hemin therapy improved cardiac structure and function as evidenced by 
suppressed cardiac hypertrophy, cardiac lesions and reduction in the ECM/pro-fibrotic proteins 
as well as improved cardiac hemodynamics (Chapter 2 and Chapter 3). Taken together, data from 
the present thesis and recent publication suggest that hemin treatment suppressed pericardial 
adiposity, improved pericardial adipose tissue morphology and function as well as improved 
cardiac function. Suppression of inflammatory and oxidative mediators, reduction of ECM 
proteins, suppression of pericardial adipocyte and cardiac hypertrophy and elevated adiponectin 
levels are some of the suggested mechanisms through which the HO system suppressed visceral 
adiposity and improved cardiac function. 
 
4.3 Role of the HO system in preventing cardiac hypertrophy and improvement in cardiac 
morphological lesions and function 
Cardiac hypertrophy and cardiac fibrosis is a pathophysiological driving force for heart 
failure (129, 150, 265, 287-289). In response to various stress stimuli myocytes grow either in 
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length and/or width as a result of increased cardiac afterload (287, 445). Since, upregulation of 
the HO system by hemin suppressed inflammatory/oxidative markers, macrophage infiltration 
and potentiated insulin signaling, I examined whether the cytoprotective role of hemin can be 
extended to cardiac tissue in the form of improvement in cardiac morphological lesions and 
function.  
In Chapter 2 and Chapter 3, I explored the effects of hemin treatment on cardiac structure 
and function. In ZF and ZDF rats, hemin treatment significantly reduced left-ventricular 
hypertrophy, cardiac fibrosis and cardiomyocyte longitudinal muscle fiber thickness and 
collagen deposition. However, co-administration of hemin and SnMP nullified the cytoprotective 
effects of hemin. Histological and morphometric analysis revealed that obesity-induced 
interstitial and perivascular collagen deposition, scarring of cardiomyocytes and cardiac fibrosis 
as observed in ZF rats was significantly attenuated by the hemin treatment (Chapter 2). As a 
parallel project, another novel and important finding of our study was that hemin therapy 
successfully reduced pericardial adipocyte hypertrophy as observed in untreated ZF rats and 
restored it to a level comparable to their ZL counterparts (54). The present research and previous 
studies support the existence of inter-organ crosstalk between the heart and pericardial adipose 
tissue (75, 78, 79). Thus, the movement of inflammatory/oxidative mediators and other 
atherogenic factors from the pericardial fat to the myocardium or vice versa in a paracrine 
manner might be suggestive of a mechanism for the subsequent development of insulin 
resistance and related cardiac complications (72, 129, 150, 260, 261, 265, 287-289). Altogether, 
the data from the present study and recent publication (54), strongly suggests that hemin-
mediated suppression of pericardial adiposity and the parallel reduction of pro-inflammatory 
cytokines and chemokines may attenuate the adverse effects of inflammatory mediators on the 
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myocardium derived from pericardial adipose tissue through a paracrine mechanism. Although, 
further research is needed to establish this interconnection, the results obtained with hemin 
treatment in the present study have given important suggestions for future work in this direction. 
Myocardial remodeling is an important pathophysiological process characterized by 
abnormal deposition of interstitial collagen and over expression of extracellular matrix proteins 
such as TGF-β, fibronectin and collagen that leads to increased myocardial stiffness and reduced 
myocardial contractility (129, 248, 265, 281, 283, 286, 292). This suggests that attenuation of 
cardiac fibrosis in turn might improve cardiac function. Another important observation of my 
thesis work is that hemin treatment improved cardiac function through a mechanism that 
involves the reduction of ECM/profibrotic proteins including TGF-β, fibronectin and collagen 
IV. Collagen IV plays an important role in cardiac hypertrophy and fibrosis (21, 446), In 
addition, TGF-β mobilizes ECM through the induction of collagen and fibronectin, and 
contributes to cardiac injury and fibrosis (21). Thus, reduction in TGF-β expression will in turn 
suppresses fibronectin and collagen protein expression. Interestingly, my work also showed that 
hemin treatment in ZF rats reduced the expression of collagen IV and TGF-β by 2.8 fold and 3.4 
fold compared to 6.9 fold and 4.6 fold above basal expression of collagen IV and TGF-β in 
untreated ZF rats. In a similar manner the 7.5 fold increase in basal expression of fibronectin in 
ZF rats was significantly suppressed 4.5 fold in hemin treated ZF rats (Chapter 2).  
To further confirm the cardioprotective effects of an upregulated HO system by hemin, I 
assessed the effect of hemin on markers of heart failure such as osteopontin and osteoprotegerin. 
Osteopontin and osteoprotegerin have been implicated to play pathophysiological roles in 
various biological processes such as adipose tissue inflammation, fibrosis, tissue remodeling, 
hypertrophy and insulin resistance (294, 295, 297-309, 311, 447). Osteopontin and 
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osteoprotegerin are highly activated in response to various inflammatory molecules such as LPS, 
TNF-α, IFN-γ, TGF-β, angiotensin-II, IL-1β (295, 297, 299, 309). It is suggested that the 
elevated expression of osteopontin and osteoprotegerin in the circulation and in cardiac tissue is 
a predictor for impaired cardiac function and subsequent heart failure (295, 297, 298, 303, 309, 
311). In Chapter 2, I have shown that in ZF rats, basal expression of osteopontin and 
osteoprotegerin in cardiac tissue was significantly elevated by 4.6 and 7.1 fold, respectively, as 
compared to ZL controls. However, hemin therapy in ZF rats reduced the expressions of 
osteopontin and osteoprotegerin by 3.5 and 3.3 fold, respectively. Similarly, our recent 
publication showed that hemin treatment significantly reduced the expression of osteopontin in 
pericardial adipose tissue of ZF rats (54).  
The novel and central observation of my thesis work is that hemin treatment improved 
cardiac structure and function as evidenced by improvement in various hemodynamic and 
echocardiographic parameters in ZF rats and ZDF rats (Chapter 2 and Chapter 3). It should be 
noted that cardiomyocyte hypertrophy and myocardial fibrosis are microscopic changes which 
are observed at initial stages in heart failure  (286, 292). Later, macroscopic changes such as 
increased left-ventricular wall thickness, altered cardiac hemodynamics, impaired diastolic 
function and subsequent systolic dysfunction becomes more prominent (287, 445). My thesis 
data showed that hemin treatment suppressed cardiac hypertrophy, fibrosis and left-ventricular 
longitudinal muscle fiber thickness (Chapter 2 and Chapter 3). Therefore, another possible 
mechanism that might be responsible for improved cardiac function by an upregulated HO 
system include improved hemodynamic and echocardiographic parameters  that eventually leads 
to a healthier heart accompanied by improved ventricular contractility (448). Interestingly, my 
thesis data showed that hemin treatment significantly reduced left-ventricular diastolic wall 
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thickness and left-ventricular systolic wall thickness and decreased mean-arterial pressure, 
arterial-diastolic pressure and arterial-systolic pressure in ZF rats and ZDF rats (Chapter 2 and 
Chapter 3). Furthermore, reduction in left-ventricular developed pressure, +dp/dt, and total 
peripheral resistance along with enhanced cardiac output was observed in hemin treated ZF rats 
(Chapter 2). Reduction in the pressure gradient that is required to maintain adequate systemic 
blood supply will reduce the left-ventricular workload and oxygen consumption and decrease the 
risk for cardiovascular abnormalities (428). Altogether, from these results, it can be inferred that 
the improvement in hemodynamic and echocardiographic parameters  by hemin decreased left-
ventricular afterload and thereby, protects against the onset of ventricular dysfunction that would 
affect cardiac performance and lead to  heart failure (80).  
Overall, my study clearly showed the beneficial effects of upregulated HO by hemin 
against obesity-induced altered cardiac structure and function. Suppression of cardiac 
hypertrophy, fibrosis and ECM/pro-fibrotic proteins are some of the mechanisms by which the 
HO system improved cardiac function in obese ZF rats. 
 
4.4 Role of the HO system against inflammation  
Excessive inflammation and oxidative stress leads to dysfunctional insulin signaling and 
compromised cardiac function (14, 15, 27, 29, 58, 68, 69, 133, 149, 150, 175, 178, 215). In 
response to obesity, adipose tissue reciprocates through the process of adipocyte hypertrophy and 
hyperplasia (1-5, 241). As obesity and corresponding adipocyte enlargement progresses, the 
insufficient blood supply leads to the process of necrosis/apoptosis of adipocytes and increased 
macrophage infiltration into the adipose tissue. As a consequence, the metabolic function of 
adipose tissue is compromised due to the overproduction of pro-inflammatory cytokines and 
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chemokines such as TNF-α, IL-6, IL-1β, and MCP-1 and inflammatory transcription factors such 
as NFκB, AP-1 and JNK (13, 67, 76, 142, 150). This leads to localized inflammation in adipose 
tissue followed by the development of systemic inflammation which is an underlying mechanism 
for obesity-related cardiovascular complications including insulin resistance (14, 15, 27, 29, 58, 
68, 69, 149, 161, 241, 448).  
During my Ph.D. research, I investigated whether hemin had any effect on the levels of 
pro-inflammatory cytokines such as TNF-α, IL-6 and IL-1β (Chapter 2). Interestingly, data from 
Chapter 2 and Chapter 3 revealed that the elevated levels of TNF-α, IL-6, IL-1β as observed in 
the left ventricle tissue of ZF and ZDF rats were successfully reduced in hemin-treated animals. 
This is consistent with recent publications from our lab which indicate that hemin therapy not 
only suppressed the elevated levels of TNF-α, IL-6 and IL-1β but also other pro-inflammatory 
and oxidative mediators such as NF-kB, AP-1, and JNK (4, 5, 53, 202). Similar results were 
observed in hemin treated lean controls, however, the reduction in the levels of TNF-α, IL-6 and 
IL-1β was found to be less intense compared to ZF and ZDF rats treated with hemin. In contrast, 
coadministration of hemin and the HO blocker SnMP nullified the effects of hemin, indicating 
the regulatory role of the HO system on these inflammatory cytokines. Thus, suppression of 
inflammatory mediators might serve as one of several mechanisms by which hemin-induced HO 
improved cardiac function, as high levels of pro-inflammatory cytokines have been implicated in 
abnormal glucose metabolism and impaired cardiac function (14, 115, 161, 241, 448).  
 
4.5 Mechanism underlying modulation of macrophage polarization by the HO system 
The strength of my thesis work is that it provides, for the first time, the credential for the 
role of an upregulated HO system on macrophage polarization in cardiac tissue of ZF rats. At the 
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time when my Ph.D. research was initiated, there were not many publications on the role of HO 
on macrophage polarization especially in cardiac tissue.  Although, Weis et al., 2009 previously 
performed an in vitro analysis to demonstrate the role of the HO-1 promoter in macrophage 
polarization, the expression levels of classical M1 and alternative M2 phenotype markers were 
not demonstrated. Therefore, I analyzed the effects of hemin on the pro-inflammatory M1-
phenotype and anti-inflammatory M2-phenotype macrophage markers in left-ventricular tissue 
of ZF rats.  
During the pathological condition of visceral obesity, increased macrophage infiltration 
leads to insulin resistance (19, 130, 137-140). My thesis results showed that hemin treatment 
successfully suppressed the pro-inflammatory cytokines implicated in the inflammatory process. 
Therefore, it was expected that suppression of these inflammatory mediators would be 
accompanied by a corresponding decrease in macrophage infiltration as cytokines and 
chemokines including IL-6, IL-1β, TNF-α, MCP-1 and MIP-1α were known to promote 
macrophage infiltration (19, 151). As expected, western blot analysis showed that in cardiac 
tissue of ZF rats hemin therapy significantly reduced ED-1 expression, which is a marker of 
macrophage infiltration to a level comparable to the healthy ZL control rats (Chapter 2). This 
result was further confirmed by immunohistochemical analysis done by using the ED-1 antibody; 
where there was a significant reduction in ED1-positively stained dark brown macrophages in 
hemin-treated ZF rats compared to unhealthy ZF controls (Chapter 2). Treatment with hemin 
also suppressed the elevated levels of MCP-1 and MIP-1α, chemokines that promote macrophage 
infiltration, in the left ventricle tissue of ZF rats (Chapter 2). However, the co-administration of 
SnMP with hemin reversed the protective effect of hemin, suggesting the role of the HO system 
in macrophage infiltration.  
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After this important observation, we examined the underlying mechanisms responsible 
for HO-mediated suppression of macrophage infiltration. It is known that macrophages have the 
potential to exist in different activation states (127, 135, 139, 151, 154, 156-160). Depending 
upon different kind of stimuli, macrophages are activated and in turn express distinct surface 
receptors and produce distinct chemokines and cytokines that lead to diverse macrophage pro-
inflammatory and anti-inflammatory functions (151, 157, 160). Macrophages are broadly 
classified into: the classically activated pro-inflammatory M1 phenotype and the alternatively 
activated anti-inflammatory M2 phenotype (151, 157, 160). The present study unveils that 
upregulation of the HO system by hemin selectively polarizes macrophages towards the anti-
inflammatory M2 phenotype in cardiac tissue of ZF and ZDF rats with corresponding attenuation 
of the pro-inflammatory M1 phenotype, indicating a novel mechanism through which hemin 
therapy attenuates obesity induced cardiac inflammation (Chapter 2 and Chapter 3). This was 
confirmed by western bolt and relative densitometry analysis of specific markers for the M1 and 
M2 phenotype of macrophages. In the left ventricle tissue of ZF and ZDF rats, basal expression 
of ED1 which is a specific marker for pro-inflammatory M1 phenotype of macrophages (381), 
was greatly elevated compared to lean controls. The basal expression of anti-inflammatory 
macrophage M2 phenotype markers including ED2, CD14, CD206 and CD36 was significantly 
reduced in untreated ZF and ZDF rats. Interestingly, treatment with hemin potentiated the 
depressed expression of anti-inflammatory ED2, CD206, CD36, and CD14 markers, whereas it 
suppressed the elevated expression of pro-inflammatory ED1 markers (Chapter 2 and Chapter 3), 
suggesting the role of the HO system in selective polarization of macrophages towards the M2 
phenotype to attenuate inflammation. 
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Taken together, in addition to the suppression of pro-inflammatory cytokines and 
chemokines, the hemin mediated polarization of macrophages towards the M2 phenotype might 
be considered as a novel anti-inflammatory mechanism employed by the HO system to 
counteract inflammatory insult associated with insulin resistance and obesity. 
 
4.6 Role of the HO system against insulin resistance 
Visceral adiposity and chronic low grade inflammation are pathophysiological driving 
forces for insulin resistance and cardiomyopathy (1, 5, 8, 15, 18, 150, 261, 266). Since hemin 
treatment successfully suppressed visceral adiposity and attenuated inflammation, it was 
believed that these beneficial effects of hemin would be accompanied by the improvement in 
insulin signaling and glucose metabolism. In general, IRS1, PI3K, GLUT4 and PKB are 
important proteins of insulin signal transduction pathways and potentiation of these proteins in 
turn potentiate insulin signaling (128, 167, 168). Therefore, during my PhD research work, I 
investigated the effect of hemin on the expression of IRS1, PI3K, GLUT4 and PKB proteins 
(Chapter 2 and Chapter 3). The basal expression of IRS1, PI3K, and GLUT4 was found to be 
depressed in ZF rats (Chapter 2). Similarly, in obese ZDF rats, a rat model characterized by 
insulin resistance and overt hyperglycemia, the basal expression of IRS1, PI3K, and PKB was 
suppressed (Chapter 3). However, treatment with hemin greatly enhanced the expression of these 
proteins. Moreover, in obese ZF rats glucose intolerance was observed as when challenged with 
a bolus injection of glucose, only a slight glucose stimulated insulin release was observed. 
(Chapter 2) In contrast, when hemin-treated ZF rats and ZL rats were challenged with a bolus 
injection of glucose, there was a high release of glucose stimulated insulin, suggesting hemin 
improved glucose tolerance. Similarly, hemin treated ZF rats showed reduction in insulin 
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resistance.  Co-administration of SnMP with hemin nullified the beneficial effects of hemin 
treatment. To further assess the beneficial role of hemin on glucose metabolism the effect of 
hemin on adiponectin was examined. Adiponectin is an important insulin-sensitizing and anti-
inflammatory adipokine (219, 220, 222, 329-338) that plays key roles in glucose metabolism. An 
inverse relationship was observed between the plasma levels of adiponectin and disease 
conditions including obesity, diabetes and cardiovascular diseases (219, 221, 222, 331, 332, 
334). Consistent with previous findings (196, 202), the present study revealed that treatment with 
hemin elevated the depressed basal adiponectin levels in both ZF rats and ZL rats (Chapter 2). In 
contrast, treatment with SnMP reversed the effects of hemin and further reduced the depressed 
levels of adiponectin. 
Taken together, my study clearly showed that the hemin-induced upregulated HO system 
enhanced insulin-sensitizing adiponectin, potentiated important proteins of the insulin signaling 
pathway and thereby, improved insulin signaling and glucose metabolism. 
 
4.7 Role of the HO system against oxidative stress  
Increased oxidative stress plays a crucial role in tissue remodeling, cardiac dysfunction 
and insulin resistance (178, 214, 215). Hence, in order to maintain metabolic homeostasis, 
enhancement of the anti-oxidant defense system that counteracts deleterious effects of increased 
ROS generation is largely needed. The anti-oxidant effect of an upregulated HO system has been 
accepted by various reports (3-5, 32-54). Interestingly, in the present study the observation that 
hemin therapy suppressed 8-isoprostane, the marker of oxidative stress, is consistent with the 
antioxidant effect of the HO system acknowledged by several studies (3-5, 32-54). In general, 
increased ROS generation leads to β-oxidation of tissue phospholipids and produces isoprostanes 
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including 8-isoprostane (225, 226). Urinary 8-isoprostane is a stable and important biomarker of 
elevated oxidative stress (224-228). Under physiological conditions, basal levels of 8-isoprostane 
is detected in plasma and urine samples; however, its level is elevated during increased oxidative 
stress conditions (225, 226). In the present study, the elevated levels of 8-isoprostane was 
suggestive of increased oxidative stress in the untreated ZF rats and ZDF rats. However, when 
treated with hemin, there was a marked reduction in levels of 8-isoprostane in ZDF and ZF rats 
(Chapter 2, Chapter 3 and Chapter 4). Hemin treatment also reduced the levels of 8-isoprostane 
in ZL controls but the magnitude of reduction was less compared to treated ZF and ZDF rats. In 
contrast, administration of SnMP along with hemin nullified the effects of hemin and restored 
the levels of 8-isoprostane comparable to untreated animals. Furthermore, in SnMP alone treated 
animals, the levels of 8-isoprostane was increased more compared to untreated ZF and ZDF rats, 
indicating that the increase in oxidative stress might be due to the suppression of basal HO 
activity via the HO blocker SnMP in ZF and ZDF rats. 
Since, 8-isoprostane stimulates ET-1 (196, 378) and both ET-1 (26, 230-235) and 8-
isoprostanes (225, 226) were implicated in oxidative stress mediated tissue injury, the effect of 
hemin on ET-1 was assessed. The left-ventricular levels of ET-1 in untreated ZF and ZDF rats 
were highly elevated but significantly reduced by hemin treatment. In contrast, SnMP+hemin 
treatment resulted in elevated ET-1 levels, suggesting the anti-oxidant role of the HO system. 
One of the possible mechanisms that accounts for the antioxidant effect of the HO system is that 
treatment with hemin leads to enzymatic degradation of heme via HO-1 into its catabolic 
products such as bilirubin, biliverdin and ferritin, all of which possess the capacity to scavenge 
superoxide radicals. Thus, the reduction of ROS generation in hemin treated animals prevented 
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oxidation of tissue phospholipids and thereby, contributed to the reduction of 8-isoprostane 
levels. 
 
4.8 Crosstalk between ANP and the HO system 
An important observation from my thesis work is the upregulation of ANP by hemin 
treatment. ANP is a cytoprotective endogenous molecule that plays an important role in blood 
pressure homeostasis and exhibits anti-inflammatory, anti-proliferative, natriuretic and diuretic 
effects (315-324). Moreover, it is reported that ANP attenuates cardiac hypertrophy (316), 
promotes peripheral vasodilation and suppresses cardiac and vascular remodeling (315, 317). In 
addition, ANP is known to stimulate various cytoprotective heat shock proteins including HO-1 
(400, 401, 449). Both HO and ANP has mutual stimulatory effects. On one hand, HO upregulates 
ANP (359, 442), similarly, ANP also potentiates HO (400, 401, 449). The exact mechanism for 
the ANP mediated cytoprotective action is not clear. However, it was shown that ANP exhibits 
its beneficial effects via the guanylate cyclase-coupled A-receptor and guanosine 3', 5'-cyclic 
monophosphate (cGMP) (449). ANP exerts its anti-inflammatory effects through the attenuation 
of pro-inflammatory cytokines including IL-6, IL-1β and TNF-α (359, 449). Interestingly, ANP 
inhibits TNF-α induced inflammatory pathways through the activation of the second messenger 
cGMP (450). In addition, ANP was shown to reduce fibrosis via the inhibition of expression of 
ECM proteins TGF-β and fibronectin (387, 450, 451). 
My research work showed that hemin treatment successfully abated inflammation and 
exhibited cardioprotection through the attenuation of pro-inflammatory/oxidative mediators, 
decreased macrophage infiltration, and suppression of ECM proteins such as collagen-IV, TGF-β 
and fibronectin. Since, HO can potentiate ANP (359, 442), it is suggested that the cytoprotective 
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action of the HO system might be attributed indirectly through the potentiation of ANP. In 
Chapter 2, my thesis results revealed that in untreated ZF rats the basal left-ventricular levels of 
ANP were markedly depressed by 1.7 fold, but significantly upregulated by 3.3 fold in hemin-
treated animals. Moreover, it is well documented that both ANP and ET-1 display reciprocal 
relationships and exhibit opposing effects (452, 453). For instance, while ANP is anti-
inflammatory, reduces insulin resistance and abates fibrosis by suppressing TGF-β1 and 
fibronectin (314, 316, 322, 324), ET-1 promotes insulin resistance by stimulating 
inflammatory/oxidative mediators and participates in fibrosis via the induction of fibronectin in 
conjunction with TGF-β1 (231, 232, 235, 237, 238).. Therefore, potentiation of ANP through 
hemin may be regarded as another mechanism for hemin-dependent suppression of ET-1. 
Altogether, since both ANP and HO exhibit endogenous cytoprotective effects by virtue 
of their anti-inflammatory, anti-oxidant and anti-proliferative properties (3-5, 32-54, 319, 322, 
324), it can be inferred that the combined beneficial effects of both the HO system and ANP 
ameliorated insulin resistance, improved glucose metabolism and cardiac function. 
 
4.9 Crosstalk between adiponectin and the HO system 
Adiponectin is an adipokine that plays major roles in tissue homeostasis (219, 220, 222, 
329-339). Owing to its anti-diabetic, antioxidant, anti-atherogenic and insulin sensitizing effects, 
it is cytoprotective against the pathological conditions of obesity, insulin resistance and 
cardiovascular disease (220, 329, 334, 336, 337). Evidence is there to support the idea that low 
levels of adiponectin are a predictor of cardiovascular disease (72, 220, 329, 331). High levels of 
adiponectin were demonstrated to be cardioprotective against impaired cardiac function, cardiac 
ischemia reperfusion injury (72, 329) and cardiomyopathy (329, 337), whereas its deficiency 
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aggravated cardiac injury as observed in the adiponectin knockout mouse model (219, 332). 
Another important observation of my thesis work was the hemin-dependent upregulation of 
depressed basal levels of adiponectin in left-ventricular tissue of ZF rats (Chapter 2). However, 
treatment with SnMP along with hemin resulted in further depression of the basal levels of 
adiponectin. This suggests that hemin treatment enhanced adiponectin levels in ZF rats. This is 
consistent with recent reports from our lab and other studies that demonstrated that the HO-
mediated upregulation of adiponectin levels contribute to improved insulin sensitivity and 
glucose metabolism (202, 444, 446). In addition, my thesis work showed that in ZF rats hemin 
treatment potentiated insulin signaling and improved glucose tolerance through the suppression 
of inflammatory/oxidative mediators and selective polarization of macrophages towards the anti-
inflammatory M2 phenotype. Moreover, it is well documented that adiponectin is anti-
inflammatory in function and reduces the expression of pro-inflammatory cytokines TNF-α and 
IL-6 (334, 336). Interestingly, adiponectin also promotes macrophage polarization towards the 
anti-inflammatory M2 phenotype (220, 329, 334, 336).  
All together, these findings indicate that an interplay exists between adiponectin and the 
HO system, as both HO and adiponectin are cardioprotective and upregulation of both contribute 
to attenuation of insulin resistance and improved glucose metabolism (38, 39, 44, 162, 205, 329-
331, 334, 337, 340, 347-352). Thus, hemin-mediated potentiation of adiponectin might serve as 






4.10 Synergistic effects between the HO system, ANP and adiponectin on glucose 
metabolism and cardiomyopathy 
The key observation of my PhD research work indicates that the upregulation of HO 
system by hemin and corresponding enhancement in adiponectin and ANP levels is an important 
cytoprotective mechanism for improved glucose metabolism and cardiac function in hemin-
treated ZF rats (Chapter-2).  No other study has reported the effects of an upregulated HO system 
on ANP or adiponectin in cardiac tissue of ZF rats and the corresponding link between HO-
ANP-adiponectin axis and the levels of IL-6, TNF-α, IL-1β, MCP-1, TGF-β, and fibronectin and 
macrophage infiltration. An interplay exists between HO, ANP and adiponectin, as mutual 
stimulatory effects have been reported between HO and ANP. On one hand, the HO system 
upregulates ANP (359, 442), similarly, ANP also potentiates the HO system (400, 401, 449). In 
addition, both ANP and HO were known to stimulate adiponectin (202, 319, 397, 443, 444). 
Based on these findings, it is possible that the elevated levels of adiponectin in hemin treated 
animals (Chapter-2) was either a consequence of direct stimulation by an upregulated HO system 
or through the indirect enhancement of ANP levels. Either way, the underlying mechanisms 
responsible for potentiation of adiponectin in response to HO and ANP still need to be clarified. 
It is well documented that ANP increases the levels of the anti-inflammatory and insulin 
sensitizing protein adiponectin in the circulation (397, 443). Moreover, ANP action is mediated 
largely by cGMP (449) and adiponectin is also reported to stimulate the second messenger 
cGMP (399). Furthermore, the HO system generates a metabolite CO, a vasodilator and a 
stimulator of cGMP that regulates vascular contractility (42, 45). Studies have shown that on 
exposure to chronic inflammatory and oxidative insults, decreased levels of adiponectin and HO-
1 contribute to the development of insulin resistance (41, 219-223, 454). Interestingly, an 
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increase in HO-1 levels was shown to be associated with a parallel increase in adiponectin levels 
that exhibit cytoprotective effects accompanied by improved insulin sensitivity and preserved 
endothelial function in different animal models (53, 196, 202, 359, 444, 446, 454). Furthermore, 
since both ANP and HO exhibit endogenous cytoprotective effects by virtue of their anti-
inflammatory, anti-oxidant and anti-proliferative properties (3-5, 32-54, 319, 322, 324), it is 
suggested that the mutual stimulatory effects between the HO system and ANP, in turn, 
ameliorate insulin resistance and  potentiate cardioprotection in synergistic manner. 
Taken together, the novel observation of my thesis work clearly shows that the 
potentiation of the HO-ANP-adiponectin axis by hemin in ZF rats has beneficial effects against 
obesity induced cardiomyopathy and improved glucose metabolism through the mechanisms that 
involved the attenuation of pro-inflammatory chemokines/cytokines and oxidative mediators 




In conclusion, my thesis has presented a detailed study on the novel effects of upregulating 
the HO system by hemin on cardiomyopathy in ZF rats and the multifaceted mechanisms by 
which hemin therapy improves insulin signaling, glucose metabolism and cardiac function in 
obese ZF rats. My results clearly showed for the first time that the enhancement of ANP and 
adiponectin by hemin-induced upregulated HO system is an important cardio-protective 





The present study for the first time unveils:  
(i)    a novel role of an upregulated HO on selective polarization of macrophages towards 
an anti-inflammatory M2 phenotype with parallel suppression of the pro-
inflammatory M1 phenotype in the cardiac tissue of ZF rats. 
(ii) hemin-induced suppression of heart failure proteins such as osteopontin and 
osteoprotegerin implicated in inflammation, tissue remodeling and hypertrophy in the 
cardiac tissue of ZF rats 
Other important observations from this study include:  
(iii) The hemin-dependent attenuation of pro-inflammatory chemokines/cytokines (TNF-
α, IL-6, IL-1β, MCP-1, MIP-1α) and oxidative mediators (8-isoprostane and ET-1).  
(iv) The hemin-dependent reduction of ECM/pro-fibrotic proteins like collagen-IV, 
fibronectin, TGF-β and suppression of cardiac lesions, fibrosis and left-ventricular 
and cardiomyocytes hypertrophy. 
(v) Hemin-induced potentiation of ANP, adiponectin and important proteins of the 
insulin signaling pathway including IRS1, PI3K and GLUT4 accompanied by 
reduction in glucose intolerance, insulin resistance and improved cardiac 
hemodynamics in ZF rats. 
Collectively, these data suggests that an upregulated HO system by hemin and the 
corresponding suppression of inflammatory/oxidative mediators, reduction of the pro-
inflammatory M1 macrophage infiltration, attenuation of ECM/heart failure proteins including 
osteopontin and osteoprotegerin, reduction in cardiac hypertrophy and potentiation of the 
components of insulin signaling, ANP and adiponectin are among the several mechanisms by 





Chronic low grade inflammation and increased oxidative stress are underlying 
mechanisms that links obesity with cardiovascular disease and insulin resistance (3, 5, 14, 15, 24, 
27, 29, 58, 68, 69, 127, 149, 255, 256). Although, considerable efforts have been made in 
elucidating mechanisms implicated in obesity-related cardiovascular disease, new therapeutic 
tools with novel mechanisms of action to counteract the adverse effects of obesity-related 
cardiometabolic complications, is greatly needed. In this context, the present study strongly 
underscore the beneficial effects of concomitantly upregulating the HO, ANP and adiponectin by 
hemin against impaired insulin signaling and cardiomyopathy. Collectively, the findings reported 
in the present study provide insights for designing novel therapeutic strategies that can 
synergistically potentiate the HO-ANP-adiponectin axis to counteract cardiometabolic 
complications related to obesity and thereby, have great translational potential. In addition, the 
drug hemin used as HO-inducer have therapeutic applications, as it has been already approved by 
the Food and Drug Administration for use against porphyria (55, 56). 
 
4.13 Future directions 
As a natural extrapolation of the findings reported so far, several important thematic 
issues can be further developed and elucidated in future studies.   
1. My study showed that treatment with hemin in both healthy ZL-control rats and insulin 
resistant obese ZF rats enhanced HO-1, adiponectin and ANP and suppressed IL-6, IL-
1β, TNF-α, MCP-1, MIP-1α, 8-isoprostane, ET-1 and lowered HOMA-IR index (Chapter 
2). Interestingly, we observed that the magnitude of suppression of these 
inflammatory/oxidative mediators in normal ZL control rats was smaller as compared to 
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unhealthy obese ZF rats. The exact mechanism for this hemin-mediated HO effect in ZL 
and ZF rats is still not clear and needs to be resolved. One of the possible explanations for 
this selective effect of HO is that the HO system is more stable in ZL rats that are normal 
and healthy animals with a normal HO system and functional insulin signaling, as 
compared to unhealthy, obese and insulin resistant ZF animals which have compromised 
cardiac function with depressed HO-1 and HO-activity. Exploring the putative alternative 
pathways for the selectivity of the HO system in diseased conditions might help in better 
understanding of the HO system that can be explored as a therapeutic tool against the co-
morbidity of obesity and cardiomyopathy. 
 
2. The present study, our recent publications and other clinical studies have well 
acknowledged the beneficial role of HO system in response to various pathophysiological 
stress conditions (3-5, 32-54). However, the activation of HO by different stress stimuli 
only results in the transient increase in HO activity that falls below the threshold level 
required for the activation of downstream signaling components such as CO, bilirubin 
and biliverdin through which the HO system confers cytoprotection. CO is a 
physiological signaling molecule with anti-inflammatory, anti-apoptotic, anti-
proliferative and vasorelaxing properties (41, 45, 50, 208, 430, 455). The proposed 
mechanism for the vasoregulatory effect of CO is through the activation of the soluble 
guanylyl cyclase (sGC)/cGMP pathway. Interestingly, CO mimics nitric oxide (an 
important gasotransmitter) in several biological functions (39, 52, 456). Both nitric oxide 
and CO shares similar vasodilatory properties via binding to the heme moiety of sGC and 
function through the activation of similar sGC/cGMP pathways with a corresponding 
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increase in cGMP levels (43, 52). It is important to determine, whether their actions are 
additive, opposite, overlapping or synergistic (456). It is documented that CO is 
chemically more stable compared to NO and has a longer half-life. However, as a 
vasodilator CO is 1000-fold less potent than NO. Although, CO and nitic oxide functions 
similarly as a vasorelaxing agent both display variations in their biological availability 
(35, 52, 456). Hence, to activate the HO/CO system above the threshold level, HO 
inducers like hemin are needed to boost the activity of the sGC/cGMP pathway (4, 53, 
54, 195, 196, 359). Inspite of these findings, some important questions need to be 
answered. Besides CO/sGC what are other alternative pathways for HO-mediated 
elevated cGMP levels? What is the optimal level of HO-1 expression that is sufficient to 
stimulate CO and bilirubin to exhibit a beneficial role? Future studies directed to explore 
these questions might help us to better understand the HO/CO system in order to exploit 
it as a therapeutic tool against cardiac complications related to obesity. 
 
3. An important observation from my research is the potentiation of the HO-ANP-
adiponectin axis by hemin in ZF rats. Although, an interplay between HO, ANP and 
adiponectin have been reported (202, 319, 397, 400, 401, 442-444, 449), the underlying 
mechanisms for the potentiation of HO-ANP-adiponectin axis by hemin is unknown. 
Several questions still remain puzzling: 
(i) What is the exact mechanism for the enhancement of ANP by HO or vice versa?  
(ii) How does upregulation of HO increase adiponectin levels?  
(iii) Does adiponectin stimulate HO?  
(iv) How does ANP stimulate adiponectin? 
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(v) On the other hand, does adiponectin stimulate ANP?  
(vi) Would the combination of both adiponectin and ANP stimulate HO differently 
than when each substances is given alone? 
(vii) Does the combination of both HO and adiponectin stimulate ANP?  
(viii) Since HO and ANP are known to stimulate adiponectin release, (202, 319, 397, 
443, 444), it remains unclear if it is a direct stimulation by the HO system or 
indirectly through the enhancement of ANP?  
With so many unanswered questions, future research is needed to discover mechanisms 
responsible for the synergistic potentiation of either adiponectin by HO and ANP or the 
potentiation of HO by ANP and adiponectin as well as the potentiation of ANP by HO or 
adiponectin. The elucidation of these complex interactions will help us to better 
understand and explore the HO-ANP-adiponectin axis as a new therapeutic target against 
obesity and cardiomyopathy. 
Collectively, the findings reported in the present study open new avenues for 
further investigation on HO inducers that can be exploited to design novel therapeutic 







Appendix A, appendix B, appendix C below are three of my first-authored published 
manuscripts. These manuscripts provides up-to-date and detailed knowledge of the functional 
significance of the HO system and its downstream signaling molecules including bilirubin, CO 
and ferritin as potential therapeutic tools for effective management of hypertension, type-1 
diabetes and associated cardio-metabolic complications. In appendix A, the current state of 
knowledge and future directions of research in the area of obesity-related cardiomyopathy and 
nephropathy have been acknowledged. 
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Appendix C: Tiwari S and Ndisang JF. Heme Oxygenase System and Hypertension: a 
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Appendix D1: Classification of obesity  
Obesity is a chronic condition of nutrient overload and the only tissue that stores excess 
nutrients is adipose tissue. Adipose tissue is mainly composed of adipocytes that are specialized 
cells and store excess nutrients in the form of lipids (23, 62, 260). Adipose tissue either produces 
new adipocytes or enlarges the existing ones to meet excess nutrient demand. In addition, 
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adipose tissue consists of preadipocytes, endothelial cells, fibroblasts and a variety of immune 
cells including, leucocytes and macrophages (62, 133, 260). Based on appearance, adipose tissue 
can be classified into white adipose tissue and brown adipose tissue. White adipose tissue is a 
predominant site of energy storage mainly in the form of triglycerides and is more distinct. In 
contrast, brown adipose tissue is dense and highly vascularized exhibiting brown coloration and 
regulates body temperature through non-shivering thermoregulation (23, 133). On the basis of 
anatomical location, white adipose tissue is further classified into visceral adipose tissue and 
subcutaneous adipose tissue (62, 251, 253, 354). 
 
1.1 Visceral adipose tissue and subcutaneous adipose tissue 
Distribution and anatomical location of fat tissue is an important feature in the 
pathophysiology of obesity and associated complications (62, 251, 253, 354). White adipose 
tissue is classified into two major depots namely, subcutaneous and visceral adipose tissue (62, 
251, 253, 354). Anatomically, visceral adipose tissue is mainly found within the abdominal 
cavity and mediastinum surrounding internal organs such as heart, pancreas and kidneys, 
whereas subcutaneous adipose tissue is found between the muscle and dermis (62, 354). Visceral 
adipose tissue is mainly comprised of tightly packed unilocular adipocytes which are 
metabolically more active compared to subcutaneous adipocytes and is more susceptible to 
lipolysis by catecholamine (62, 457). Besides adipocytes, visceral adipose tissue is composed of 
stromal vascular components such as preadipocytes, ECM proteins (collagen, fibronectin, 
osteopontin and metalloproteinase), fibroblasts and endothelial cells (62, 260, 458). During 
obesity, visceral adipose tissue is the most altered tissue (4, 5, 71, 459). Alterations occur in both 
adipocytes and stromal vascular components in response to the increased storage of triglycerides. 
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As a result, adipocytes undergo hypertrophy and enlargement of visceral adipose tissue takes 
place (1-5). Due to the expansion of visceral adipose tissue, dysfunctional adipocytes and ECM 
remodeling, infiltration of macrophages and other immune cells occurs that activates adverse 
morphological and inflammatory responses in visceral adipose tissue (3, 5, 15, 124-127, 133). In 
addition, enlarged visceral adipose tissue is found to be associated with elevated levels of pro-
inflammatory cytokines such as IL-6, IL-1β and TNF-α (3, 5, 15, 124-127, 133). In contrast, low 
levels of anti-inflammatory adipokines such as adiponectin was reported in visceral adipose 
tissue compared to subcutaneous adipose tissue (72, 220, 329, 331, 337). Thus, excess 
accumulation of visceral adipose tissue accounts for a pro-inflammatory state (4, 5, 71, 75, 459). 
Although, both visceral and subcutaneous adipose tissue contribute to pathological conditions 
associated with obesity, however, excess visceral adipose tissue is more deleterious than 
subcutaneous adipose tissue (2, 25, 62, 460). Various studies confer that excess deposition of 
visceral adipose tissue leads to a higher risk for obesity associated metabolic and cardiovascular 
complications including, dyslipidemia, insulin resistance and diabetes (1-14). Studies showed 
that the removal of abdominal subcutaneous adipose fat from obese individuals with insulin 
resistance had no effect on metabolism, while, insulin sensitivity was improved with the removal 
of visceral adipose fat in these subjects (461, 462). Thus, excess visceral fat is a major risk factor 
for obesity associated adverse metabolic outcomes (3, 5, 15, 124-127, 463). 
 
Appendix D 2: Adipokines in obesity related metabolic disorders  
1.1 Leptin 
First identified in 1994 by Zang et al. leptin is an adipokine mainly secreted by adipocytes 
that plays a major role in energy metabolism (18, 75). Leptin regulates energy metabolism 
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through its direct or indirect actions on the brain. It is proposed that leptin stimulates distinct 
centers in the hypothalamus which in turn releases neuropeptides and neurotransmitters that 
reduce food intake, enhance the energy expenditure as well as modulate glucose and lipid 
metabolism (18, 75). Leptin possess anti-diabetic properties and was reported to attenuate 
hyperglycemia in obese mice (464, 465). Moreover, treatment with leptin reversed hepatic 
steatosis and improved insulin resistance in lipodystrophic patients diagnosed with relatively 
decreased levels of circulating leptin (466). However, it should be taken into account that during 
obese conditions leptin therapy is highly ineffective due to leptin resistance. Leptin resistance is 
a condition, where high levels of leptin are unable to exert anorexic effects (18, 467) owing to  
unresponsiveness towards the hormone (75, 459, 468). The underlying mechanisms responsible 
for leptin resistance during obesity are still not clear. However, it is suggested that SOCS3  and 
protein tyrosine phosphatase 1B (PTP1B)  are among the possible signaling molecules involved 
in the regulation of leptin resistance (75). It is suggested that the different metabolic effects of 
leptin are mediated by multiple signaling pathways (18). For example, leptin exerts its anti-
diabetic effects through the stimulation of PI3K/Akt pathway while, its anorexic effects are 
governed by the activation of  JAK-STAT signaling pathway (18). Thus, an understanding of the 
mechanisms underlying leptin resistance will be helpful in exploring new therapeutic strategies 
to target leptin against obesity and associated metabolic disorders. 
 
1.2 Resistin 
Resistin is an adipokine that belongs to a family of cysteine-rich proteins termed as 
resistin like molecules (RELMs) (78, 469). Resistin expression was first identified in adipose 
tissue of obese mice (78). The name resistin has been derived due to its resistance towards 
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insulin action. Various rodent models of obesity and insulin resistance were found to be 
associated with elevated levels of resistin (75, 470).  However, improved glucose metabolism 
was observed in resistin knockout mice fed a high fat diet (471), suggesting the possible role of 
resistin in the pathogenesis of obesity-mediated insulin resistance and type-2 diabetes (75, 470). 
The underlying mechanism responsible for the pathological role of resistin in various disease 
conditions is still not very clear. However, an in vitro study using a pre-adipose 3T3-L1 cell line 
demonstrated that resistin impaired normal insulin signaling via the alteration of expression of an 
insulin receptor as well as IRS1 and IRS2 (472). Furthermore, resistin has been reported to 
modulate AMP-activated protein kinase (AMPK) activation that plays important roles in insulin 
sensitization during insulin signaling (75). However, in humans, the role of resistin regarding 
insulin resistance is uncertain. Epidemiological studies demonstrated the association between 
high levels of resistin and increased risk for insulin resistance, type-2 diabetes, myocardial 
infarction and atherosclerosis (18, 75). In addition, resistin was shown to stimulate the 
production of several pro-inflammatory cytokines and chemokines including, IL-6, TNF-α, 
MCP-1 all of which are implicated in the development of insulin resistance during obese 
conditions (18, 75). This suggests that in human obesity, resistin alters insulin signaling 
indirectly through the elevation of inflammatory cytokine production (473). Thus, the therapeutic 
approach that targets resistin inhibition will be of great relevance for the treatment of obesity. 
 
Appendix D 3: Altered cardiac structure and function in obesity 
1.1 Hemodynamic alterations 
  Obesity independent of other cardiovascular risk factors such as hypertension, 
atherosclerosis and myocardial infarction can alter both diastolic and systolic function (1, 14, 23, 
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71, 244-252, 254). Obesity has detrimental effects on cardiac diastolic function (129, 265, 289). 
It is reported that impaired diastolic function often precedes systolic dysfunction and can occur 
either independently or in combination with systolic dysfunction (129, 265, 289, 474). Diastolic 
dysfunction is characterized by alterations in left-ventricular filling indices that results in 
abnormal diastolic pressure in response to reduced ventricular compliance due to the 
enlargement in the left-ventricular mass and impaired pressure and volume load (129, 265, 289). 
Abnormal load conditions including increased afterload and duration of obesity also contribute to 
compromised left-ventricular systolic function (129, 289, 474). In addition, increased cardiac 
output and heart rate was also found to be associated with obesity (129, 265, 289, 474). It is 
suggested that the elevated heart rate in obese patients might be due to the suppressed 
parasympathetic tone instead of increased sympathetic activity (129, 265, 289). Moreover, 
increased extracellular volume and higher blood flows to adipose and non-adipose tissues with 
increased venous return and cardiac output has been observed during obese conditions (129, 265, 
289). Thus, obesity-mediated impaired cardiac hemodynamics and ventricular function 
contribute to the pathogenesis of cardiomyopathy. 
 
1.2 Cardiac hypertrophy 
Cardiac hypertrophy is one of the important clinical features associated with heart failure 
(129, 287-289). In general, obesity is an independent risk factor for left-ventricular hypertrophy 
independent of conventional risk factors (1, 14, 23, 71, 244-252, 254, 288). The severity and 
duration of obesity influences the degree of left-ventricular hypertrophy and myocardial 
remodeling (129, 254, 288). Myocardial remodeling and fibrosis, cardiomyocytes hypertrophy 
and thickening of cardiac myofibrils are characteristic features of left-ventricular hypertrophy 
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(129, 287-289). Studies have shown that compared to lean controls increase in both left-
ventricular cavity size and wall thickness were observed in obese subjects. However, wall 
thickness increased more than cavity size, indicating the prevalence of concentric hypertrophy 
more than eccentric hypertrophy during obese conditions (288).  However, obesity has been 
found to be associated with both concentric and eccentric forms of cardiac hypertrophy. An 
increase in right ventricular wall thickness and volume were also found to be associated with 
obese individuals (129, 257, 265). Obesity induced altered hemodynamic changes in response to 
increased blood volume and corresponding venous return amplifies cardiac load and triggers a 
series of hemodynamic, neurohormonal and molecular factors. This result in increased left-
ventricular mass and wall thickness, elevated left-ventricular pressure, ventricular dilatation as 
well as decreased systolic performance that eventually leads to the development of left-
ventricular hypertrophy (129, 150, 265, 287-289). Moreover, obesity associated hypertension 
further exacerbate the condition of left-ventricular hypertrophy and myocardial remodeling (60, 
150, 254). 
 
1.2.1 Concentric and eccentric hypertrophy 
In response to pressure overload caused by pathological insults including hypertension, 
myocardial infarction and aortic stenosis, the heart triggers a concentric hypertrophic response to 
counter balance the increased wall stress and intraventricular pressure (129, 257, 265, 286, 287). 
The heart responds to increased left-ventricular systolic wall stress and high systolic pressure by 
adding new sarcomeres units (which are repeating micro-anatomical units of myofibrils of 
cardiomyocytes) in parallel to the previous sarcomeres. This leads to the development of 
increased left-ventricular wall thickness and smaller cavities (286, 287). The increased 
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myocardial stiffness and reduced compliance, eventually leads to left-ventricular diastolic 
dysfunction and diastolic heart failure (286, 293). It is reported that as a consequence of 
concentric hypertrophy, there is a prolongation in the early filling phase of diastole accompanied 
by reduced rate and volume of rapid filling (286, 287). 
In contrast, pathological insults such as chronic mitral regurgitation and aortic 
regurgitation cause ventricular dilation due to volume overload and increases diastolic wall 
stress. As a result, myocytes lengthen by adding new sarcomeres in a series to existing 
sarcomeres that develops into eccentric cardiac hypertrophy (286, 287). Volume overload related 
eccentric hypertrophy in the heart is characterized by large dilated cavities and a relatively thin 
myocardial wall together with decreased left-ventricular systolic function and performance (286, 
287, 293). It is suggested that individuals with systolic heart failure display left-ventricular 
eccentric hypertrophy (293). 
 
1.2.2 Physiological hypertrophy 
In contrast to concentric and eccentric cardiac hypertrophy, the physiological stimulus 
that induces physiological hypertrophy includes strength and endurance exercise training (286, 
287, 293). Another common example for physiological hypertrophy was observed in pregnant 
females characterized by left-ventricular enlargement with preserved wall thickness and ejection 
fraction (287, 293). The cardiac structural changes observed during isotonic exercise, such as 
running, walking, cycling and swimming might be considered a form of eccentric hypertrophy 
where both chamber enlargement and proportional increase in left-ventricular mass was observed 
in response to increased venous return to the heart and volume overload (287, 293). However, 
high level resistance training such as weight lifting is associated with a large pressure load 
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compare to volume load on the heart and thereby, develops a form of concentric hypertrophy 
(286, 287). Furthermore, compared to concentric and eccentric hypertrophy, physiological 
hypertrophy does not lead to left-ventricular dilation or heart failure (286, 287, 293). 
 
Appendix D 4: ANP (Synthesis, tissue distribution and functions) 
Initially, ANP was isolated from the atria of heart (313-316). During embryonic 
development, ANP is highly expressed by both atrium and left-ventricle. Apart from cardiac 
tissue the pituitary gland, lungs, hypothalamus and kidneys express ANP at lower levels (314).  
The exact mechanism that governs ANP secretion is still not very clear. However, mechanical 
stretching and external stimuli exerted by angiotensin II, catecholamine and vasopressin may 
have stimulatory effects on ANP release (315). Structurally, ANP is 28-amino acid long peptide 
with a single intra-chain disulfide bond. Initially, ANP is synthesized as a precursor pro-ANP in 
cardiac cells (313). Upon secretion from atrial cardiomyocytes, pro-ANP is cleaved by a 
myocardium-specific type-II transmembrane protease to yield biologically active ANP and an 
inactive amino terminal fragment NT-pro ANP (314, 316). The process is followed by the 
release of Pro-ANP, NT-pro ANP and ANP in the circulation (313). The biological effects of 
ANP are mainly mediated by its active form via binding to specific high affinity receptors 
natriuretic peptide receptor (NPR)-A and NPR-C on the surface of target cells (315, 318).  NPR-
A is known to be abundantly expressed by several tissues including kidney, adrenal gland, heart, 
brain, testis, eye, intestine and vascular system (315). Binding of ANP to NRP-A activates 
intrinsic guanylyl cyclase activity of the receptor that leads to the increase in intracellular 
secondary messenger cGMP levels (313, 314). It is reported that impaired or absence of NRP-A 
gene expression results in the development of hypertension, cardiac hypertrophy and ventricular 
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fibrosis (314). Furthermore, NPR-C is also known as a clearance receptor, as it plays a major 
role in clearance of ANP from the circulation via a receptor-mediated endocytosis process (315). 
NPR-C is expressed by several tissues including kidneys, adrenals, lungs, vascular system, 
intestine, brain, and heart (315). In addition, NPR-C coupled with adenylate cyclase activity 
reduced cAMP production and promotes phospholipase-C stimulation there by, increasing 
inositol triphosphate (IP3) and diacylglycerol (DAG) production (315). Binding of ANP to NRP-
C promotes endothelial nitric oxide synthase expression as well as inhibition of endothelin 
stimulated MAPK pathway (315). These findings suggest that ANP and its receptors plays 
important role in biological processes. 
 
1.1 ANP and inflammation  
ANP is anti-inflammatory in function and exerts an inhibitory effects on pro-
inflammatory chemokines, cytokines and adipokines (315-324). ANP inhibits the activation of 
pro-inflammatory transcriptional factors such as NFκB and AP-1 as well as attenuates TNF-α 
secretion via ANP/cGMP signaling that attenuates p38 MAPK downstream signaling pathway 
(322). Furthermore, in humans, ANP has been demonstrated to suppress pro-inflammatory 
chemokines and cytokine production from adipocytes and macrophages of adipose tissue (322). 
Besides having anti-inflammatory function, ANP has a regulatory role on adipokines related to 
energy metabolism (319). Studies demonstrated that a positive correlation exists between ANP 
and adiponectin levels. For example, an increase in ANP levels results in a parallel increase in 
total and high molecular weight (HMW) adiponectin in humans (319, 443). An ANP-mediated 
reduced levels of leptin has been observed in human adipocytes (319). Thus, the decreased levels 
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of ANP and its corresponding effect on other adipokines might be one of the mechanisms that 
aggravate the metabolic disorders during obesity. 
During the inflammatory process, macrophages release large amounts of nitric oxide 
through iNOS stimulation (450). The interaction  of ANP with NPR-A receptors were known to 
attenuate nitric oxide release from macrophages in an autocrine manner through the subsequent 
enhancement of  intracellular cGMP levels that inhibits the NFκB signaling cascade involved in 
iNOS synthesis (450). In addition, in vitro experiments showed that ANP attenuates LPS-
induced TNF-α and IL-6 synthesis and thereby, protects against inflammatory cell injury (450, 
475). TNF-α plays a major role in the pathogenesis of diseases including obesity, insulin 
resistance, hypertension and atherosclerosis (81, 83, 84, 90). It is demonstrated that ANP/NPR-A 
show anti-inflammatory effects against TNF-α induced endothelial cell injury through the 
inhibition of the downstream p38MAPK signaling pathway, increased production of cGMP and 
mitogen-activated protein kinase phosphatase-1 (MKP-1) (450, 475). ANP is also known to 
suppress endothelial TNF-α induced MCP-1 production via the inhibition of p38MAPK pathway 
(450). Interestingly, another mechanism by which ANP inhibits the TNF-α-induced 
inflammatory pathway through the activation of cGMP mediated HO-1 production, an enzyme 
that is known to be cytoprotective under different conditions of tissue insults (38, 39, 44, 205, 
347-352). In addition, ANP produced locally by macrophages was shown to inhibits the 
production of LPS-induced cyclooxygenase-2 (COX-2), an enzyme that plays an important pro-
inflammatory role during inflammation (450).  
Thus, ANP has emerged as an important anti-inflammatory molecule that functions in an 
autocrine or paracrine manner to counteract the effects of pro-inflammatory chemokines, 




1.2 ANP and oxidative stress 
Epidemiological studies suggested the anti-oxidant role of ANP against different 
pathological conditions (315, 323). The exact mechanism by which ANP counteracts the 
deleterious effects of ROS is not known. However, it is suggested that at physiological 
concentration, ANP protects against ROS-induced tissue damage by the activation of a NPR-
A/cGMP mediated signaling pathway (315). Similarly, in liver tissue ANP was shown to be 
cytoprotective against oxidative stress through the mechanism of NPR-A/cGMP system 
activation (315, 449). A recent study reported the cardioprotective and anti-oxidant effect of 
ANP in cardiomyocytes (315, 324). In patients with heart failure, infusion of synthetic ANP not 
only improved hemodynamic features but also suppressed free radical generation, thereby, 
exhibiting protection against oxidative stress injury in cardiomyocytes (315). In addition, the 
stress stimuli generated by mechanical stretch, pressure overload and angiotensin-II promotes 
cardiac hypertrophy via ROS generation (315). ANP has been shown to suppress angiotensin-II-
mediated oxidative stress and reduced hypertrophic responses in neonatal rat cardiomyocytes 
(315, 324). Another mechanism for ANP mediated cardioprotection against oxidative stress in 
vascular smooth muscle cells is via the inhibition of phospholipase-D activity and reduction of 
intracellular calcium ions (315). Moreover, it is demonstrated that ANP promotes an increase in 
the plasma levels of adiponectin under pathological condition of type-2 diabetes and heart 
failure, suggesting another possible mechanism for an ANP-mediated cardioprotective effect 





1.3 ANP, glucose metabolism and insulin resistance  
ANP plays an important role in glucose homeostasis (319, 476, 477). In isolated rat 
pancreatic islets, ANP increased insulin secretion in response to glucose and promotes growth of 
β-cells, whereas, ANP knock-out mice were shown to have reduced β-cell mass, suggesting the 
regulatory effect of ANP on β-cell function (319, 477). During obesity, metabolic organs such as 
liver and skeletal muscle are strongly associated with insulin resistance due to excess deposition 
of lipid content such as triacylglycerol (319). On the other hand, increased lipid oxidation in 
these metabolic organs improved insulin sensitivity (319, 476). ANP has been reported to 
improve insulin sensitivity through increased lipid oxidation in liver and skeletal muscles (319). 
Moreover, there exists a correlation between plasma glucose and insulin levels and ANP levels 
in circulation.  Low levels of natriuretic peptides were found to be associated with high glucose 
and insulin levels independent of body fat distribution (326).  In addition, data from the recent 
Framingham Heart Study showed that low levels of natriuretic peptides were found to be 
associated with a greater risk for insulin resistance in both lean and obese individuals (327). 
Increased levels of natriuretic peptides were reported to be beneficial against insulin resistance 
and type-2 diabetes (319, 320). Thus, these data suggests that ANP plays a cytoprotective role 
against the pathological condition of insulin resistance and diabetes. 
 
1.4 Cardioprotective role of ANP  
ANP displays a regulatory role in cardiovascular homeostasis and governs blood pressure 
and extracellular fluid volume (314, 318, 450). It is reported that at basal levels ANP participates 
in the regulation of blood pressure by enhancing microvascular permeability (314). Moreover, 
ANP attenuates cardiac hypertrophy, promotes peripheral vasodilation and has inhibitory role in 
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cardiac and vascular remodeling (315, 317). Depending upon the severity and type of disease 
various pathophysiological stress conditions acts as a trigger for the release of ANP from atria 
and ventricles. For example, under normal conditions ANP is mainly secreted from the atria. 
However, during diseased conditions the ratio of ANP secretion from the left ventricle was 
reported to be proportional to left-ventricular dysfunction and end diastolic pressure (315, 317). 
This suggests that release of ANP from the atria and ventricles depends upon the severity of 
disease condition and represent the extent of cardiac overload. Under stressful conditions of 
hemodynamic load or myocardial ischemia, ANP was shown to be  cardioprotective and reduced 
cardiac preload and afterload (313, 314) without initiating reflex tachycardia (316). It suppressed 
total peripheral resistance via its inhibitory effect on the release of rennin, vasopressin and 
aldosterone (315). It is reported that during hypertension, ANP relaxes vascular smooth muscle 
cells through the activation of the protein kinase G (PKG) pathway that contribute to reduction in 
intracellular calcium ions and hyperpolarization of endothelial cells of the vasculature (313, 
314). 
ANP also possess anti-proliferative properties (450). In vascular smooth muscle cells and 
cardiomyocytes, ANP promotes anti-proliferative effects against platelet-derived growth factor 
and insulin-induced cell growth. It is suggested that the anti-proliferative effect of ANP was 
mediated through the mechanisms that involves the reduction of intracellular cAMP levels and 
inhibition of MAPK and PKG signaling pathways (315, 317, 450). In a similar manner, ANP- 
mediated inhibition of PI3K/Akt signaling is another mechanism for ANP anti-proliferative 
effect and attenuation of ROS production (450).  
Another mechanism by which ANP can regulate blood pressure is through its action on 
the RAAS system (314). ANP has been reported to attenuate renin production via a PKG-II 
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dependent mechanism and suppresses aldosterone production at the adrenal gland (314, 316). 
Moreover, ANP exerts its diuretic and natriuretic effects through its direct action on renal 
hemodynamics. It is predicted that in the kidney, ANP increases glomerular filtration rate (GFR) 
via the dilation of the afferent arteriole and constriction of the efferent arteriole (314). ANP in 
circulation reduces sodium and water reabsorption through its inhibitory effect on angiotensin II-
induced sodium and water transport in the proximal tubules as well as inhibition of aldosterone 
secretion from the adrenal cortex and cardiac tissue (314, 316). The regulation of extracellular 
fluid volume and cardio renal homeostasis by ANP demonstrate its cardioprotective properties. 
Taken together, these findings highlights ANP as an important therapeutic diagnostic tool for 
cardiovascular and renal disease. 
 
Appendix D 5: Adiponectin (receptors, structure and function) 
Structurally, adiponectin is a 30-kDa plasma protein (220) having a globular head at the 
C-terminal and collagen like domain at the N-terminal (331). In circulation, adiponectin is 
secreted from adipocytes as three large oligomeric complexes that are modified post-
translationally in the endoplasmic reticulum by molecular chaperons (220, 331) (Figure: 
Appendix D 5). These oligomeric complex formations may be regarded as a mechanism to 
modulate various adiponectin mediated biological functions (329). The first class is comprised of 
a low molecular weight (LMW) trimeric adiponectin approximately 90 KDa with basic units. 
The second class includes approx. 180 KDa middle molecular weight (MMW) hexamers. The 
third class is of high molecular weight (HMW) isomers (dodecamers and octadecamers) (220, 
331). The HMW adiponectin undergoes through extensive post-translational modifications 
(hydroxylation and glycosylation) at its collagen-like domain to maintain its stability in the 
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circulation (329, 331). HMW adiponectin is the most biologically active oligomeric isomer that 
is important in regulation of cardiometabolic complications (331). Furthermore, it is reported that 
elevated levels of HMW adiponectin is correlated with reduced levels of cardiovascular disease 
and improved insulin sensitivity (222, 331, 333). Adiponectin is a multipotent adipokine that 
mediate its biological functions with the help of three receptors namely, adiponectin receptor 
protein-1 (Adipo-1), adiponectin receptor protein-2 (Adipo-2) and T-cadherin (333, 340). 
Adiponectin receptors are specific in their distribution and functions and differ with regards to 
their affinity for adiponectin oligomeric isomers (222). For example, globular adiponectin has 
affinity for Adipo-1, while full length oligomeric adiponectin binds to Adipo-2 receptors (222). 
Adipo-1 and Adipo-2 are structurally related transmembrane receptors that have seven 
transmembrane domains (220). However, both Adipo-1 and Adipo-2 were reported to be 
functionally and structurally different from G-protein-coupled receptors (220, 222). 
 
Figure, Appendix D 5:  Schematic representation of adiponectin structure. Adapted from 
Vascular Health and Risk Management 2015:11 55–70. 
Abbreviations: High molecular weight (HMW). 
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Adiponectin receptors are widely expressed by different cardiac, vascular and immune 
cell types (329, 340). Adipo-1 is mainly expressed by skeletal muscles, whereas liver is the site 
for Adipo-2 expression (220, 331). Moreover, both Adipo-1 and Adipo-2 were expressed by 
endothelial cells and cardiomyocytes (220), suggesting that they have important signaling roles 
in mediating cardiovascular effects of adiponectin (220, 329, 334, 336, 337, 339). Evidence 
suggests that adiponectin exhibits its different biological actions through the activation of various 
signaling molecules such as AMPK, PPARα and p38MAPK and display ceramidase activity 
(222, 451, 478-480). Adipo-1 and Adipo-2 convert pro-apoptotic ceramides to anti-apoptotic 
sphingosine-1-phosphate (SIP), thus exhibiting anti-apoptotic effects in cardiomyocytes (222, 
451, 478-480). Adipo-1 and Adipo-2 also participate in the modulation of fatty acid oxidation 
and glucose uptake (222, 331, 451, 478-480). Besides, Adipo-1 and Adipo-2, T-cadherin is a 
surface cell receptor for full length and oligomeric adiponectin. It functions as a co-receptor with 
adiponectin receptors to mediate adiponectin signaling pathways in different cell types (329).  It 
is abundantly expressed by myocardium, smooth muscle cells as well as by endothelium (222, 
329, 478). T-cadherin is cardioprotective and is essential for adiponectin mediated AMPK 
phosphorylation (329). In T-cadherin knockout mice, high levels of adiponectin was found in 
circulation due to the inability of adiponectin to bind with cardiac tissue and display similar 
defects as observed in adiponectin null mice, suggesting that T-cadherin participates in 
mediating adiponectin biological action (222, 329, 478). Thus, the specific structure of the three 
adiponectin isomers, adiponectin receptors and their post translational modifications and distinct 
expression pattern, altogether participates in mediating a cytoprotective role of adiponectin 




1.1 Adiponectin and inflammation 
Adiponectin possess anti-inflammatory, antioxidant and insulin-sensitizing properties. 
(219, 220, 222, 329-338). Adiponectin acts in a feedback loop manner and regulates the 
expression of TNF-α and IL-6. Interestingly, adiponectin can modulate macrophage phenotype 
and function by promoting macrophage polarization towards anti-inflammatory M2 phenotype 
(220, 329, 334, 336). Adiponectin regulates inflammatory signals and prevents TNF-α-induced 
monocyte adhesion and expression of cell adhesion molecules (220, 329). In a recent study in 
adiponectin knock-out mice, elevated expression of pro-inflammatory macrophage M1 
phenotype markers and lower expression of anti-inflammatory M2 markers was observed in 
adipose tissue and peritoneal macrophages. However, administration of recombinant adiponectin 
suppressed oxidative stress and increased the expression of anti-inflammatory M2 phenotype 
markers, thereby, providing protection against systemic inflammation (329). In a similar manner, 
treatment with globular adiponectin protected adiponectin null mice against micro-vascular 
inflammation (220). In addition, adiponectin has been demonstrated to augment the secretion of 
anti-inflammatory cytokines such as IL-10 and IL-1 receptor antagonist in monocytes, 
macrophages and dendritic cells (329), which might be one of the possible mechanism for anti-
atherosclerotic and cytoprotective effects of adiponectin against vascular inflammation (329, 
331). It is proposed that adiponectin exerts its anti-diabetic and anti-atherogenic effects due its 
ability to suppress NFκB activation in response to an inflammatory stimuli (334). It is reported 
that adiponectin mediated PPARα and AMPK activation promotes suppression of NFκB and 
COX2 gene expression and protects against inflammatory conditions (334). In contrast, under 
normal conditions, adiponectin has been shown to favor NFκB activation in various cell types 
(334). One possible explanation for adiponectin-induced NFκB activation would be that 
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adiponectin augments IL-6 production through the stimulation of NFκB pathway with the help of 
receptors distinct from Adipo-1 and Adipo-2, which in turn promotes increased expression of 
IRS-2 via STAT3 signaling. This altogether results in increased insulin sensitivity (220, 329, 
334, 336). Further research is needed to clarify how adiponectin maintains the balance between 
suppression of NFκB activation induced by inflammatory stimuli and adiponectin mediated 
NFκB activation under physiological conditions (334). 
 
1.2 Adiponectin and insulin resistance 
Insulin resistance associated with obesity is a major risk factor for diabetes and 
cardiovascular diseases (3, 5, 13-15, 24, 29, 68, 69, 127, 135, 143-149, 170). Elevated FFA 
levels in the circulation during obesity reduces insulin-induced glucose uptake. This in turn 
reduces the production of glycogen in skeletal muscle and liver (the principal insulin target 
organs responsible for regulation of energy metabolism) that subsequently leads to insulin 
resistance (337). A recent study revealed that in insulin resistant obese mice, the levels of 
adiponectin as well as expression of its receptors (Adipo-1 and Adipo-2) were significantly 
reduced in skeletal muscle and adipose tissue in response to the obesity-induced 
hyperinsulinemia that leads to the dysfunctional adiponectin-mediated AMPK signaling (333, 
334, 340). Similarly, in type-2  diabetic patients reduced levels of Adipo-1 and Adipo-2 were 
reported in the skeletal muscles (334). Thus, during the pathological obese condition, 
adiponectin sensitivity is significantly reduced due to low circulating levels of adiponectin and 
reduced expression of its receptors. As a result a vicious cycle is generated leading to 
hyperinsulinemia and a gradual development of  insulin resistance (162, 329, 330, 333, 334, 
340). It is well known that adiponectin possess insulin-sensitizing effects and a beneficial role of 
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adiponectin against insulin resistance and dysfunctional insulin signaling was reported both in 
vitro and in vivo (162, 329-331, 334, 337, 340). With regards to the molecular mechanism 
responsible for insulin-sensitizing effects of adiponectin, it is demonstrated that in both liver and 
skeletal muscle, adiponectin increased glucose uptake and promotes fatty acid oxidation by 
stimulating the AMPK pathway and inhibiting acetyl coenzyme-A carboxylase (162, 331, 334). 
However, inhibiting AMPK activation by a blocker reverses the beneficial effect of adiponectin, 
suggesting that enhancement in glucose uptake and fatty acid oxidation by adiponectin is 
mediated via AMPK activation (331, 334). Moreover, both Adipo-1 and Adipo-2 were known to 
play a regulatory role in normal glucose metabolism and fatty acid oxidation (162, 329-331, 334, 
337, 340) and serves as a receptors for globular and full length adiponectin (334). It is reported 
that Adipo-1 activates AMPK, while Adipo-2 activates PPARα ligand activity that results in 
increased glucose uptake and improved insulin sensitivity in liver (334). Besides liver and 
skeletal muscle, adiponectin improved insulin signaling in the pancreas. Recent studies showed 
that adiponectin promotes β-cells survival and function and thereby, improved glucose 
metabolism in a high fat diet obese mice model (162, 333). Thus, further research on adiponectin 
and its receptors will prove beneficial in treating obesity-related insulin resistance and glucose 
intolerance. 
 
1.3 Cardioprotective role of adiponectin 
Evidences support the idea that low levels of adiponectin is a predictor for cardiovascular 
diseases (72, 220, 329, 331, 337). Adiponectin has been reported to be cardioprotective against 
impaired cardiac function, cardiac ischemia reperfusion injury and cardiomyopathy (72, 220, 
329, 331, 337, 481), whereas its deficiency aggravates cardiac injury in adiponectin knock-out 
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mice model (329, 337). Adiponectin knock-out mice were shown to be more prone to cardiac 
hypertrophy, impaired cardiac function and aggravated fibrotic response compared to normal 
control mice (329). The cardioprotective role of adiponectin in both the cardiac and vascular 
systems is attributed to its anti-inflammatory, anti-atherogenic and anti-fibrotic properties (72, 
220, 329, 331, 335). The underlying mechanisms for the protective role of adiponectin against 
vascular diseases is still not clear, however, it is proposed that adiponectin protects against 
dysfunctional endothelium via the stimulation of  nitric oxide and attenuation of inflammation 
and oxidative stress (329, 332, 337, 481). For example, it was shown that adiponectin promotes 
vasodilation of cardiomyocytes via the regulation of nitic oxide synthesis through eNOS and 
attenuation of nitrative stress. Adiponectin exerts protection against ROS-stimulated cardiac 
remodeling through the activation of AMPK, p38MAPK and ERK1/2 signaling cascade and 
inhibition of ERK phosphorylation (338, 339). Moreover, adiponectin-induced AMPK activation 
and related inhibition of ERK phosphorylation is an important mechanism to counteract the 
deleterious effect of angiotensin-II and ET-1 induced hypertrophic signals through the 
suppression of NFκB pathway in cardiomyocytes (478, 481). It is reported that the 
administration of adiponectin to adiponectin deficient mice and isolated rat heart was 
cardioprotective against ischemia injury (329). The anti-apoptotic effect of adiponectin is 
mediated by the activation of AMPK and Akt signaling pathways (451) and increased expression 
of COX-2 (479). In a similar manner, administration of agonists of adiponectin receptors to 
diabetic mice exerted protective effects similar to adiponectin mediated by Adipo-1 and Adipo-2 
in both liver and skeletal muscle (480). Taken together, these studies support that adiponectin 
plays a pivotal regulatory role in cardiovascular homeostasis and exerts protection against 
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